S100A1 acts positive inotropic

and prevents Ca2+ triggered after-contractions

in a model of Engineered Heart Tissue by Ritterhoff, Julia
  
 
 
 
 
 
 
 
Dissertation 
 
 
 
 
submitted to the 
 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
 
for the degree of 
 
Doctor of Natural Sciences 
 
 
 
 
 
 
presented by 
Julia Ritterhoff 
M.Sc. Molecular Medicine 
born in Twistringen 
 
 
 
Oral examination:……………….  
  
 
 
 
 
 
 
 
S100A1 acts positive inotropic 
 and prevents Ca2+ triggered after-contractions  
in a model of Engineered Heart Tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees: PD. Dr. rer. Nat. Martin Müller 
          Prof. Dr. med. Patrick Most
 3 
 
I. Statement of independent work  
 
I hereby declare that this submission is my own work and that it contains no material previously 
published or written by another person and that no additional assistance was provided except where the 
acknowledgment has been made in the text. 
 
 
 
 
 
 
 
 
 
…………………………       ……………………. 
Place and date          Signature 
 
Table of content 
4 
 
II. Table of content 
 
I. Statement of independent work ................................................................................................. 3 
II. Table of content ........................................................................................................................... 4 
III. List of figures ............................................................................................................................... 7 
IV. Abbreviations .............................................................................................................................. 9 
0. Abstract… .................................................................................................................................. 12 
1. Zusammenfassung ..................................................................................................................... 13 
2. Introduction ............................................................................................................................... 14 
2.1 Epidemiology of heart failure ..................................................................................................... 14 
2.2 Calcium – the main factor controlling cardiomyocyte contractility............................................ 14 
2.2.1 Calcium – an intracellular signaling molecule .................................................................... 14 
2.2.2 Regulation of cardiomyocyte function: Cardiac excitation contraction coupling ............... 15 
2.2.3 Fine-tuning contractile force: Modulation of calcium signaling ......................................... 16 
2.3 Heart failure – from deranged calcium handling to ventricular arrhythmias .............................. 17 
2.4 Special focus on the RyR2: SR Ca2+ release channel and scaffolding protein............................ 18 
2.4.1 Regulation of RyR2 by phosphorylation ............................................................................. 19 
2.4.2 Regulation of RyR2 by accessory proteins ......................................................................... 19 
2.4.3 Regulation of RyR2 by redox-modification ........................................................................ 20 
2.5 S100A1 - function and fiction ..................................................................................................... 21 
2.5.1 S100A1 structure and expression pattern ............................................................................ 21 
2.5.2 S100A1 action in cardiomyocytes ....................................................................................... 22 
2.5.3 S100A1 in heart failure: Development of S100A1 gene therapy ........................................ 23 
2.5.4 S100A1 positive inotropic and anti-arrhythmic potential? ................................................. 24 
2.6 Aim of the study .......................................................................................................................... 25 
3. Materials and Methods ............................................................................................................. 26 
3.1 Materials...................................................................................................................................... 26 
3.1.1 Equipment ........................................................................................................................... 26 
3.1.2 Consumables ....................................................................................................................... 26 
3.1.3 Chemicals and reagents ....................................................................................................... 27 
3.1.4 Primers ................................................................................................................................ 28 
3.1.5 Antibodies ........................................................................................................................... 28 
3.1.6 Prepared buffers, solutions and media................................................................................. 30 
3.1.7 Non-standard software ........................................................................................................ 31 
3.2 Methods.. ..................................................................................................................................... 31 
3.2.1 Cell culture techniques ........................................................................................................ 31 
3.2.1.1 Virus production ........................................................................................................ 31 
3.2.1.1.1 General cell culture.............................................................................................. 31 
3.2.1.1.2 Amplification of replication-deficient adenoviruses ........................................... 31 
3.2.1.1.3 Virus enrichment by cesium chloride density gradient centrifugation ................ 32 
3.2.1.1.4 Titer determination .............................................................................................. 33 
3.2.1.2 Isolation and cultivation of neonatal rat cardiomyocytes .......................................... 34 
3.2.1.3 Cultivation of neonatal rat cardiac fibroblasts ........................................................... 34 
Table of content 
5 
 
3.2.1.4 Generation and cultivation of Engineered Heart Tissue (EHT) ................................ 35 
3.2.1.4.1 Generation of EHT .............................................................................................. 35 
3.2.1.4.2 Functional analyses of EHT ................................................................................ 35 
3.2.1.4.3 Arrhythmia-Assay ............................................................................................... 37 
3.2.1.5 Isolation of adult rat cardiomyocytes ........................................................................ 37 
3.2.2 Biochemical methods .......................................................................................................... 37 
3.2.2.1 Western blot .............................................................................................................. 38 
3.2.2.1.1 Isolation of proteins ............................................................................................. 38 
3.2.2.1.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS page) ........... 38 
3.2.2.1.3 Immunological detection ..................................................................................... 38 
3.2.2.2 Immunoprecipitation (IP) .......................................................................................... 39 
3.2.3 Cell biological methods ....................................................................................................... 39 
3.2.3.1 Immunofluorescence Staining ................................................................................... 39 
3.2.3.2 Proximity Ligation Assay (PLA)............................................................................... 39 
3.2.3.3 TUNEL staining ........................................................................................................ 40 
3.2.3.4 Microscopy ................................................................................................................ 40 
3.2.4 Molecular biology methods ................................................................................................. 41 
3.2.4.1 RNA Isolation ............................................................................................................ 41 
3.2.4.2 Reverse Transcription ................................................................................................ 41 
3.2.4.3 Real-time PCR ........................................................................................................... 41 
3.2.5 Statistics .............................................................................................................................. 41 
4. Results… .................................................................................................................................... 42 
4.1 Engineered Heart Tissue resembles functional syncytium.......................................................... 42 
4.2 Development of an EHT model with contractile impairment ..................................................... 43 
4.2.1 Chronic ET-1 treatment diminishes contractile performance of EHT ................................ 44 
4.2.2 Chronic ET-1 treatment induces cellular remodeling ......................................................... 45 
4.2.3 Chronic ET-1 treatment might induce necrosis ................................................................... 47 
4.3 Induction of store-overload induced Ca2+ release (SOICR) in EHT ........................................... 49 
4.3.1 Ca2+-Stress and β-AR stimulation induce after-contractions ............................................... 49 
4.4 S100A1-mediated gene transfer in normal and failing EHT ....................................................... 52 
4.4.1 Adenoviral-mediated S100A1 overexpression increases S100A1 protein levels in EHT ... 52 
4.4.2 S100A1 overexpression increases isometric force generation in EHT ............................... 55 
4.4.3 S100A1 overexpression prevents Ca2+-induced after-contractions ..................................... 57 
4.5 Elucidating S100A1’s molecular effects ..................................................................................... 60 
4.5.1 S100A1 overexpression does not change expression of major Ca
2+
-handling proteins ...... 60 
4.5.2 S100A1 overexpression might reduce pro-inflammatory activation ................................... 61 
4.5.3 S100A1 overexpression does not change Cx43 expression in EHT ................................... 62 
4.5.4 S100A1 overexpression does not change global PKA or CamKII downstream signaling .. 63 
4.5.5 S100A1 overexpression does not change RyR2 phosphorylation ....................................... 65 
4.6 Impact of S100A1 on the RyR2 macrocomplex ......................................................................... 67 
4.6.1 S100A1 overexpression increases S100A1 protein levels in ACM .................................... 67 
4.6.2 S100A1 overexpression does not change PKA or CamKII downstream signaling............. 67 
4.6.3 S100A1 overexpression does not change complex formation of RyR2 .............................. 69 
4.6.4 S100A1 overexpression enhances S100A1/RyR2 interaction............................................. 70 
4.6.5 S100A1 overexpression blunts RyR2 s-nitrosylation after β-AR stimulation .................... 70 
Table of content 
6 
 
5 Discussion ................................................................................................................................... 72 
5.1 Pharmacological stimulation of EHT with ET-1 – an in vitro model of failing cardiac tissue ... 72 
5.1.1 Classification of EHT into current models for cardiac hypertrophy or heart failure........... 72 
5.1.2 After-contractions – a model for Ca2+-triggered arrhythmias ............................................. 74 
5.2 Validation of S100A1’s therapeutic potential in normal and failing EHT.................................. 75 
5.2.1 S100A1 acts positive inotropic and anti-arrhythmic in EHT .............................................. 76 
5.2.2 S100A1 effects are independent of changes in contractile protein expression pattern ....... 77 
5.3 Challenging current concepts for the development of Ca2+ triggered arrhythmias ..................... 78 
5.3.1 S100A1 acts independent of PKA/CamKII signaling ......................................................... 78 
5.3.2 Regulating the RyR2 macrocomplex - S100A1/RyR2 interaction as key for anti-arrhythmic 
effects……… ................................................................................................................................ 79 
5.4 Conclusion and Outlook .............................................................................................................. 81 
6 References .................................................................................................................................. 83 
V. List of publications .................................................................................................................... 96 
V.I Poster presentation and talks ....................................................................................................... 96 
 
List of figures 
7 
 
III.  List of figures 
 
Figure 1: Cardiac EC coupling .............................................................................................................. 16 
Figure 2: EC coupling in failing CMs ................................................................................................... 18 
Figure 3: The RyR2 macrocomplex: Ca2+ release channel and scaffolding protein.............................. 21 
Figure 4 : Conceptual framework of S100A1 target structures in CM. ................................................ 22 
Figure 5: S100A1 actions in cardiomyocytes ........................................................................................ 23 
Figure 6: Schema of S100A1 effects on Ca2+ transients, SR Ca2+ load and the development of the 
diastolic Ca2+ leak in isolated CM ......................................................................................................... 24 
Figure 7: CsCl density gradient after first centrifugation step .............................................................. 33 
Figure 8: Setup for EHT preparation, culture and analysis of contractile function:.............................. 35 
Figure 9: Original force recording of Ca2+ stimulated EHT .................................................................. 36 
Figure 10: Schema of twitch measurement and functional parameters deduced from it ....................... 36 
Figure 11: EHT shows an adult-like structural organization ................................................................. 42 
Figure 12: Dose-respond curves of Ca2+ and Iso stimulated EHT ........................................................ 43 
Figure 13: Chronic ET-1 treatment impairs contractility of EHT ......................................................... 45 
Figure 14: ET-1 treatment induces marker gene expression reminiscent of HF-like remodeling ......... 46 
Figure 15: ET-1 treatment induces pro-inflammatory and fibrotic gene activation .............................. 47 
Figure 16: Chronic ET-1 treatment increases hsTNT and LDH levels in culture medium ................... 47 
Figure 17: Chronic ET-1 treatment does not induce apoptosis ............................................................. 48 
Figure 18: Chronic ET-1 treatment does not reduce CSQ protein expression ...................................... 49 
Figure 19: Ca2+-Stress induces after-contractions in a concentration-dependent manner ..................... 50 
Figure 20: Ca2+-Stress induces after-contractions that can be inhibited by low-dose ryanodine .......... 51 
Figure 21: Combined β-AR/ Ca2+ stimulation induces after-contractions ............................................ 52 
Figure 22: AdGFP is predominantly expressed in cardiomyocytes ...................................................... 53 
Figure 23: Adenoviral-mediated gene transfer in EHT ......................................................................... 54 
Figure 24: S100A1 overexpression increases S100A1 protein levels in normal and normalizes S100A1 
protein expression in HF-like EHT ....................................................................................................... 55 
Figure 25: S100A1 overexpression increases isometric force generation in normal and failing EHT . 56 
Figure 26: S100A1 overexpression increases isometric force generation after β-AR stimulation ........ 57 
Figure 27: S100A1 overexpression reduces the incidence of calcium-triggered after-contractions in 
normal and failing EHT ......................................................................................................................... 59 
Figure 28: S100A1 overexpression does not changes expression of Serca2, PLB, RyR2 and NCX .... 61 
Figure 29: S100A1 overexpression after ET-1 treatment reduces pro-inflammatory activation .......... 62 
Figure 30: S100A1 overexpression does not change Cx43 expression and phosphorylation ............... 63 
Figure 31: S100A1 overexpression does not change PLB phosphorylation after Ca2+ stimulation ...... 64 
List of figures 
8 
 
Figure 32: S100A1 overexpression does not change PLB phosphorylation after β-AR stimulation .... 65 
Figure 33: S100A1 overexpression does not change RyR2 phosphorylation ....................................... 66 
Figure 34: S100A1 overexpression increases S100A1 protein levels in adult rat cardiomyocytes ...... 67 
Figure 35: S100A1 overexpression does not change PLB and RyR2 phosphorylation pattern ............ 68 
Figure 36: S100A1 overexpression does not change CaM/RyR2, FKBP12.6/RyR2 and Sorcin/RyR2 
interaction .............................................................................................................................................. 69 
Figure 37: S100A1 overexpression enhances S100A1/RyR2 stoichiometry ........................................ 70 
Figure 38: S100A1 overexpression normalized RyR s-nitrosylation .................................................... 71 
 
 
   Abbreviations 
9 
 
IV. Abbreviations 
 
[Ca2+]i   intracellular Ca2+ concentrations  
[K+]i   reduces intracellular potassium concentrations 
[Na+]i   intracellular sodium concentrations 
aa   amino acid 
AC  adenylatecyclase 
ACM   adult rat cardiomyocytes 
ANOVA analysis of variance 
ANT  adenosine nucleotide translocator 
AP  action potential 
apoCaM  Ca2+-free CaM 
Ca2+  calcium 
CaM   calmodulin  
CamKII calcium/calmodulin-dependent protein kinase II 
cAMP  cyclic adenosine monophosphate 
cDNA  complementary deoxyribonucleic acid  
CICR  Ca2+ induced Ca2+ release  
CM  cardiomyocyte 
CsCl   cesium chloride 
CSQ  calsequestrin 
CTGF   connective tissue growth factor 
Cx43  Connexin43 
DAD  delayed after-depolarization 
E1/E3  Early 1/3 genes 
EC  excitation-contraction  
ECG  electrocardiography 
EHT  Engineered Heart Tissue 
ET-1  endothelin-1 
FCMs  failing rat ventricular cardiomyocytes  
FCS   Fetal calf serum 
FKBP12.6 FK506 binding protein 12.6 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GFP  green fluorescent protein 
Hek293A  human embryonic kidney carcinoma 293A cells 
HF  heart failure 
Ica   Ca2+ influx 
   Abbreviations 
10 
 
ICAM-1 intercellular adhesion molecule 1 
IF   immunofluorescence  
IK1  inward rectified potassium current 
IL-6  interleukin 6 
IP   immunoprecipitation  
Iso  isoproterenerol 
K+  potassium 
LAD  left anterior descending 
LTCC  L-type Ca2+ channel 
MOIs   multiplicities of infections 
Na+  sodium 
Na+K+-ATPase sodium-potassium-ATPase 
NCF   neonatal rat cardiac fibroblasts 
NCM   neonatal rat cardiomyocytes 
NCX  sodium-calcium-exchanger 
ON   over night 
PCR  polymerase chain reaction 
PKA   cAMP-dependent kinase 
PKG  Protein kinase G 
PLA  proximity ligation assay 
PLB  phospholamban 
Po  open probability  
PP1, PP2a protein phosphatases 1 and 2a 
PTMs  post-translational modifications 
RNA  ribonucleic acid 
ROS   reactive oxygen species 
Rpm  revolutions per minute 
RT  room temperature/ reverse transcription 
RyR2  SR Ca2+ release channel/ryanodine receptor  
SDS page  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM  standard error of mean 
Ser   serine  
SERCA2a sarco/endoplasmic reticulum calcium-ATPase 
SMA  smooth muscle actin 
SNO  s-nitrosylation 
SOICR  store overload-induced Ca2+ release  
sorcin   soluble resistance-related calcium-binding protein 
   Abbreviations 
11 
 
SR  sarcoplasmic reticulum 
TGF-β   transforming growth factor β 
Thr   threonine  
TNF-α   tumor necrosis factor α 
TnI  Troponin I 
TT   twitch tension 
TTP   time to peak  
TUNEL  TdT-mediated dUTP-biotin nick end labeling 
WB   western blot 
β-AR  β-adrenergic receptor 
 
Physical units  
A  ampere 
°C   degree Celsius 
g  gram/ acceleration of gravity on earth 
h  hour 
L   liter 
m  meter 
M   molar (mol/L) 
min  minute 
pH  negative common logarithm of the proton concentration 
sec  second 
V   volt 
 
Prefixes  
k  kilo- 103 
c  centi- 10-2 
m  mili- 10-3 
μ  micro- 10-6 
n  nano- 10-9 
 
 
 
 
 
   Abstract 
12 
 
0. Abstract 
 
The small calcium (Ca2+) binding protein S100A1 is as a critical regulator of cardiomyocyte Ca2+ 
handling thereby enhancing cardiac performance in vivo and in vitro. Our previous studies demonstrated 
that the positive inotropic effects of S100A1 are due to enhanced Ca2+ transients and sarcoplasmic 
reticulum (SR) Ca2+ load in isolated adult cardiomyocytes. These effects are independent of and in 
addition to cAMP-dependent positive inotropic mechanisms. However, inotropic interventions come at 
the risk of arrhythmogenic diastolic Ca2+ leakage when the SR Ca2+ content exceeds the threshold for 
spontaneous diastolic Ca2+ release. In a more recent study we could demonstrate that enhanced Ca2+ 
transients after S100A1 overexpression are associated with a reduced incidence of diastolic Ca2+ sparks 
and Ca2+ waves. These results favor the assumption that S100A1 might reduce the diastolic RyR2 leak, 
thereby impeding the development of pro-arrhythmogenic events.  
Thus, the aim of this work was to investigate the effect of S100A1 on diastolic Ca2+ handling and on the 
impact of Ca2+-triggered arrhythmias in a multicellular system. For this reason, the 3-dimensional tissue 
culture model of Engineered Heart Tissue (EHT) was chosen. Due to its syncytial architecture, EHT 
closely mimics functional alterations, intercellular communication and reverse remodeling of whole 
hearts in vivo despite eased handling and pharmacological as well as therapeutic manipulations. 
Pharmacological stimulation of EHT with endothelin-1 resulted in a heart failure-like phenotype with 
strong impairment of contractile performance. Adenoviral-mediated S100A1 overexpression was able 
to rescue failing EHT and resulted in superior contractility in normal EHT. Triggered contraction 
abnormalities, referred to as after-contractions, were induced by Ca2+ and β-AR stimulation and served 
as a surrogate of SOICR (store-overload-induced-Ca2+-release). S100A1 overexpression significantly 
protected against Ca2+ and β-adrenergic receptor (β-AR) triggered after-contractions in normal and 
failing EHT. Despite persistent abnormal phosphorylation-dependent changes at the RyR2 and altered 
complex formation with accessory proteins, S100A1 overexpression enhanced S100A1/RyR2 
stoichiometry, which seems to be key for S100A1’s effects, combining inotropic and anti-arrhythmic 
potency.  
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1. Zusammenfassung 
 
Das kleine Kalzium (Ca2+) bindende Protein S100A1 ist ein wichtiger Regulator der Ca2+-Homöostase 
in Kardiomyozyten, welches die kardiale Leistungsfähigkeit in vivo und in vitro steigert. Unsere 
bisherigen Untersuchungen zeigten, dass die positive inotrope Wirkung von S100A1 auf erhöhte Ca2+-
Transienten und einem erhöhten sarkoplasmatischen Retikulum (SR) Ca2+ Gehalt in isolierten adulten 
Kardiomyozyten zurückzuführen ist. Diese Effekte sind unabhängig von und zusätzlich zu den cAMP-
abhängigen positiven inotropen Mechanismen. Allerdings können inotrope Interventionen zu einem pro-
arrhythmogenen diastolischen Ca2+-Leck führen, wenn der SR Ca2+-Gehalt die kritische Schwelle für 
die spontane diastolische Ca2+-Freisetzung übersteigt. In einer aktuellen Studie konnten wir zeigen, dass 
die erhöhten Ca2+-Transienten nach S100A1 Überexpression mit einer verringerten Inzidenz für 
diastolische Ca2+-Sparks und Ca2+-Wellen einhergehen. Diese Ergebnisse unterstützen die Hypothese, 
dass S100A1 das diastolische Leck am RyR2 reduzieren und somit die Entwicklung von pro-
arrhythmogenen Ereignissen entgegenwirken kann. 
Daher war das Ziel dieser Arbeit, den Effekt von S100A1 auf die Ca2+-Homöostase und den Einfluss 
auf Ca2+-induzierte ventrikuläre Arrhythmien in einem multizellulären System zu untersuchen. Aus 
diesem Grund wurde das 3-dimensionale Gewebekulturmodell des Engineered Heart Tissue (EHT) 
verwendet. Das EHT hat eine gewebeähnliche Architektur und eignet sich daher, funktionelle und 
molekulare Veränderungen in vitro zu simulieren. Außerdem ist es leicht zu kultivieren und 
pharmakologische und therapeutische Manipulationen sind einfach durchzuführen. 
Die pharmakologische Stimulation der EHT mit Endothelin-1 resultierte in einem Herzinsuffizienz-
ähnlichen Phänotyp mit starker Beeinträchtigung der kontraktilen Funktion. Die adenovirale 
Überexpression von S100A1 konnte die insuffizienten EHTs rescuen und führte zu einer verbesserten 
Kontraktilität in normalen EHTs. Kontraktionsanomalien, die so genannten After-contractions, wurden 
durch Ca2+ und β-Adrenorezeptor (β-AR) Stimulation induziert und dienten als Surrogat der Ca2+-
Überladung des SRs und des so genannten SOICR (store-overload-induced-Ca2+-release). Die 
adenovirale Überexpression von S100A1 schützte normale und insuffiziente EHT vor Ca2+ und β-AR-
induzierten After-contractions. Diese Effekte waren trotz bestehenden abnormalen Veränderungen des 
Phosphorylierungsmusters und einer unveränderten Komplexbildung mit akzessorischen Proteinen am 
RyR2 zu sehen. Die S100A1-Überexpression erhöhte die S100A1/RyR2 Stöchiometrie, die sich als 
Schlüssel für die S100A1-vermittelten Effekte darstellt und damit die inotrope und antiarrhythmische 
Potenz zu kombinieren scheint. 
Introduction 
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2. Introduction 
 
2.1 Epidemiology of heart failure 
Heart failure (HF) belongs to the main causes of deaths worldwide, showing an increasing prevalence 
particularly in Western civilizations.[1, 2] It is a multifaceted syndrome, which manifests itself when 
the heart is unable to supply the whole body adequately with blood.[3] Major symptoms include reduced 
contractile performance, reduced energy utilization, chronic neurohumoral stimulation and an increased 
incidence of tachyarrhythmias.[1, 2, 4] 
Current therapeutic strategies for the treatment of HF are limited to the deceleration of disease 
progression and the attempt to improve cardiac output by reducing neurohumoral activation, increasing 
contractile performance or reducing the incidence of tachyarrhythmias.[1, 2, 4] However, in the majority 
of cases, these measures are unable to reverse the disease progression and might even become 
contraindicative in the long-term.[1, 2, 4] Thus, there is a great need for the development of novel 
innovative therapeutic approaches that are able to stop and reverse HF. Yet, before dealing with novel 
therapeutic concepts, one needs to understand the underlying basic mechanisms controlling 
cardiovascular function in the physiological and pathophysiological state. 
 
 
2.2 Calcium – the main factor controlling cardiomyocyte contractility 
2.2.1 Calcium – an intracellular signaling molecule  
Calcium (Ca2+) is involved in the control of almost all cellular processes: Gene transcription, 
proliferation, muscle contraction and cell death - the small ion seems to be a universal second messenger 
controlling a diverse range of cellular processes.[5, 6] To transmit information, Ca2+ needs to be 
accumulated in the cytosol, where it is precisely controlled by different Ca2+ signaling toolkits, 
coordinating the above mentioned functions.[7-11] Each cell type has its own components of the toolkit, 
comprising a variety of signaling, homeostasis and sensory machineries that enables it to regulate Ca2+ 
signals to its physiology.[6, 12] This allows spatial, temporal and quantitative Ca2+ sensing and sets the 
basis for its versatility.[5, 6, 8] 
In the cytosol, Ca2+ acts by binding to specific targets, the calcium-binding proteins (to which also 
S100A1 belongs, see 2.6).[13] These are mainly homologous proteins containing EF-hand motifs (helix-
loop-helix structural domains in which the Ca2+ ions are coordinated), which either have a very high 
binding affinity for Ca2+ and act as Ca2+ buffers or show Ca2+-dependent target protein interaction and 
act as Ca2+ sensors.[7, 14-16] Despite the great number of known calcium-binding proteins, their exact 
mechanism often remains elusive. 
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2.2.2 Regulation of cardiomyocyte function: Cardiac excitation contraction coupling 
Ca2+ is also the main factor controlling cardiomyocyte (CM) function, including excitation-contraction 
coupling (EC) and contractile response.[17, 18] Oscillations in intracellular Ca2+ concentrations ([Ca2+]i) 
that link cardiomyocyte excitation to myocyte contraction in the whole heart are the basis for each 
heartbeat. The sarcoplasmic reticulum (SR) is the Ca2+ store within the CM and Ca2+ release from this 
internal store activates the contractile machinery. 
EC coupling is initiated with the depolarization of the plasma membrane that activates voltage gated L-
type Ca2+ channels (LTCC) which are located in the t-tubules and plasma membrane (Fig. 1.1). [19, 20] 
This causes Ca2+ influx, however the amount is not sufficient to induce contraction.[21] This rather small 
increase in local [Ca2+]i triggers opening of the ryanodine receptor 2 (RyR2), which are located in the 
SR membrane and the so called Ca2+ induced Ca2+ release (CICR) leads to extrusion of Ca2+ from the 
SR into the cytoplasm (Fig. 1.2).[22-24] Due to the ultrastructure of cardiomyocytes, t-tubules and 
junctional SR form dyads, where 10–25 LTCCs and 100–200 RyR2 are clustered to one couplon.[18, 
21, 25] Hence, LTCC-induced Ca2+ influx stimulates Ca2+ release from adjacent RyR2, that manifest as 
Ca2+ spark and can further synchronize neighboring RyR2 across the whole couplon (coupled gating). 
[17, 18, 26, 27] Synchronous activation of all couplons rises [Ca2+]i from about 100nM to 1µM and 
finally activates contraction by the binding of Ca2+ to Troponin C, which induces conformational 
changes at the myofilaments and initiates action-myosin crossbridge (Fig. 1.3).[6, 17, 18, 21, 28]  
This systolic Ca2+ rise and following contraction is terminated by the rapid inactivation of LTCC and 
RyR2 by rising [Ca2+]i.[29] Furthermore, the sodium-calcium-exchanger (NCX) and the SR Ca2+-
ATPase 2 (Serca2), which are located in the plasma membrane and in the SR membrane, respectively, 
are activated by rising [Ca2+]i.[18] During diastole, both extrude Ca2+ from the cytoplasm into the cytosol 
or back into the SR (Fig. 1.4, 1.5). Thereby, systolic Ca2+ influx through the LTCC matches diastolic 
Ca2+ extrusion through the NCX and systolic SR Ca2+ extrusion through the RyR2 matches diastolic 
Ca2+ uptake through Serca2.[18, 30-32] Importantly, Ca2+ flux is always balanced, providing the basis 
for constant Ca2+ cycling during EC coupling.[18, 33] Serca2 activity is further regulated by 
phospholamban (PLB), a pentameric protein that inhibits Serca2 activity by reversible interaction (Fig. 
1.5).[20, 31, 34] 
In diastole, the RyR2 is normally inactive. However, stochastic diastolic Ca2+ release can occur. These 
resting sparks are normally rare and spatial isolated, so that they do not trigger Ca2+ release from other 
couplons and are not able to initiate contraction.[26, 35]  
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Figure 1: Cardiac EC coupling 
Left: Basal EC coupling in normal CM: During systole, action potential-dependent opening of the LTCC enables 
Ca2+ entry (1), triggering Ca2+ induced Ca2+ release from the SR via RyR2 (2) that activates myoﬁlament 
crossbridge and mechanical contraction (3). During diastole, SR Ca2+ resequestration occurs through NCX (4) and 
Serca2 (5), allowing Ca2+ dissociation from the myoﬁlaments and initiation of relaxation. To maintain EC coupling, 
Ca2+ extrusion always balances Ca2+ entry.  
Right: EC coupling during β-AR stimulation: β-AR stimulation (6) activates PKA (7), which increases 
phosphorylation of PLB (8), TnI (9), LTCC (10) and RyR2 (11). This increases Ca2+ flux during EC coupling and 
acts positive inotropic (=increased force) and positive lusitropic (=facilitated relaxation). Adapted from [36-38] 
 
 
2.2.3 Fine-tuning contractile force: Modulation of calcium signaling 
β-adrenergic receptor (β-AR) stimulation is one way of the body to adjust cardiac output to the needs of 
increasing oxygen consumption. On the cellular level, β-AR stimulation modulates amplitude and 
duration of Ca2+ transients, resulting in positive inotropic (=increased force) and positive lusitropic 
(=facilitated relaxation) actions.[39, 40]  
Agonist binding to β-ARs activates the adenylate cyclase (AC) (Fig. 1.6), which increases cyclic 
adenosine monophosphate production (cAMP).[41] cAMP in turns activates protein kinase A (PKA) 
(Fig. 1.7) that phosphorylates its downstream target as LTCC, PLB, RyR2 and Troponin I (TnI) (Fig. 1 
right).[21, 42-44] Phosphorylation of PLB releases Serca2 which increases the activity of the ATPase 
and facilitates SR Ca2+ uptake (Fig. 1.8).[31, 34] This seems to be the major reason for increased 
lusitropy.[18, 21] Furthermore, phosphorylation of TnI facilitates Ca2+ dissociation from the 
myofilaments, increasing relaxation (Fig. 1.9).[18] Increased Serca2 activity also leads to increased SR 
load. Besides, phosphorylation of LTCC increases systolic Ca2+ influx (Ica) and RyR2 phosphorylation 
results in enhanced open probability (Po) of the channel pore (Fig. 1.10 and 1.11). All together, the 
effects increase systolic [Ca2+]i and Ca2+ transients that act positive inotropic.[39, 40, 42, 45] Increased 
[Ca2+]i furthermore enhance Ca2+/calmodulin-dependent protein kinase (CamKII) activity, which also 
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phosphorylates LTCC, PLB and RyR2. Although phosphorylation sites are distinct from the PKA site, 
CamKII phosphorylation also operates positive inotropic and lusitropic. 
Lusitropy and inotropy are further regulated at the myofilaments. Upon cardiomyocyte stretch, on the 
one hand, sarcomere overlapping becomes more efficient and results in stronger contraction; on the 
other hand Ca2+ sensitivity increases, facilitating relaxation.[21, 46] 
 
 
2.3 Heart failure – from deranged calcium handling to ventricular 
arrhythmias 
Abnormal Ca2+ handling has been identified as a hallmark of failing cardiomyocytes and is held 
responsible for the progression towards HF.[42, 47] This leads to defective EC coupling, which is mainly 
characterized by reduced SR Ca2+ load, reduced systolic Ca2+ transient amplitudes, increased Ca2+ decay 
and increased diastolic [Ca2+]i.[9, 48-50] It is the result of altered expression, function and interplay of 
proteins required for Ca2+ homeostasis, however, deducing cause and effect is often difficult if not 
impossible.[51, 52]  
Despite maintained LTCC activity, reduced Serca2 expression and enhanced suppression by PLB (by 
either increased phosphorylation or reduced Serca/PLB ratio) together lead to reduced SR Ca2+ load 
(Fig. 2.1).[9, 48, 52, 53] Reinforcing this effect, increased expression of NCX results in an improved 
competition of NCX with Serca2 for diastolic Ca2+ extrusion (Fig. 2.2).[54] Systolic RyR2 Ca2+ release 
is also reduced (possibly by RyR2 hyperphosphorylation, see 2.5.1), supporting negative impact on Ca2+ 
transient amplitude (Fig. 2.3).[55] To maintain contractile response, β-AR activity might be able to 
compensate for defective EC coupling at the beginning; however, chronic sympathetic overdrive results 
in desensitization of β-ARs, further contributing to contractile deterioration (Fig. 2.4).[56] On the other 
hand, RyR2 function is also compromised in diastole, as its proper closure is impaired (Fig. 2.5). This 
increases the diastolic leak, which manifests itself in an increased frequency of Ca2+ sparks.[50, 57] 
When Ca2+ sparks get more pronounced, these normally exclusive stochastic events become more 
frequent and synchronized.[58-62] Due to residual β-AR activity, the SR Ca2+ load can exceed the 
threshold for spontaneous diastolic Ca2+ leakage (Fig. 2.6).[59] This can lead to Ca2+ waves that 
propagate across the whole cell.[21]  
As NCX expression is increased, the increased diastolic Ca2+ is mainly extruded in exchange with 
sodium (Na+). In addition, the sodium-potassium-ATPase (Na+K+-ATPase) activity is reduced, as well 
as the inward rectified potassium current (IK1), which leads to reduced intracellular potassium 
concentrations ([K+]i) (Fig. 2.7).[63, 64] In combination, increased intracellular sodium concentrations 
([Na+]i) and reduced [K+]i destabilize the resting potential, so that Ca2+ waves can trigger delayed after-
polarizations (DADs) (Fig. 2.8).[26, 58, 59] When these depolarisations exceed the threshold for action 
potential (AP) generation, they can trigger mature APs, leading to extra-contractions that can results in 
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ventricular arrhythmias.[65] Aggravating this mechanism, prolonged AP duration also occurs in failing 
CM. [21, 66-68] 
Clinically, it is assumed that about 50% of ventricular tachyarrhythmias in ischemic and non-ischemic 
cardiomyopathies originate from non-reentrant mechanisms such as DADs.[69] This phenomenon also 
explains the contraindication of positive inotropic agents for the treatment of heart failure, as they indeed 
improve inotropy in the short term, but might trigger ventricular arrhythmias in the long term.  
 
Figure 2: EC coupling in failing CMs 
Left: Reduced Serca2 activity impairs SR Ca2+ resequestration and diminishes SR Ca2+ load that results in 
contractile dysfunction (1). Additionally, increased NCX activity (2) and reduced Na+K+-ATPase (7) activity lead 
to increased [Na+]i. Right: Furthermore, the resting potential is destabilized, reducing [K+]i (7). As the RyR2 is 
leaky in diastole (5), residual β-AR activity, which increases the diastolic Ca2+ leak (5), can trigger DADs (blue 
inlet, 8), which might result in mature action potential generation and finally lead to ventricular arrhythmias. 
Adapted from [37] 
 
 
 
2.4 Special focus on the RyR2: SR Ca2+ release channel and scaffolding 
protein 
RyR are homotetrameric receptors with high molecular weight. They have a large cytosolic N-terminal 
domain, which serves as scaffold for the binding of regulatory proteins and the intramembrane C-
terminal domain which forms the channel pore.[70] 
RyR2 are important regulators of systolic and diastolic Ca2+ flux. In systole, they promote SR Ca2+ 
release and form the basis for myocyte contraction, whereas in diastole they are supposed to be sealed 
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to maintain relaxation. Thus, RyR2 activity needs to be tightly yet flexibly regulated in order to sustain 
cellular function.[5] Therefore, RyR2 opening is not only controlled by cytosolic and luminal [Ca2+] but 
also by phosphorylation and other post-translational modifications (PTMs) as well as by the binding of 
accessory proteins such as calmodulin (CaM), FK506 binding protein 12.6 (FKBP12.6), soluble 
resistance-related calcium-binding protein (sorcin) and also S100A1.[71] 
 
2.4.1 Regulation of RyR2 by phosphorylation 
RyR2 is targeted both by PKA and CamKII at the N-terminal domain. Both enzymes interact with the 
RyR2 in cardiomyocytes and phosphorylate it under physiological conditions.[21, 43]  
Upon β-AR stimulation, increased PKA activity enhances phosphorylation at serine 2808.[72, 73] This 
activates the RyR2 and increases systolic Ca2+ release, but also the incidence of diastolic Ca2+ sparks.[44, 
74, 75] Furthermore, PKA also phosphorylates RyR2 at serine 2030, which is reported to increase RyR2 
activity as well.[44, 76, 77] However, this phosphorylation site is not well analyzed so far.  
Upon increased [Ca2+]i and CaM activation, CamKII phosphorylation occurs at serine 2814. CamKII-
mediated RyR2 phosphorylation also activates RyR2 and increases Po in systole.[21] Similarly, it also 
increases Ca2+ sparks frequency in diastole.[78, 79] 
To maintain cellular equilibrium, dephosphorylation is sustained by the protein phosphatases PP1 
(serine 2808) and PP2a (serine 2814), which are also associated to the RyR2.[77]  
In heart failure, general phosphatase activity is enhanced, but local activity of PP1 and PP2a at the RyR2 
is reduced.[53] Despite generally maintained PKA activity, this reduced phosphatase activity in 
combination with increased cAMP levels can lead to hyperphosphorylation of RyR2 at serine 2808.[44, 
80] This phosphorylation may be responsible for the increased diastolic Ca2+ leak in failing 
cardiomyocytes; however, this effect is discussed quite controversially at presence.[74, 75, 81-83]  
CamKII activity is also increased in failing cardiomyocytes, which leads to increased serine 2814 
phosphorylation.[84, 85] Recent work suggests that this phosphorylation is the major reason for the 
increased diastolic Ca2+ leak and that PKA-mediated phosphorylation at serine 2808 has only minor 
impact on RyR2 regulation.[39, 40, 86-88] 
 
2.4.2 Regulation of RyR2 by accessory proteins 
At their large N-terminal cytosolic domain, RyR2 tetramers are occupied by different accessory proteins, 
which also modulate channel gating properties in the pore region. But also the C-terminal domain of 
RyR2 is occupied by accessory proteins. 
In the SR, junctin and triadin bind to the C-terminal part of RyR2. These proteins are associated with 
calsequestrin (CSQ), the primary Ca2+-binding protein of the SR.[89] Triadin establishes a functional 
connection between RyR2 and CSQ, enabling adjustment of SR Ca2+ release to SR Ca2+ load.[71, 90] 
On the N-terminal domain, proteins like CaM, FKBP12.6 and sorcin bind to the RyR2. 
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CaM is a small Ca2+ binding protein that interacts with the RyR2 in a Ca2+ dependent manner.[71, 91, 
92] CaM:RyR2 stoichiometry is reported to be 1:1, whereas apo-CaM and Ca2+ bound CaM can bind 
with equal affinity.[92] Planar lipid bilayer recordings of RyR2 demonstrated that CaM inhibits RyR2 
Po at low as well as at high cytosolic and luminal [Ca2+].[30, 91] Contrary, overexpression of CaM in 
intact cardiomyocytes increased Ca2+ transient amplitude and decay, however these effect were mainly 
due to enhanced CamKII activity.[25] In HF, CaM shows reduced affinity for RyR2.[93] However, it is 
assumed that beat-to-beat variability in CaM binding or dissociation do not account for increased RyR2 
activity under e.g. β-AR stimulation.[71, 92]   
FKBP12.6, also known as calstabin2, is supposed to have a major role on RyR2 coupled gating.[27] 
Four molecules are reported to bind per RyR2 tetramer under physiological conditions, however latest 
research indicated that this number is overestimated and corrected it to 20-30% of RyR2 that are 
occupied by FKB12.6.[94] FKBP12.6 functionally couples RyR2 clusters, stabilizing the receptor and 
inhibiting subconductance state.[27] In failing cardiomyocytes, RyR2 hyperphosphorylation is 
supposed to mediate FKBP12.6 dissociation, thereby prompting the diastolic Ca2+ leak.[44, 95] 
However, the so called “Marks paradigm in HF” is still discussed controversially and current data also 
suggests that FKBP12.6 has not such a strong impact on RyR2 function.[44] 
Additionally, sorcin also binds to the RyR2 already to resting [Ca2+].[96, 97] In saponin-skinned 
cardiomyocytes, addition of sorcin reduced Ca2+ transients and Ca2+ decay rate but also decreased Ca2+ 
spark frequency.[97-99] This reduces the EC coupling gain and might be a negative feedback 
mechanism to quench CICR. Furthermore, sorcin is supposed to translocate quickly upon increasing 
[Ca2+]i, indicating that sorcin might be able to change its location during EC coupling [Ca2+].[97] 
However, the exact consequences of this translocation remain unclear. 
 
2.4.3 Regulation of RyR2 by redox-modification  
Additionally to alterations in phosphorylation status, other PTMs of the RyR2, such as oxidation, 
nitrosylation or glutathionylation, can affect its function. RyR2s contain 80–100 cysteines per monomer 
with approximately 25–50 in the reduced state. An additional six to eight are considered hyperreactive, 
making them suitable for redox modification.[100, 101] Current research focuses on the activation of 
RyR2 by cysteine nitrosylation (SNO): On the one hand, previous work demonstrated that enhanced 
RyR2-SNO increased mean Po in lipid bilayer recordings of RyR2 preparations.[101] On the other hand, 
inhibition of NOS1-mediated RyR2-SNO increased Ca2+ spark frequency and Ca2+ wave in isolated 
cardiomyocytes.[102, 103] In general, protein-nitrosylation is supposed to be cardioprotective.  
In HF, increased oxidative stress results from the formation of reactive oxygen species (ROS) (e.g. 
superoxide anion, hydrogen peroxide, and hydroxyl radical). These compounds are capable of 
interacting with the reactive cysteines, causing RyR2 oxidation.[85, 103-109] This can change RyR2 
function and increase the diastolic Ca2+ leak; however, there is still a lot of research ongoing and the 
exact interplay of different redox-modifications needs to be understand in greater detail.  
Introduction 
21 
 
 
 
Figure 3: The RyR2 macrocomplex: Ca2+ release channel and scaffolding protein 
Left: On the N-terminal domain, RyR2 is subjected to phosphorylation by PKA and CamKII, which increases 
RyR2 activity. Further regulation occurs from the binding of accessory proteins that modulate RyR2 activity. On 
the luminal side, SR Ca2+ load and RyR2 opening is also controlled by accessory proteins. 
Right: In heart failure, hyperphosphorylation by PKA or CamKII might mediate the diastolic Ca2+ leak. Potential 
dissociation of CaM and FKBP12.6 support this effect. Modified from [110, 111]  
 
 
2.5 S100A1 - function and fiction  
2.5.1 S100A1 structure and expression pattern 
S100A1 belongs to the family of S100 proteins, a group of small Ca2+ binding proteins exclusively 
expressed in vertebrates. S100 proteins control numerous cellular and molecular functions including 
proliferation, differentiation, cell survival and motility as well as protein phosphorylation, NO 
homeostasis and Ca2+ handling.[112, 113]  
In general, S100 proteins reside as dimers, whereas their tertiary structure compromises two EF hand 
motifs that recognize Ca2+ and change their 3-dimensional structure, enabling target protein 
recognition.[112-115]  
In special, S100A1 has a high Ca2+ affinity, which is further enhanced by PTMs such as s-nitrosylation 
or s-glutathionylation. [116-119] Nevertheless, it has low Ca2+ binding capacity, which makes it an 
optimal intracellular Ca2+ sensor. 
S100A1 shows highest abundance in cardiac muscle and it is expressed to lower levels in skeletal 
muscle, the brain and the kidneys. It shows highest expression levels in the left ventricle and lower 
abundance in the right ventricle and the atria. In the heart, S100A1 mainly resides in CM, with no 
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evidence for expression in cardiac ﬁbroblasts. To a small extent, S100A1 is also expressed in endothelial 
cells and the vasculature.[120-124]  
  
2.5.2 S100A1 action in cardiomyocytes 
S100A1 has been identified as a major regulator of cardiovascular function, controlling the Ca2+ driven 
networks in cardiomyocytes. S100A1 was shown to interact with structures in the mitochondria, at the 
myofilaments and at the SR (Fig. 4). 
 
 
Figure 4 : Conceptual framework of S100A1 target structures in CM.  
S100A1 regulates the Ca2+ driven key compartments in CM: the sarcoplasmic reticulum, the sarcomere and the 
mitochondria. Modified from [125] 
 
At the mitochondria, S100A1 increases energy generation and utilization, as it interacts with key factors 
from the ATP-producing machinery e.g. with the F1-ATPase of complex V and the adenosine nucleotide 
translocator (ANT) (Fig. 5.4).[126, 127]  
At the myofilaments at the I-Band, S100A1 interacts with the PEVK-domain of the giant protein 
titin.[128, 129] Titin normally contributes to the passive tension of the myofilaments, as actin binding 
to the PEVK-domain is supposed to inhibit action/myosin crossbridge and increase diastolic 
stiffness.[28, 130-132] S100A1/titin interaction therefore might liberate actin before active contraction, 
thereby reducing pre-contractile passive tension and facilitating contraction. Furthermore, S100A1 
might decrease the Ca2+ sensitivity of the myofilaments (Fig. 5.3).[133] However, the mechanism for 
this effect is still unclear.  
At the SR, S100A1 facilitates Ca2+ cycling by regulating Serca2 and RyR2 activity. In diastole, 
S100A1/Serca2 interaction enhances Serca2 activity, augmenting SR Ca2+ load and facilitating 
relaxation (Fig. 5.1). In systole, S100A1 ameliorates RyR2 activity and improves Ca2+ extrusion (Fig. 
5.2).[134, 135] In combination with the increased SR Ca2+ load, enhanced systolic Ca2+ transients 
manifest in positive inotropy and increased EC coupling gain.[136] As enhanced SR and myofilament 
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ATPase activity rise energy demands, S100A1 might be able to meet this demand by increasing ATP 
generation and availability. 
In general, S100A1 effects are similar to β-AR stimulation; however, S100A1 acts independent of 
known cAMP/ PKC pathways, enhancing target protein activity by direct interaction.[137]  
 
 
 
Figure 5: S100A1 actions in cardiomyocytes 
Enhanced Serca2 activity increases SR Ca2+ resequestration and SR Ca2+ load (1), facilitating relaxation and 
systolic Ca2+ release via RyR2 (2). Together, this results in improved EC coupling gain and mechanical force 
generation. Additionally, myoﬁlament stiffness is decreased alleviating relaxation (3). Finally, enhanced 
mitochondrial ATP production and retrieval matches increased energy demands (4). Modified from [36, 125] 
 
 
2.5.3 S100A1 in heart failure: Development of S100A1 gene therapy 
Different studies revealed diminished S100A1 expression in failing human hearts which could be 
confirmed in vitro and in various HF animal models in vivo.[134, 135, 138-140] 
However, the actual rationale for S100A1 genetically targeted therapy originated from comprehensive 
studies in S100A1 transgenic and knockout mice, which showed opposite phenotypes when subjected 
to cardiac stress and underlined the importance of S100A1 for proper cardiomyocytes function.[138, 
141, 142] First experiments with adenoviral-mediated S100A1 overexpression in normal and failing 
isolated rat and human cardiomyocytes confirmed increased Ca2+ transients and SR Ca2+ load.[134, 143-
145] Further in vivo experiments with experimental HF in mice and rats using AAV-vectors with 
cardiomyocyte-specific S100A1 expression confirmed success and feasibility of S100A1 re-expression, 
resulting in beneficial long-term inotropic, anti-hypertrophic and anti-apoptotic therapeutic effects and 
restored energy homeostasis in the failing myocardium.[135, 139, 146] Although not all effects of 
S100A1 in cardiomyocytes and in the heart have been clarified, these studies clearly demonstrate 
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efficacy of viral-mediated S100A1 gene therapy and foster the development of positive inotropic 
S100A1 gene therapy for chronic heart failure.  
 
2.5.4 S100A1 positive inotropic and anti-arrhythmic potential?  
As described above, in failing cardiomyocytes, the reload of unstable SR (e.g. under β-AR stimulation) 
with Ca2+ can trigger diastolic SR Ca2+ leakage, as the SR load exceeds the critical threshold for 
spontaneous diastolic Ca2+ release (Fig. 6 right).[26, 37, 58, 59] This can induce delayed after-
depolarizations which can result in lethal ventricular arrhythmias. 
S100A1 enhances the SR Ca2+ load in a similar way than β-AR stimulation (Fig. 6 left). Raising concerns 
about this potential pro-arrhythmogenic potential of positive inotropic S100A1 gene therapy prompted 
most recent studies in isolated CMs. Surprisingly, these studies indicated that adenoviral-mediated 
S100A1 overexpression in quiescent normal CMs and failing CMs decreased SR Ca2+-spark frequency 
and prevented β-AR-triggered compound Ca2+-sparks and Ca2+ waves (Fig. 6 left, right) (unpublished 
data).[147, 148] These effects were independent of PKA-mediated RyR2 phosphorylation. Thus, despite 
persistent changes in RyR2 phosphorylation, S100A1 overexpression rather seems to prevent diastolic 
Ca2+ leakage and therefore might act positive inotropic and anti-arrhythmic. 
 
Figure 6: Schema of S100A1 effects on Ca2+ transients, SR Ca2+ load and the development of the diastolic 
Ca2+ leak in isolated CM 
Left: In normal CMs, β-AR stimulation increases SR Ca2+ load and Ca2+ transient amplitudes, as well as diastolic 
Ca2+ release. S100A1 has similar effects on SR Ca2+ load and Ca2+ transient amplitudes; however it does not trigger 
diastolic Ca2+ release.  
Right: In failing CMs, the threshold for spontaneous Ca2+ release is reduced, so that diastolic Ca2+ release already 
occur under basal conditions. β-AR stimulation aggravates the diastolic Ca2+ leak, further increasing diastolic Ca2+ 
release, which manifests as Ca2+ waves. However, S100A1 inhibits the diastolic Ca2+ leak despite maintained 
increased SR Ca2+ load. Modified from [149, 150]  
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2.6 Aim of the study 
The investigation of the potential anti-arrhythmic mechanism of S100A1 has only been performed in 
single cells so far but Ca2+ regulation in the multicellular heart is far more complex. So it remained 
unclear, if the inhibition of the diastolic Ca2+ leak also impedes mature arrhythmogenic contractions. 
Furthermore, the exact mechanism and effects of S100A1 on RyR2 modifications remained unclear, as 
most studies propose normalized RyR2 phosphorylation and restored binding of accessory proteins as 
prerequisite for proper RyR2 function. Although a most recent study demonstrated that S100A1 effects 
are irrespective of PKA-mediated RyR2 phosphorylation, CamKII-mediated RyR2 phosphorylation has 
not been analyzed so far. 
Thus, the aim of this work was to investigate the effect of S100A1 on Ca2+-and β-AR-triggered cellular 
arrhythmias in a multicellular system and to determine changes in RyR2 phosphorylation or complex 
formation.  
For that reason, I chose the model of Engineered Heart Tissue, which represents a 3-dimensional tissue 
culture model composed of neonatal rat heart cells. EHT outmatches conventional 2-dimensional cell 
culture, as neonatal rat cells (whole heart isolates) are cultivated in a collagen matrix under cyclic stretch 
(referred to as loaded conditions). After almost two weeks of maturation, this cell culture model 
resembles adult myocardium and forms a functional syncytium.[151, 152] Still, cellular or 
pharmacological manipulations as well as biochemical analysis are as easy to conduct as in conventional 
2-dimensional cultures. Furthermore, functional force analyses are carried out under isometric 
conditions, which is an improvement over conventional cell shortening analysis in adult rat 
cardiomyocytes. Still, it is not as complex as a whole body, as compensatory mechanisms or secondary 
effects do not bias outcomes in this model. 
 
Accordingly, the first goal of this study was to induce a HF-like phenotype in EHT and to develop a 
stimulation protocol, where potential arrhythmogenic events can be analyzed on a contractile level. The 
second part aimed to confirm the inotropic effects of 100A1 gene transfer in normal and HF-like EHT 
before investigating S100A1’s potential anti-arrhythmic effects. The last part focused on the underlying 
mechanisms that might mediate S100A1 anti-arrhythmic effects. 
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3. Materials and Methods 
3.1 Materials  
3.1.1 Equipment 
Device  Purchased from 
37°C water bath  Karlheinz Dosch 
Aspirator for cell culture  Neolab 
Centrifuge Rotina 420 R  Hettich Zentrifugen 
Custom-designed organ bath equipment  Föhr Medical Instruments 
EHT casting molds Self-made 
Electrical stimulator STI-08  Föhr Medical Instruments 
Force transducer Ing. Büro Jäckel, Hanau 
Heating block Neolab 
Hera Safe Laminar Flow  Thermo Electron cooperation  
Incubator Hera cell 150  Thermo Electron cooperation  
McILWAIN Tissue Chopper The mickle laboratory engineering co. Hd 
Microscope for cell culture Leica 
My iQ Single Color Real-Time PCR Detection 
System  
Bio Rad  
NanoDrop Spectrophotometer ND-1000  Peqlab Biotechnologie GmbH  
Neubauer counting chamber  Brand  
Odyssey Infrared Imaging System +Software  LI-COR Biosciences  
Organ bath solution (custom design) FMI 
pH meter WTW 
Pipetboy accu IBS Integra Biosciences  
Pipettes Eppendorf 
Power Pac 300  Bio Rad  
Precellys Homogeniser Peqlab 
Recording System (Powerlab, Measuring Amplifier) ADI Instruments 
Rotor for ultracentrifuge SW41 Ti Beckman 
Rotor wheel Neolab 
Shaker Hermed SW, Neolab 
Stretching device Precision engineering workshop University 
of Heidelberg 
Table top centrifuge  Roth  
Tank blot  University Heidelberg  
Thermomixer 5436  Eppendorf 
U-2000 Spectrophotometer  Hitachi  
Ultracentrifuge WXUltra 80 Thermo Electron cooperation  
Vortex  Bender und Hobein AG  
X cell Sure Lock Mini-cell  Invitrogen  
 
3.1.2 Consumables 
 
Item Purchased from 
0.5, 1.5, 2.0 ml tubes  Sarstedt 
5ml, 15ml, 50 ml tubes  Greiner Bio-One GmbH  
Balance paper VWR 
Cell culture plates and dishes Greiner Bio-One GmbH, Nunc 
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Cell scraper Greiner Bio-One GmbH 
Cell strainer BD 
Detachable needles BD 
Dialysis cassette 10000 MWCO Thermo Scientific 
Disposable scalpel Feather 
Filter paper 0.5mm for western blot Neolab 
Immobilon-FL PVDF membrane  Millipore  
Magnetic stir bar Neolab 
Microscope cover glasses  Marienfeld GmbH&Co.KG  
Microscope slides  Thermo Scientific  
Pipette tips with filters Sarstedt 
Serological pipettes  Greiner Bio-One GmbH  
Sterile syringes  BD  
Ultracentrifugation tubes Herolab 
 
3.1.3 Chemicals and reagents 
Common chemicals were obtained from AppliChem, CARL ROTH GmbH, Merck, Serva and Sigma-
Aldrich. Some selected chemicals, reagents and enzymes are listed below: 
 
Chemical/ Reagent Purchased from  
CaCl2 Sigma-Aldrich 
Chick embryo extract Seralab biologicals  
Collagen Type I, rat tail  Promocell 
Collagenase Cellsystems 
DEPC water Roth 
DMEM high glucose PAA 
DMEM low glucose PAA 
DNAse I (4.1 mg/ml) Roche  
Dulbecco’s PBS (Ca2+-free and Mg2+-free)  PAA 
Duolink In Situ Detection Reagents Red Olink 
Duolink In Situ PLA probe anti-Mouse PLUS Olink 
Duolink In Situ PLA probe anti-Rabbit MINUS Olink 
Fetal Calf Serum (FCS) gold EU approved  PAA 
Heparin-Natrium 25 000 (25000 I.E.) ratiopharm 
Horse serum PAA 
I-block blocking buffer LI-COR Biosciences 
In situ cell death detection kit TRD Roche 
Insulin Insuman Rapid 40 I.E./ml Sanofi Aventis 
iQ SYBR Green Supermix Bio Rad  
iScript cDNA Synthesis Kit  Bio Rad  
Isoproterenol bistitrate salt Sigma-Aldrich 
Laminin Sigma-Aldrich 
L-glutamine, 200 nM PAA 
Matrigel BD 
Medium 199  Sigma-Aldrich  
Penicillin-Streptomycin (10 000 U/ 10 mg/ml)  PAA 
Phosphatase inhibitor 1,2,3 Sigma-Aldrich  
Protease inhibitor tablets  Roche  
Protein A/G PLUS-Agarose Santa Cruz 
Protein standard for SDS-PAGE  New England Biolabs 
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Thiopental Inresa (5 mg/10 ml) Inresa Arzneimittel GmbH 
Tris-glycine gels (4-20 %) ANAMED 
Trizol reagent  Invitrogen  
Tropix I-Block Applied Bioscience 
Trypsin-EDTA (0.05 %/ 0.02 %) PAA 
Vectashield Mounting Medium with DAPI  LINARIS  
 
3.1.4 Primers 
All primers were obtained from Eurofins MWG Operon and annealing temperature optimized by a 
temperature gradient PCR. Collagen-1 primer was obtained from Life Technologies, which do not 
give information about primer sequences.  
 
Name Gene 
name 
Primer forward Primer reverse Size 
(bp) 
Annealing 
Temp 
18s Rn18s 5´- TCA AGA ACG AAA 
GTC GG – 3´ 
5´- GTG ATG CCC TTA 
GAT GTC C – 3´ 
488 57-63.5 
ANP Nppa 5`-TGC CGG TAG AAG 
ATG AGG TC  -3` 
5`-TGC TTT TCA AGA 
GGG CAG AT  -3` 
205 63.5 
Collagen-
1 
Col1A - - - 60 
CTGF Ctgf 5`-GAG GAA AAC ATT 
AAG AAG GGC AAA -3` 
5`- CGG CAC AGG TCT 
TGA TGA -3` 
235 63.5 
GFP Egfp 5`- TGA CCT ACG GCG 
TGC AGT GC -3` 
5`- TGC TGG TAG TGG 
TCG GCG AG  -3` 
361 63.5 
ICAM-1 Icam1 5’- CTG TCG GTG CTC 
AGG TAT CC -3’ 
5’- CCA ACT TCT CAG 
TCA CCT CC -3’ 
620 63.5 
IL-6 Il6 
 
5´- CTT CCA GCC AGT 
TGC CTT CT -3` 
5´- GAG AGC ATT GGA 
AGT TGG GG -3` 
496 57 
NCX Slc8a1 5´- GCT CAT ATT ACT 
GTA AGA AAG GGG TG -
3` 
5´- GGC GGC GCT TCC 
CAC AAT GG -3` 
377 57 
RyR2 Ryr2 TAA CCT ACC AGG CCG 
TGG AT -3` 
GCT GCG ATC TGG 
ATA AGT TCA A  -3` 
114 57 
S100A1 S100a1 5`-CCA TGG AGA CCC 
TCA TCA AT  -3` 
5`-TTG AAG TCC ACT 
TCC CCA TC  -3` 
210 63.5 
Serca2a Atp2a2 
 
5`- TGA GAC GCT CAA 
GTT TGT GG  -3` 
5`-ATG CAG AGG GCT 
GGT AGA TG  -3` 
189 63.5 
SMA Acta2 5´- TGC TGG ACT CTG 
GAG ATG -3` 
5´- GTG ATC ACC TGC 
CCA TC -3` 
292 63.5 
TGF-β1 Tgfb1 5`-ACC TGC AAG ACC 
ATC GAC ATG -3` 
5`- CGA GCC TTA GTT 
TGG ACA GGA T -3` 
85 63.5 
 
3.1.5 Antibodies 
 
Primary 
Antibody 
Clonality Host Application Molecular 
weight 
(kDa) 
Dilution Obtained 
from 
Calmodulin Monoclonal  
EPR5028 
Rabbit Duolink 17 1:50 Epitomics 
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Calsequestrin Polyclonal Rabbit WB 55 1:2000 Affinity 
Bioreagents 
CamKII Monoclonal 
IgG1  
G-1 
Mouse WB 50 1:1000 Cell 
signaling 
Connexin43 Monoclonal 
IgG1 
4E6.2 
Mouse WB 43-47 1:1000 Millipore 
FKBP12.6 Polyclonal Rabbit Duolink 12 1:50 Novus 
biologicals 
GFP Polyclonal Mouse WB 27 1:30000 Clontech 
Glyceraldehyde-3-
Phopsphate-
Dehydrogenase 
(GAPDH) 
Monoclonal 
IgG1 
6C5 
Mouse WB 38 1:30000 Millipore 
Phospho-Connexin 
43 (Ser368) 
Polyclonal Rabbit WB 43-47 1:1000 Millipore 
Phospholamban Monoclonal  
IgG2a 
sD12 
Mouse WB 5-25 1:5000 Thermo 
Scientific 
Phospho-
Phospholamban 
(Ser16) 
Polyclonal Rabbit WB 5 1:5000 Upstate 
Phospho-
Phospholamban 
(Thr17) 
Polyclonal Rabbit WB 5 1:5000 Badrilla 
Phospho-RyR2 
(Ser2808) 
Polyclonal Rabbit WB 350 1:1000 Badrilla 
Phospho-RyR2 
(Ser2814) 
Polyclonal Rabbit WB 350 1:1000 Badrilla 
Ryanodine 
Receptor  
Monoclonal 
IgG1 
C3-33 
Mouse Duolink 350 1:50 Abcam 
Ryanodine 
Receptor  
Monoclonal 
IgG1 
C3-33 
Mouse WB/ IP 350 1:1000 Thermo 
Scientific 
S100A1 Polyclonal Rabbit WB/ 
Duolink/ IF 
10 1:1000/ 
1:50/1:200 
Acris 
Serca2 Polyclonal  
N-19 
Goat WB 100 1:2000 Santa Cruz 
s-Nitroso-Cysteine 
(SNO-Cys) 
Polyclonal Rabbit Duolink --- 1:50 Sigma-
Aldrich 
Sorcin Polyclonal Rabbit Duolink 12 1:50 Acris 
α-Actinin 
(sarcomeric) 
Monoclonal 
IgG1 
EA-53 
Mouse IF 100 1:800 Sigma 
Aldrich 
 
Secondary Antibody Host Emission Application Dilution Obtained from 
Anti-goat donkey 680 WB 1:10000 LI-COR Biosciences 
Anti-mouse goat 680/800 WB 1:10000 LI-COR Biosciences 
Anti-rabbit goat 680/800 WB 1:10000 LI-COR Biosciences 
Anti-mouse  goat 488/568 IF 1:200 Invitrogen 
Anti-rabbit goat 488/568 IF 1:200 Invitrogen 
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3.1.6 Prepared buffers, solutions and media 
Buffers and stock solutions were prepared in deionized water unless noted otherwise. Buffers were 
titrated with sodium hydrochloride. 
 
Buffer/Solution Preparation Protocol 
1.3 g/ml CsCl  402.4 mg/ml in H2O 
1.4 g/ml CsCl 548.3 mg/ml in H2O 
ACM medium 5.4 mM KCl, 3.5 mM MgSO4, 0.05 mM NaPyruvate, 20 mM 
NaHCO3, 10 mM glucose, 20 mM HEPES, 23.5 mM 
NaGlutamate, 4.87 mM NaAcetate, 0.05 mM phenol red, 15 
mM butaedionemonoxime, 20 mM creatinine, 15 mM 
creatinphosphate, 15 mM taurine, 27 IU/ml Insulin, adjusted 
to pH 7.2, sterile filtrated 
ACM-EDTA medium 5.4 mM KCl, 3.5 mM MgSO4, 0.05 mM NaPyruvate, 20 mM 
NaHCO3, 10 mM glucose, 20 mM HEPES, 23.5 mM 
NaGlutamate, 4.87 mM NaAcetate, 100 µM EDTA, 0.05 mM 
phenol red, 15 mM butaedionemonoxime, 20 mM creatinine, 
15 mM creatinphosphate, 15 mM taurine, 27 IU/ml Insulin, 
adjusted to pH 7.2, sterile filtrated 
Anode buffer  1 M Tris adjusted to pH 8.6 
BlueJuice 3x loading dye 
 
150 mM Tris, 6% SDS, 0.3% bromphenolblue, 10% glycerol, 
5% β-mercaptoethanol, adjusted to pH 6.8 
Ca2+ buffer 10% glycerol, 135 mM Nacl, 1 mM CaCl2, 20 mM Tris-HCl, 
adjust to pH 7.4 
Ca2+-NP40 buffer 1% NP-40, 10% glycerol, 135 mM NaCl, 1 mM CaCl2, 20 mM 
Tris-HCl, adjust to pH 7.4 
Digestion-solution 
 
1.5 ml sterile-filtrated Trypsin (10 ml Stock; 1g Trypsin 
(1:250) for 10 ml HBSS), 300 U/ml DNAse I, 2% P/S, 40 mM 
HEPES, 3.2 µM NaOH 
EHT-Medium DMEM low glucose, 10% horse serum, 2% chicken embryo 
extract, 1% P/S 
I-Block blocking solution 0.2% (w/v) Tropix I Block, 1% Tween 20 in TBS 
Kathode buffer  0.1 M taurine,  0.1 M Tris, 0.1% SDS 
modified - M199  Medium 199 supplemented with 5 mM taurine, 5 mM 
carnitine, 5 mM creatine, 5 mM N-mercaptoproprionyl 
glycine, 27 IU/ml insulin, 1% P/S, adjusted to pH 7.25, sterile 
filtrated 
NCF-Medium DMEM high glucose, 10% FCS, 1% P/S 
NCM-Medium Medium 199, 10/0.5% FCS, 1% l-glutamine, 1 mM CaCl2, 1% 
P/S 
PFA 4% PFA in H2O, adjusted to pH 7.2 
SDS-lysis buffer  PBS, 1 mM EDTA, 1 mM EGTA, 1% SDS, 1% phosphatase 
inhibitor 2 and 3, 1 tablet protease inhibitor in 10ml 
Stop-solution 4% FCS, 300 U/ml DNAse I, 2% P/S, 60 mM HEPES 
TBS -Tween  0.1% (v/v) Tween in 1x TBS  
Transfer buffer  20% methanol, 15 mM Tris-HCl, 15 mM taurine 
Tris buffer (TBS)  25 mM Tris, 150 mM NaCl, 1 mM CaCl2, adjusted to pH 7 
Tyrode solution 119.8 mM NaCl, 5.4 mM KCl, 1.05 mM MgCl2, 0.2 mM 
CaCl2, 0.42 NaH2PO4, 22.6 mM NaHCO3, 5.05 mM glucose, 
0.05 mM Na2EDTA, 0.28 mM ascorbic acid (total Na+ 142.9 
mM, total Cl- 130.9 mM, O2/CO2(%) 95/5), pH adjusted by 
gassing 
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Virus buffer 10 mM Tris pH 8.1, 10% glycerol, 150 mM NaCl, 1 mM MgCl 
 
3.1.7 Non-standard software 
 
Software version Author/ company 
Lab Chart v7.1.2 ADI Instruments 
ImageJ Version 1.43u National Institute of Health 
MyIQ Optical System Software Version 
1.0 
BioRad 
Odyssey Infrared Imaging Software 
Version 2.0 
LI-COR Biosciences  
Prism Version 5.01 GraphPad software Inc. 
Xcellence rt1.2 Olympus soft Imaging Solutions GmbH 
Endnote X6 Thomson Reuters 
 
 
3.2 Methods 
 
3.2.1 Cell culture techniques 
All cells were incubated in a humidified 37°C incubator gassed with 5% CO2. 
 
3.2.1.1 Virus production 
3.2.1.1.1 General cell culture 
Human embryonic kidney carcinoma 293A cells (Hek293A) were used for the production of 
recombinant adenoviruses. This cell line was established by transforming normal embryonic kidney 
cells with the adenovirus 5.[153] Thus, Hek293A cells contain genes that are needed for adenovirus 
replication. In that way, replication-deficient viruses can be produced from preexisting virus stocks.  
Hek293A were grown in 10% FCS DMEM-Medium and were used between passages 20-40. For 
subculturing, culture medium was removed and cells washed with PBS once. Trypsin was added and 
incubated for 3 minutes (min) at 37°C. The reaction was stopped by adding the double amount of culture 
medium and the cells were carefully resuspended. Subculturing was performed when cells had reached 
80% confluence by splitting in ratio 1:5. 
 
3.2.1.1.2 Amplification of replication-deficient adenoviruses 
Adenoviruses are used for the transduction of cardiomyocytes, which are difficult to transfect with 
standard reagents.[154] Current adenoviral vectors are depleted for viral genes that control replication 
(Early 1 and 3 genes, E1/E3), however they are still infectious and can integrate into the host genome. 
Cloning techniques allow the insertion of target gene cDNA, so that adenoviruses can be used for 
overexpression studies. 
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For this study, an adenovirus system described by He et. al. (1998) was used to drive expression for the 
human S100A1 cDNA.[155] The virus was constructed with two promoters, driving S100A1 and GFP 
expression under two separate basal CMV promoters (AdS100A1). As control vector, a virus containing 
only GFP was used (AdGFP).[133] Thus, GFP expression could directly be monitored after transduction 
of primary cells to monitor transduction efficiency. 
The production of adenoviruses was performed in Hek293A cells, which contain the E1/E3 genes that 
are missing in the recombinant adenovirus. Virus amplification was performed according to Akther et 
al.[156]  
Hek293A cells were grown on 20 25 cm dishes until they reached 80% confluence and were transduced 
with 80 µl of working aliquots of AdGFP or AdS100A1 (titer approx. 2·1011 VP/ml). From the next day 
on, cells were monitored three times a day for GFP expression and morphological changes. When all 
cells displayed GFP expression and first cells started to detach (after 1-3 days), cells were carefully 
harvested with a cell scraper or by carefully washing the cells of the plate with the cell culture medium. 
The cell suspension was centrifuged for 15 min at 1200 g and 4°C. The supernatant was discarded and 
the cell pellet, which had a greenish color, was stored at -80°C until further processed. For one virus 
batch, the virus production was repeated twice. For cell lysis, 1 ml of PBS per cell pellet was added and 
3 freeze-thaw cycles in liquid nitrogen and a 37°C water bath performed. To eliminate Hek293A cell 
DNA and inhibit clotting of broken viruses particles, DNAse digestion was performed (2 U/ml) for 30 
min at 37°C. Afterwards, residual cell debris was removed by a centrifugation steps at max. speed (ca. 
4800 g) for 10 min at 4°C. The supernatant containing the adenovirus was kept and the centrifugation 
step repeated 3 times. The virus solution was directly subjected to virus enrichment by cesium chloride 
density gradient centrifugation. 
 
3.2.1.1.3 Virus enrichment by cesium chloride density gradient centrifugation 
Virus enrichment was performed by a modified protocol from Tollefsen et al. using a cesium chloride 
(CsCl) density gradient.[157] 
CsCl density gradients were prepared in ultracentrifugation tubes by carefully sublayering 3 ml of the 
heavy CsCl-solution (1.4 g/ml) under 3 ml of light CsCl-solution (1.3 g/ml). 4 ml of virus solution was 
layered on top filling the tubes to the edge. The first centrifugation step was performed for 2-4 hours (h) 
at 220000 g and 4°C in an ultracentrifuge (rotor SW41 Ti). As the virus has a density of about 1.33 g/ml, 
it appeared as a whitish-bluish band slightly above the border between the two CsCl-solutions (Fig. 7). 
Another lighter band was visible slightly above the proper virus, which most likely contained empty 
virus capsid. The correct virus band was punctured with a 16 G needle and 2 ml syringe and layered on 
top of another CsCl density gradient for further enrichment. The second gradient was run over night 
(ON). The final amount of concentrated virus (about 1-2 ml) was complemented with 25 µl 40% sucrose-
solution in PBS and dialyzed in 10000 dalton molecular weight cut off dialyzation cassettes against PBS 
for two times for 4 h and one time ON. Finally, 10% glycerol were added to the dialyzed virus solution 
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and aliquoted à 100-200 µl for subsequent experiments or à 20 µl for titer determination and stored at -
80°C.  
 
 
3.2.1.1.4 Titer determination 
Titer determination was performed with the end point dilution assay in Hek293A cells. Hek293A cells 
were seeded at a density of 20000 cells/well in 96 well plates and grown ON. The next day, sequential 
virus dilutions were performed, from 1·10-2 to 1·10-12 in 8 replicates for each concentration. After 24 h, 
GFP expression was inspected by eye and wells were scored positive if one cell/well was green. The 
viral titer was calculated by the following deviation according to the Spearman-Kärber formula: 
 
Titer (pfu/ml)= 10(1+Z(X-0.5) 
Z= log 10 of starting dilution (for 1:100 Z=2) 
X= the sum of the fraction of positive wells (number of positive wells/number of total wells for each 
dilution) 
 
Typical virus yields were between 1·1011-2·1012 pfu/ml. Virus enrichment after ultracentrifugation was 
about 100-fold compared to before.  
Exact virus titration was performed in neonatal rat cardiomyocytes. For this purpose, virus stocks were 
thawed on ice, diluted according to the virus concentration with virus buffer and shock frozen in liquid 
nitrogen in 20 µl working aliquots. Different multiplicities of infections (MOIs) (1-50) of new virus 
were added to neonatal rat cardiomyocyte cultures, incubated ON and subjected to western blot analysis 
for S100A1 overexpression. MOIs yielding desired S100A1 overexpression was 4-8-fold compared to 
control and were chosen for subsequent experiments. GFP expression was always adapted so that both 
viruses had matching GFP expression.  
 
Figure 7: CsCl density gradient after first centrifugation step 
After the first centrifugation for 2-4 h, the virus is concentrated between the heavy and light CsCl solution and 
manifests as whitish/ bluish band. Above the proper virus is another band, which consists only of virus capsid 
and has a lower density. For preparation of the second gradient, the virus was removed by punctuation with a 
16 G needle. 
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3.2.1.2  Isolation and cultivation of neonatal rat cardiomyocytes 
Neonatal rat cardiomyocytes (NCM) were isolated by gradual trypsin digestion.  
One to three day old neonatal Wistar rat pubs (normally 28-36) were decapitated and the chest opened 
with a medial incision. The heart was removed and transferred to a 25 cm culture dish with ice-cold 
HBSS containing 2% P/S. Next, the adjacent tissue, remaining atria and vessels were removed and the 
heart pieces transferred to a small 6 cm culture dish. Hearts were minced using a tissue chopper (medium 
blade force and speed, pieces size 8.00 mm, one time longitudinal, one time transverse chopping). 5 ml 
digestion solution was added, heart pieces transferred to a 50 ml reaction tube and washed twice with 
digestion solution. To remove the supernatant, heart pieces were allowed to sediment by gravity for 
some seconds and the supernatant removed. Next, 10 ml digestion solution was added and incubated 
under constant shaking for 10 min at room temperature (RT). 10 ml stop solution was added and tissue 
mechanically homogenized using a 25 ml serological pipette for 30 times. The tissue was allowed to 
sediment and the supernatant, containing heart cells, transferred to 2.5 ml pre-cooled FCS and stored on 
ice. These digestion steps were repeated 9 times. At the end, almost all tissue pieces were digested. Cells 
were centrifuged for 15 min at 60 g at 4°C and pellets carefully resuspended in 50 ml 10% FCS M199. 
2 ml DNAse solution was added to inhibit cell clotting and the cell solution was filtered through a cell 
strainer (100 µm pore size) to remove residual tissue pieces. For the generation of EHT, cells were 
counted and the desired cell number doffed of. For the cultivation of neonatal cardiomyocytes, the cell 
suspension was transferred to a 25 cm dish and pre-plated to deplete for cardiac fibroblasts for 90 min 
at 37°C. As fibroblast attach faster to tissue culture surfaces, the cardiomyocyte fraction was enriched 
by this procedure from approx. 45% to 70%.[126] Afterwards, the culture dish was carefully hit on the 
bench to detach slightly adherent cardiomyocytes, the supernatant transferred to a 50 ml tube and 
carefully homogenized with a 25 ml serological pipette. Cells were counted using a Neubauer counting 
chamber and plated with a density of 2·106 cells/well in 6 well plates. The next day, cells were washed 
once with PBS and new medium was added. On the second day, medium was changed to 0.5% FCS 
M199. Experiments were normally started on day 3 or 4. 
 
3.2.1.3  Cultivation of neonatal rat cardiac fibroblasts  
Neonatal rat cardiac fibroblasts (NCF) attach faster to plastic surfaces than cardiomyocytes. After pre-
plating of NCM, the culture dish was filled with 10% FCS DMEM medium and cells were allowed to 
attach ON. The next day, cells were washed twice with PBS and medium changed. When cells had 
reached 90% confluence (after 3 days) they were subcultured in the ratio 1:3 as described above. As this 
passage still contained cardiomyocytes, cell were passaged one or two more times for pure NCF cultures. 
For experiments, cells in passage 2 or 3 were used in 6 well plates by splitting one T175 culture dish in 
four 6 well plates. 
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3.2.1.4 Generation and cultivation of Engineered Heart Tissue (EHT) 
3.2.1.4.1 Generation of EHT 
EHT is a 3-dimensional cell culture model, that outmatches conventional 2-dimensional cell culture, as 
neonatal rat cells (whole heart isolates) are cultivated in a collagen matrix under cyclic stretch (referred 
to as loaded conditions), which, after almost two weeks of maturation, resembles adult myocardium and 
forms a functional syncytium.[151, 152] EHT were produced in ring-shaped form, which eases its 
handling. 
EHT was constructed as described previously.[151] After isolation of neonatal rat cells, before the pre-
plating step to enrich cardiomyocyte fraction, cells were counted using a Neubauer counting chamber 
and the desired number of cells (2.75·106 cells/EHT) centrifuged at 60 g for 15 min. The pellet was 
resuspended in the according volume of cold EHT Medium. For each ring, 0.9 mg rat tail type I collagen 
were mixed with the same amount of 2x concentrated DMEM medium and neutralized with 0.1 M 
NaOH until neutral color change (reddish to pinkish). 10% Matrigel and 2.75·106 isolated heart cells 
were added for 1 EHT (final volume 1 ml). 1 ml of this mixture was pipetted into ring-shaped casting 
molds and allowed to solidify for 1 h in a CO2 incubator (Fig. 8.1). Afterwards, the medium was 
carefully added and changed every 2nd day thereafter. After 7 days, hardened EHT (Fig. 8.2) were 
transferred onto custom-made stretching device to facilitate phasic stretch (from 100 to 110% of length 
at 2 Hz) (Fig. 8.3). EHT were stimulated with ET-1 (day 8) or transduced with AdGFP or AdS100A1 
(day 10) at the indicated time points. EHT were completely matured on day 12 (Fig. 8.4) 
 
 
Figure 8: Setup for EHT preparation, culture and analysis of contractile function:  
1. Casting mold assembly, 2. EHT condensation around the central cylinder until culture day 7, 3. EHT after 
transfer onto a stretching apparatus (10% unidirectional and cyclic stretch at 2 Hz), 4. Mature EHT at day 12, 5. 
EHT in a thermostated organ bath for isometric force measurement under pulsefield stimulation (37°C, 2Hz, 5ms, 
100 mA). Arrow point towards ring shaped EHT. 
 
3.2.1.4.2 Functional analyses of EHT 
On day 12, isometric contraction experiments were performed: EHT were subjected to fluorescent 
microscopy to monitor GFP expression, if transduced with adenovirus, before being transferred to an 
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organ bath equipment. EHT were hung between hook and force transducer (Fig. 8.5) and were allowed 
to equilibrate for 30 min without pacing in tyrode solution (0.2 mM Ca2+). Then, EHT were electrically 
stimulated with rectangular pulses (2 Hz, 5 ms, 100-120 mA) for another 30 min at 1 mM Ca2+. Length 
of EHT was adjusted to maximal force generation, which most likely resembles optimal sarcomere 
length. Tyrode solution was changes twice and contractility was recorded with LabChart software for 
cumulative Ca2+ concentrations (0.2 mM-1.6 mM) with a recording period of approx. 150 sec/step (Fig. 
9). 
 
Figure 9: Original force recording of Ca2+ stimulated EHT 
Ca2+ in the tyrode solution was increased stepwise and contractility recorded with LabChart. Addition of Ca2+ 
increased twitch tension to its maximum at 1.6 mM Ca2+. Asterisks indicate artifacts from the force transducer 
when Ca2+ was added manually.  
 
Contractile performance was analyzed in offline mode with a semiautomatic custom designed plugin. 
Figure 10 displays a representative twitch: Twitch tension (TT) was calculated as amplitude between 
TTmax-TTmin. Time to peak (TTP) was calculated as start of twitch until TTmax. Tau, the relaxation 
constant was integrated from the relaxation velocity.  
After functional recordings, EHTs were shock-frozen in liquid nitrogen and stored at -20°C until further 
processing. 
 
Figure 10: Schema of twitch measurement and functional parameters deduced from it 
Twitch tension (TT), Time to peak (TTP) and tau were analyzed using Labchart software and a semiautomatic 
plugin. 
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3.2.1.4.3 Arrhythmia-Assay 
For the arrhythmia assay, EHT was equilibrated as described above. Ca2+ in the tyrode solution was 
adjusted to 0.2 mM and stepwise increased up to 4 mM with a recording period of approx. 150 sec/step.  
For quantifications of after-contractions, the number of after-contractions was counted manually for 
each Ca2+ concentration and the recorded time. The incidence of after-contractions was calculated as 
ratio number of after-contractions to total number contractions. For quality control, at 0.2 and 0.4mM 
Ca2+, EHT should not display any after-contractions and at 4 mM Ca2+, all EHT should display 100% 
after-contractions. By applying this method, 10% of EHT were discarded from the analysis. For 
combined Ca2+/ β-AR stimulation, after adjustment in 0.2 mM Ca2+, 1 µM Iso was added before 
incrementally increasing Ca2+ to 2 mM. Again, EHT that displayed after-contractions at 0.2 mM Ca2+ 
or 1 µM Iso were excluded from the analysis.  
For the experiments with ryanodine or Flecainide, EHT was adjusted to 1.6 mM Ca2+ (EC50 for control 
EHT) for 10 min. 50 nM ryanodine/ 3 µM Flecainide were added to the tyrode solutions and after-
contractions analyzed for further 10 min as described before.  
 
3.2.1.5 Isolation of adult rat cardiomyocytes 
Isolation of adult rat cardiomyocytes (ACM) was performed according to a protocol from Piper.[158] 
Male wistar rats were anesthetized with 1 ml thiopental until expiration of adverse-effect reflexes. The 
thorax was opened with a median incision and 10 U heparin injected into the vena cava inferior to 
prevent blood clotting. Afterwards, the heart was dissected and placed into pre-cooled 0.9% NaCl 
solution. The aorta was probed on a 1.5 mm wash point penetrometer and placed into a Langendorf 
equipment. Ca2+ free ACM-EDTA medium was infused retrograde in an open circle with a flow rate of 
12 ml/min to wash out residual free Ca2+. After 5 min, circular flow was established and 2 mg/ml 
collagenase added in ACM medium. After approx. 30 min the digestion was stopped, the heart 
transferred to a 6 cm dish and minced using a tissue chopper (medium blade force and speed, size 7.17 
mm, twice along both axes). The heart pieces were resuspended in ACM-EDTA medium and passed 
through a cell strainer (pore size 200 µm). The obtained cell suspension was subjected to several Ca2+ 
toleration steps, where Ca2+ in the ACM medium was increased stepwise (0 mM, 0.05 mM, 0.1 mM, 0.2 
mM, 1 mM, 2.5 mM final). Cells were allowed to sediment for 10 min at each step, the supernatant 
removed and new medium with higher Ca2+ concentration was added. After the last step, cells were 
resuspended in modified-M199. Laminin was added in a final concentration of 1:100 and cells were 
plated in 6 well plates for immunoprecipitation (IP) and western blot analysis or in 8 well chamber slides 
for immunofluorescence/ PLA assay. After 1 h incubation, medium was changed and viral transduction 
was performed as indicated. 
 
3.2.2 Biochemical methods 
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3.2.2.1 Western blot 
3.2.2.1.1 Isolation of proteins 
For preparation of cell homogenates, frozen EHT were transferred to a reaction tube containing 150 µl 
SDS-lysis buffer or 200 µl Ca2+-NP40 buffer and 4 ceramic balls. They were homogenized using a tissue 
lyser (1 min, 5500 rpm) and the debris was removed by centrifugation for 10 min at 13000 g. The 
supernatant was transferred to a new reaction tube and stored at 4°C until used for SDS-page or stored 
at -20°C until used for IP.  
ACM and NCM were harvested by pooling two 6 wells in 80-100 µl of the same SDS-lysis buffer/ Ca2+-
NP40 buffer using a cell scraper and homogenized by passing through a 32 G needle with a syringe 5-
10 times. Homogenates were centrifuged at 13000 g for 10 min, the supernatant transferred to a new 
reaction tube and stored at 4°C or -20°C until used for SDS-page or IP. As previous experiments 
indicated that protein concentrations did not vary between different stimulations and experiments, there 
was no routine measurement of protein concentration but samples were rather loaded by volume.  
 
3.2.2.1.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS page) 
Separation of proteins was performed by SDS page according to the system described by Laemmli with 
some modifications.[159] 
Approx. 130 µg from EHT and 80 µg from ACM/ NCM protein lysates (always 25 µl) were mixed with 
5 µl loading dye and boiled for 3 min at 95°C before loading on pre-casted gradient tris-glycine gels (4-
20%). Gels were run with anode and cathode buffer for approx. 2 h at 100 V until the tracking dye 
reached the end of the gel. 
 
3.2.2.1.3 Immunological detection 
Prior to immunological detection, proteins from tris-glycine gels were transferred onto PVDF 
membranes using a custom made tank blot western blot apparatus.[160] 
PVDF membranes were activated for 10 sec in 100% methanol and placed into transfer buffer for 2 min. 
The gel was also pre-soaked in transfer buffer for 2 min. The gel and membrane were mounted between 
presoaked filter paper and proteins transferred for 2 h at 50 V onto the membrane. Transfer efficiency 
was controlled by complete marker transfer. Afterwards, the membrane was washed 3 times with TBS 
to remove residual methanol. Unspecific binding sites were blocked for 1 h at RT with I-block solution 
on a shaker. For immunological detection, membranes were probed with the appropriate set of primary 
antibodies in I-block solution according to table 3.2.5 ON at 4°C under constant shaking. After 3 short 
washing steps with TBS-Tween, the fluorescent-labelled secondary antibody were incubated for 1 h at 
RT in the dark on a shaker. After 3 further washing step with TBS-Tween, the membrane was washed 
3 additional time in TBS to remove the tween before scanning. Proteins were visualized with a LI-COR 
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infrared imager directly afterward and quantitative densiometric analysis was performed. Signals were 
normalized to GAPDH densiometric levels or others as indicated. 
 
3.2.2.2 Immunoprecipitation (IP) 
IPs were performed to enrich RyR2 proteins from ACM and EHT, as this protein shows too low 
abundance for straight western blotting.  
All steps were carried out on ice. EHT and ACM protein lysates were prepared as described above. As 
protein material from one EHT was too little, two EHT were pooled for one IP. Protein suspension was 
filled up to 500 µl to guarantee optimal stirring during rotation. After incubation of protein homogenates 
for 30 min on ice and centrifugation for 15 min at 13000 g, 25 µl protein A/G-Agarose was added and 
rotated for 2-4 h. Lysates were centrifuged again at 2000 g for 5 min to remove protein non-specifically 
bound to agarose beads. The supernatants were then mixed with 4 µl precipitating RyR2 antibodies and 
rotated ON at 4°C. Again, 25 µl protein A/G-Agarose was added, samples rotated for additional 6 h and 
centrifuged at 3000 g for 5 min. Pellets were washed three times with Ca2+ buffer and 20 μl loading dye 
without bromophenolblue was added. Samples were boiled at 95°C for 3 min, centrifuged at 2000 g for 
5 min at RT and the supernatant was subjected to SDS page as described above. 
 
3.2.3 Cell biological methods 
3.2.3.1 Immunofluorescence Staining 
Immunfluorescence stainings (IF) were performed to visualize protein localization in NCM, ACM and 
EHT. Control EHT was embedded in mounting medium, frozen in liquid nitrogen and stored at -80°C 
until further analysis. 10 µm thick sections along the longitudinal axis were cut on a cryotom and 
transferred to Superfrost slides. Slides were shortly rinsed with ice-cold PBS and fixed with PFA for 15 
min.  
NCM and ACM were grown on cover slips or 6 well chamber slides. Before PFA fixation for 15 min, 
they were washed with ice cooled PBS.  
After washing 3 times with PBS for 5 min, all cells were permeabilized with 0.5% Triton in PBS for 5 
min. After another washing step, unspecific binding was blocked with I-block for 1 h. Primary antibodies 
were diluted in I-block according to table 3.2.5 and incubated ON at 4°C. The next day, cells were 
washed with PBS 3 times for 5 min before adding secondary antibody (in I-block) for 1-2 h at RT. After 
a final washing step, cells were mounted with Vectashield and allow to dry ON at RT before long time 
storage at 4°C in the dark. Negative controls were produced in the same manner without using primary 
antibodies.  
 
3.2.3.2 Proximity Ligation Assay (PLA) 
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The proximity ligation assay detects protein interaction in situ, when the distance between two proteins 
is 40 nm or less. Primary antibodies raised in different species are used to recognize the target antigen. 
Species-specific PLA probes, which have a unique short DNA strand attached to it, bind to primary 
antibodies. If PLA probes are in close proximity (<40 nm), ligation of the oligonucleotides is possible. 
Rolling circle amplification enables a several-hundredfold replication of the DNA circle, which encodes 
a fluorescent signal. This becomes visible as a distinct bright dot under a fluorescence microscope.[161] 
ACM were grown on 6 well chamber slides and transduced with AdGFP or AdS100A1. Stimulation 
with isoproterenol (Iso, 1·10-7 M) was performed for 10 min and cells were treated as described under 
3.3.3.1 until blocking. Primary antibodies (see table 3.2.5) were diluted in antibody diluent and 
incubated ON at 4°C. Cells were washed with wash buffer A three times and then incubated for 1 h at 
37°C with the corresponding PLA probes (PLUS and MINUS probes depending on primary antibody) 
diluted in blocking buffer 1:5. For detection, cells were again washed three times with wash buffer A 
and ligase mixture (1:40 in Ligation stock) was added and incubated on each sample for 30 min at 37°C. 
After another washing step, polymerase solution (1:80 in amplification buffer) was added following an 
incubation period of 100 min at 37°C. Final washing was performed with wash buffer B before mounting 
using Vectashield. Negatives controls were obtained by omitting primary antibodies. Slides were 
allowed to dry at RT ON before long time storage at 4°C in the dark.  
 
3.2.3.3 TUNEL staining  
For apoptosis staining, the TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed 
according to the user manual. For the staining procedure, EHT slides were fixed with PFA for 20 min 
at RT. After a washing step with PBS, slides were permeabilized with 0.2% Triton-X in PBS for 2 min 
before another washing step with PBS was performed. 50 µl of enzyme solution were mixed with 450 
µl of label solution and incubated for 60 min at 37°C in a humidified chamber. For negative controls, 
label solution without enzyme solution was used. After another washing step with PBS, slides were 
mounted using Vectashield and allowed to dry ON at RT. For long time storage, slides were stored at 
4°C. For quantification of TUNEL positive cells, at least four pictures from two slides were taken for 
each replicate with 3 replicates for each condition.    
 
3.2.3.4 Microscopy 
Images were taken with a 10 x, 40 x objective or 60 x oil immersion objective with an Olympus IX81 
microscope. For quantification, images were subjected to deconvolution using Xcellence rt 1.2 software 
with the following settings: numerical apparatus 1.35, spherical apparatus 1.5, no neighbor 
deconvolution, haze removal factor 70%, sub-volume overlap 10, spherical aberration detection off. 
Images were further processed using Image J. 
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3.2.4 Molecular biology methods 
3.2.4.1 RNA Isolation 
Isolation of entire RNA from EHT was performed using phenol-chloroform extraction with trizol 
reagent. All steps were performed on ice. After functional recordings, EHT was transferred to 1 ml trizol 
and vortexed for 5 min to dissolve EHTs. 200 µl chloroform was added and briefly mixed. Phase 
separation was performed by centrifugation for 15 min at 14000 g and 4°C. The aqueous phase (approx. 
400 µl), which contained the RNA, was transferred to a new reaction tube. To increase RNA yield, 1.5 
µl of polyacryl carrier was added. RNA was precipitated by adding 400 µl ice-cold isopropanol and 
incubated at -20°C ON before centrifugation for 15 min at 14000 g and 4°C. The pellet was washed 
twice with ice-cold 70% ethanol and allowed to dry for 15 min at RT. After dissolving in 20 µl DEPC-
treated H2O, RNA concentration was measured using a Nano Drop and stored at -20°C or directly 
subjected to reverse transcription. 
 
3.2.4.2 Reverse Transcription 
cDNA synthesis was performed using iScript cDNA synthesis kit according to the manufactures 
instructions: 1 µg RNA was mixed with 4 µl RT buffer, 1 µl reverse transcriptase in a total of 20 µl.  
Reverse transcription was performed at 25°C for 5 min, extended at 42°C for 30 min and inactivated at 
85°C for 5 min and stored on ice. The obtained cDNA was diluted 1:100 in DEPC-treated H2O and 
stored at -20°C if not used for real-time PCR. 
 
 
3.2.4.3 Real-time PCR 
The real-time PCR reaction was set up mixing 7.5 μl iQ SYBR Green Supermix, 0.5μl 3 μM forward 
and reversed primer (see table 3.2.4) and 6.5 μl diluted cDNA. 40 cycles were applied in the MyIQ PCR 
cycler:  
First, incubation at 95°C for 3 min, denaturation at 95°C for 10 sec, annealing at 57°C or 63.5°C for 45 
sec, elongation at 72°C for 30 sec, final denaturation at 95°C for 1 min and final elongation at 55°C for 
1 min. Fluorescence intensity was measured after each elongation step. Melting curves were performed 
routinely after each run by increasing the temperature stepwise by 0.5°C from 55-90°C. Fluorescence 
intensity was recorded at the end of each temperature step to ensure that only one product was amplified.  
 
3.2.5 Statistics 
All values shown are mean ± SEM unless indicated otherwise. An unpaired two-tailed Student’s t-test 
was performed for statistical comparison of two groups. One-way ANOVA or two-way repeated 
ANOVA with Bonferroni-post test were performed to compare more than two groups and with two 
variables, respectively. For all tests, a p value of p<0.05 was considered significant. 
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4. Results 
 
4.1 Engineered Heart Tissue resembles functional syncytium 
Engineered Heart Tissue (EHT) has been widely appreciated as a model of functional syncytium, similar 
to isolated papillary muscle. Over the culture period, cardiomyocytes (CMs) in EHT form a dense 
network of muscle bundles. Despite made of neonatal CMs, CMs in EHT adopt an adult-like phenotype 
over time, which manifests itself in high sarcomeric organization, increased numbers of mitochondria 
and a striated pattern of CMs. Immunofluorescence staining of EHT sections confirmed a longitudinal 
orientation of CM along the stretching axis in the EHT matrix (Fig. 11A), displaying a striated pattern. 
S100A1 showed a similar striated pattern. Comparative staining in adult and neonatal rat CMs (ACM 
and NCM respectively) showed that ACM had a similar degree of structural organization, as S100A1 
also displayed a striated pattern (Fig. 11B). In contrary, NCM had less structural organization, as 
S100A1 did not show the striated pattern (Fig. 11C). Thus, CMs in EHT showed a similar adult-like 
structural organization than isolated adult CMs. 
 
 
Figure 11: EHT shows an adult-like structural organization 
A) Representative immunofluorescent image of cardiomyocytes in EHT. EHT were cryopreserved, cut into 10 
µm thick sections and stained for S100A1 (red, upper left). CMs were labeled with α-actinin (green, middle left). 
CMs formed muscle bundles along the stretching axis and displayed a striated pattern. S100A1 co-localized with 
α-actinin, indicating an adult-like phenotype. B) Representative staining of S100A1 (red, upper left) in ACMs. 
CMS were labeled with RyR2 (green, middle left). In ACM, S100A1 also displays a striated pattern. B) 
Representative staining of S100A1 (red) in NCM. Cardiomyocytes were counterstained with and α-actinin (green). 
S100A1 did not show a striated pattern.  Scale bare represent 20 µm.  
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EHT has been used to monitor cardiac contractile function in vitro, again showing similar features as 
isolated papillary muscle. However, EHT is more easily to produce and culture than isolated muscle. 
Previous studies reported that EHT develop increased force in response to external stimuli as Ca2+ and 
β-AR agonists. Indeed, increasing Ca2+ concentrations ([Ca2+]) in the recording solution increased force 
generation in a concentration dependent manner (Fig. 12A). Here, maximum contractility (0.3 mN) was 
achieved at 1.6 mM Ca2+, which was also reported by Zimmermann et. al. [151] Similarly, stimulation 
with β-AR agonist isoproterenol (Iso) also increased twitch tension (TT) (Fig. 12B), while maximum 
contractility (0.3 mN) was achieved at 1 µM Iso/0.4 mM Ca2+. The half-maximum of the force–calcium 
curve, expressed as EC50, can be interpreted as the “calcium sensitivity” of muscle cells. When Ca2+ 
sensitivity is decreased, more Ca2+ is required to get force to the midpoint and when Ca2+ sensitivity is 
increased, less Ca2+ is required to get the force to the midpoint.[162] 
After Iso stimulation EC50 was reduced from 0.43 mM Ca2+ to 0.24 mM Ca2+ in comparison to exclusive 
Ca2+ stimulation (Fig. 12C). Thus, β-AR agonist stimulation sensitized EHT to lower Ca2+ levels, despite 
equal maximum force generation.  
 
Figure 12: Dose-respond curves of Ca2+ and Iso stimulated EHT 
A) Ca2+ in the tyrode solution was increased stepwise and contractility recorded with LabChart. Addition of Ca2+ 
increased TT to its maximum of 0.3 mN at 1.6 mM Ca2+. n=22 B) Similarly, stimulation with Iso also increased 
TT to its maximum of 0.3 mN at 1 µM Iso/0.4 mM Ca2+. n=3 C) Calculated EC50 from A and B. Stimulation with 
Iso increased Ca2+ sensitivity of EHT and reduced EC50. # p<0.05 vs. calcium; student’s t-test. 
 
Summarizing, EHT could be generated in a reproducible manner and showed similar features as in 
previous studies. Thus, they can be used a model system in the subsequent work.  
 
 
 
4.2 Development of an EHT model with contractile impairment 
Until recently, it was not possible to generate EHT from failing CM and test therapeutic interventions 
in these EHT. However most recently, a similar model of fibrin-based EHT was reported to show 
contractile impairment and hypertrophic remodeling in respond to afterload enhancement and 
stimulation with hypertrophic factors as endothelin-1 (ET-1) or phenylephrine (PE).[163] Still, this 
model was constructed in a different way than in this study. Thus, the first part of this work aimed to 
A B C 
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establish a model of hypertrophic or HF-like EHT, which shows most features of failing hearts in vivo 
using pharmacological stimuli. 
For this reason, EHT were chronically stimulated with ET-1 to induce hypertrophic remodeling. These 
first experiments focused on the comprehensive characterization of ET-1 stimulated EHT and its effect 
on contractile performance and cellular remodeling. 
 
4.2.1 Chronic ET-1 treatment diminishes contractile performance of EHT 
EHT were stimulated with 4·10-8 M ET-1 for 96 h. After 48 h, they were transduced with the control 
virus (AdGFP) for 48 h with continuing ET-1 stimulation. Dose-respond-curves were recorded from 0.2 
mM-1.6 mM Ca2+ and contractile performance was analyzed. 
An increase in Ca2+extra (Ca2+ in the tyrode solution) from 0.4 to 1.6 mM resulted in an increase in twitch 
tension from 0.14 mN to 0.3 mN in control (AdGFP transduced) EHT (Fig. 13A, B). Chronically ET-1 
stimulation severely impaired contractility: Basal twitch tension (0.4 mM Ca2+) was strongly diminished 
to 0.04 mN and Ca2+ stimulation (1.6 mM Ca2+) only increased twitch tension to the level of control 
basal (0.16 mN). This reduced twitch tension manifested in a reduced sensitivity to Ca2+, as EC50 was 
increased from 0.43 mN to 0.68 mN in ET-1 stimulated EHT. 
Time to peak (TTP) was only slightly increased after ET-1 treatment at 0.4 mM Ca2+ (from 63.7 ms to 
71 ms). However, at 1.6 mM Ca2+, TTP significantly increased from 69.8 ms to 88.6 ms, indicating 
stronger effects at higher [Ca2+]. Similarly, Tau was only slightly increased after ET-1 treatment (from 
0.03 s to 0.032 s). Yet, calcium stimulation did not affect Tau further.  
Thus, chronic ET-1 stimulation resulted in a severe systolic contractile impairment, measured as a 
reduction in TT. Nevertheless, responsiveness to Ca2+ stimulation was maintained. Effects on TTP were 
not very pronounced and only manifested at higher [Ca2+]. Tau, which indicates diastolic function, 
displayed a tendency towards reduced relaxation. 
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Figure 13: Chronic ET-1 treatment impairs contractility of EHT 
A) Representative isometric force twitches from control and ET-1 treated EHT at 0.4 mM Ca2+ and 1.6 mM Ca2+. 
EHT were stimulated with low dose ET-1 (4·10-8 M) for 96 h and subjected to contractile force analysis afterwards. 
Cells were stimulated with a biphasic pulse of 5 ms length and 110 mA at 2 Hz. [Ca2+]extra was stepwise increased 
after a recording time of 150 sec and contractile parameter analyzed. B) Corresponding quantification of twitch 
tension, EC50, Tau and time to peak (TTP) at 0.4 mM and 1.6 mM Ca2+. ET-1 stimulation resulted in an overall 
impaired contractile performance. n=17 control, n=13 ET-1, from at least 6 isolations; * p<0.05 vs. 0.4 mM Ca2+, 
# p<0.05 vs. 1.6 mM Ca2+; 2-way ANOVA/ student’s t-test. 
 
4.2.2 Chronic ET-1 treatment induces cellular remodeling 
Next, the cellular effects of chronic ET-1 treatment were investigated to confirm HF-like remodeling. 
Common marker proteins and genes that indicate failing remodeling of CMs were analyzed by western 
blotting or real-timer PCR. As a common marker of hypertrophy and the activation of fetal gene 
program, ANP mRNA levels were analyzed by real-time PCR. They increased approx. 2-fold after 
chronic ET-1 treatment (Fig. 14B). Similarly, S100A1, Serca2 and PLB protein levels as well as RyR2 
mRNA levels were also downregulated to approx. 50% of control levels (Fig. 14A, B). These effects 
are in line with the current understanding of hypertrophic remodeling during the progression towards 
HF. In conflict to this, NCX mRNA levels were also reduced, which are reported to be increased in 
chronic HF in vivo.[52, 68, 164] 
 
A 
B 
control ET-1 control ET-1
0.0
0.1
0.2
0.3
0.4
*
#
0.4 mM 1.6 mM Ca
2+
T
w
it
c
h
 T
e
n
s
io
n
 [
m
N
]
control ET-1 control ET-1
0.00
0.01
0.02
0.03
0.04
0.4 mM 1.6 mM Ca
2+
T
a
u
 [
s
]
control ET-1 control ET-1
0
50
100
150
*
#
0.4 mM 1.6 mM Ca
2+
T
T
P
 [
m
s
]
Results 
46 
 
 
Figure 14: ET-1 treatment induces marker gene expression reminiscent of HF-like remodeling  
A) Representative immunoblots and statistical analysis for S100A1, Serca2 and PLB protein expression from 
control and ET-1 treated EHT. After functional recordings, proteins were isolated and subjected to western blot 
analysis for S100A1, Serca2 and PLB expression, which were all reduced to about 50%. Two duplicates for each 
condition were depicted and densiometric values were normalized to GAPDH. n=4, from 4 isolations; * p<0.05 
vs. control; student’s t-test. B) mRNA analysis for ANP, RyR2 and NCX. mRNA levels were analyzed with real-
time PCR and normalized to 18s. ANP levels were increased approx. 2-fold, whereas RyR2 and NCX expression 
levels were reduced. n=4, from 4 isolations; * p<0.05 vs. control; student’s t-test. 
 
 
Furthermore, the effects of chronic ET-1 treatment on typical fibrosis and inflammation markers were 
analyzed. Both CMs as well as cardiac fibroblast can be activated by ET-1, resulting in a pro-
inflammatory and pro-fibrotic remodeling.[165] 
In EHT, ET-1 stimulation increased mRNA expression of connective tissue growth factor (CTGF), a 
general marker of fibroblast activation (Fig. 15). Furthermore, pro-fibrotic markers as smooth muscle 
actin (SMA) and collagen-1 were increased as well as inflammatory markers as interleukin 6 (IL-6) and 
intercellular adhesion molecule 1 (ICAM-1). Yet, the increase in collagen-1 and IL-6 expression levels 
was not significant. Besides, there were no effects on transforming growth factor β (TGF-β) and tumor 
necrosis factor α (TNF-α) mRNA levels after ET-1 treatment (data not shown). In conclusion, ET-1 
treatment induced pro-inflammatory and pro-fibrotic gene activation.  
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Figure 15: ET-1 treatment induces pro-inflammatory and fibrotic gene activation 
EHT were stimulated with ET-1 (4·10-8 M) for 96 h before subjected to mRNA analysis by real-time PCR for 
CTGF, SMA, collagen-1, ICAM-1 and Il-6. CTGF, SMA and ICAM-1 expression levels were significantly 
increased after ET-1 treatment. mRNA expression was normalized to 18s. n=4; * p<0.05 vs. control; student’s t-
test. 
 
4.2.3 Chronic ET-1 treatment might induce necrosis 
One explanation for the massive loss of contractility could be substantial cell death by apoptosis, 
necrosis or other forms of cell deaths. For this reason, comprehensive cell death analyses were 
performed.  
After 96 h of ET-1 treatment, cell culture supernatants were collected and subjected to analyses for high 
sensitive Troponin T (hsTNT) and lactate dehydrogenase (LDH) by enzyme linked immunosorbent 
assay (ELISA) in the analysis center of the University Hospital Heidelberg. These are two markers that 
are used to monitor tissue damage and can indicate necrosis. hsTNT is a standard marker for the 
diagnosis of myocardial infarction (MI), as it is released from damaged tissue can be measures with high 
sensitivity at low levels.[166] Similarly, increased LDH levels have been measured in culture 
supernatants from necrotic CMs.[167] As there was a strong increase in hsTNT levels in cell culture 
supernatants after ET-1 treatment (544 pg/ml vs.1667 pg/ml) and a slight increase in LDH levels (57 
U/l vs. 80 U/l) (Fig. 16), this indicated that ET-1 stimulation induced necrosis in EHT. 
 
Figure 16: Chronic ET-1 treatment increases hsTNT and LDH levels in culture medium 
After stimulation with ET-1 for 96 h, supernatant of cell cultures was collected and analyzed for hsTNT and LDH 
levels in the analysis center of the University Hospital Heidelberg. hsTNT increased significantly after ET-1 
treatment, but LDH levels only slightly. n=2; * p<0.05 vs. control; student’s t-test.  
 
Next, apoptotic cell death in EHT was determined. Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) allows to specifically label apoptotic cells in tissue sections or isolated cells. 
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EHT was cryopreserved after 96 h of ET-1 treatment and cut into sections on the cryotom. After the 
specific TUNEL staining, cells were counterstained with DAPI to calculate percentage of TUNEL 
positive cells (Fig. 17A). The overall apoptosis rate of cells in EHT was about 4%, which is in line with 
previous reports about small numbers of apoptotic cell death in EHT (Fig. 17B).[151, 152] However, 
there was no increase in TUNEL positive cells after ET-1 stimulation, indicating that ET-1 stimulation 
did not induce apoptosis. 
The same slides allowed calculations about absolute cell numbers per slide to quantify cell numbers in 
EHT after ET-1 stimulation. Although counting nuclei is only a rough approximation of the overall cell 
number, this still gives a good estimation if nuclei numbers change essentially during different 
stimulations. Control slide contained 260 nuclei, whereas after ET-1 treatment there was a slight increase 
in nuclei (386) (Fig. 17B).  
 
Figure 17: Chronic ET-1 treatment does not induce apoptosis 
A) Cryopreserved EHT was cut into 10 µm thick sections and TUNEL staining performed (red signal). Nuclei 
were counterstained with DAPI (blue). B) Quantification of A. About 4% of cells were TUNEL positive in control 
and ET-1 treated EHT. Nuclei numbers per slide slightly increased after ET-1 treatment. For quantification of 
TUNEL positive nuclei and nuclei/ slide, at least 3 images were taken from each section. Two sections from 
different layers were analyzed for each EHT. n=4 different isolations; student’s t-test. Scale bar represents 200 
µm. 
 
The slight increase in nuclei number can have two major reasons: Either specifically fibroblasts 
proliferate and CMs die after ET-1 stimulation, or the total cell number does not change and CMs 
become polynucleated, which has been described after hypertrophy of isolated CMs before.[152, 168] 
For this reason, protein expression of calsequestrin (CSQ) was analyzed to estimate changes in CM 
content after ET-1 treatment. CSQ is only expressed in CMs and loss of CMs should lead to a decreased 
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CSQ expression. However, western blotting confirmed no changes in CSQ protein expression after ET-
1 treatment (Fig. 18). 
 
Figure 18: Chronic ET-1 treatment does not reduce CSQ protein expression 
Representative immunoblots (left) and statistical analysis (right) for CSQ from control and ET-1 treated EHT. 
After functional recordings, proteins were isolated and subjected to western blot analysis for CSQ expression. Two 
duplicates for each condition were depicted and densiometric values were normalized to GAPDH. n=4, from 4 
isolations; student’s t-test. 
 
In conclusion, these data indicate that necrosis might have occurred after ET-1 stimulation in EHT, 
similar to the in vivo situation after MI. Still, there was no increase in apoptosis and no specific loss of 
CMs after ET-1 treatment, which could be responsible for the massive loss of contractility.  
 
Since ET-1 treated EHT showed most characteristics of hypertrophic remodeling in addition to a strong 
contractile impairment, they will be referred to as failing or HF-like EHT form here on. 
 
 
 
4.3 Induction of store-overload induced Ca2+ release (SOICR) in EHT 
The previous paragraph confirmed that EHT can be stimulated with pharmacological substances as ET-
1 to induce a HF-like phenotype, which resulted in strong diminished contractile force and hypertrophic 
remodeling. The next part aimed to establish a protocol where possible arrhythmogenic events can be 
analyzed in this model under isometric stretch. 
 
4.3.1 Ca2+-Stress and β-AR stimulation induce after-contractions 
Cellular Ca2+ overload is known to inhibit proper RyR2 closure during diastole, rendering RyR2 “leaky”. 
This SOICR in turn can result in extra-contractions, which might lead to cellular arrhythmias.[26, 37, 
58] If this mechanism also acts in part in EHT was tested by stimulating EHT with incremental doses of 
Ca2+. These exceeded physiological levels (up to 4 mM Ca2+extra) and might potentially induce SOICR, 
finally leading to pro-arrhythmogenic extra-contractions. 
As shown before, an increase in Ca2+extra resulted in an improved contractility as depicted in Fig.1. With 
increasing Ca2+ concentrations, non-stimulated after-contractions occurred first sporadically but then 
with increasing frequency (Fig. 19). At the same time, force from stimulated twitches started to decline. 
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By further raising Ca2+extra, all normal contractions were followed by these after-contractions, so that 
overall twitch tension was strongly diminished. Tracking of individual recordings elucidated that after-
contractions originated after stimulated, normal contractions. Therefore, they were called after-
contractions. 
 
Figure 19: Ca2+-Stress induces after-contractions in a concentration-dependent manner 
Representative isometric force twitches of Ca2+ stressed EHT. Ca2+extra was stepwise increased from 0.2 mM to 4 
mM during functional recordings. An increase in Ca2+ first increased twitch tension to its maximum. At higher 
[Ca2+], non-stimulated extra-contractions occurred first sporadically which reduced amplitude of stimulated 
twitches. By further increasing Ca2+extra, their frequency increased, until all stimulated contractions were followed 
by extra-contractions and the overall twitch tension was strongly diminished. Asterisks indicate artifacts from the 
force transducer when Ca2+ was added manually.  
 
To test if these after-contractions originate from RyR2 malfunction, ryanodine was added in low 
concentrations when after-contractions occurred. Ryanodine specifically binds to the RyR2 and inhibits 
channel opening without further affecting systolic Ca2+ handling.[169] Application of low dose 
ryanodine (50 nM) was able to profoundly inhibit after-contractions at 1.6 mM Ca2+ from 43% to 16%, 
while overall twitch amplitude was maintained (Fig. 20A, B). Similarly, Flecainide (class Ic anti-
arrhythmic agent that blocks diastolic RyR2 opening as well as the Nav1.5 sodium channel) was also 
able to inhibit after-contractions, however, this effect was not that strong (Fig. 20C). 
Thus, Ca2+ stimulation was able to induce pro-arrhythmogenic after-contractions that might originate 
from diastolic RyR2 malfunction. 
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Figure 20: Ca2+-Stress induces after-contractions that can be inhibited by low-dose ryanodine 
A) Representative isometric force twitches of Ca2+ stressed EHT. Lines above indicate stimulation pulses (110 
mA, 5 ms width, 2 Hz), which induce a regular twitch; arrows below indicate non-stimulated after-contraction. 
Ca2+-stress increased the development of extra-contractions that originate after stimulated contractions (after-
contractions). Administration of low dose ryanodine (50 nM) profoundly inhibited the appearance of after-
contractions. B) Quantification of after-contractions. Stimulation of 1.6 mM Ca2+ increased the incidence of after-
contractions to 43%, whereas application of 50 nM ryanodine reduced it to 16%. Overall twitch tension was 
maintained after the addition of ryanodine. n=15; * p<0.05 vs. control; student’s t-test. C) Quantification of after-
contractions after addition of Flecainide. Flecainide was also able to reduce the incidence of after-contractions, 
whereas twitch tension was maintained. n=5; student’s t-test. 
 
Inducing SOICR and after-contraction could also be obtained by combining Ca2+ and β-AR-stimulation: 
EHT were stimulated with 1 µM Isoproterenol (Iso) before incrementally increasing Ca2+extra to 2 mM.  
This combined stimulated also resulted in a dose-dependent increase of after-contractions (Fig. 21); 
however they started at much lower Ca2+ concentrations, as β-AR-stimulation normally increases SR 
Ca2+ load, thereby lowering the threshold for diastolic Ca2+ leakage.[86] Thus, β-AR-stimulation 
increased the sensitivity for Ca2+-overload-induced after-contractions in EHT. 
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Figure 21: Combined β-AR/ Ca2+ stimulation induces after-contractions 
Representative isometric force twitches of β-AR/ Ca2+ stressed EHT. After addition of 1 µM Iso, Ca2+extra was 
stepwise increased from 0.2 mM Ca2+ to 2 mM during functional recordings. An increase in Ca2+extra first increased 
twitch tension to its maximum. At higher [Ca2+], non-stimulated extra-contractions occurred, which reduced 
amplitude of stimulated twitches. With further increasing Ca2+extra, their frequency increased, until all stimulated 
contractions were followed by extra-contractions and the overall twitch tension was strongly diminished. Asterisks 
indicate artifacts from the force transducer when Iso/ Ca2+ was added manually.  
 
 
Summing up, EHT can be used to monitor effects of SOICR after Ca2+ and β-AR stimulation. After-
contractions represent the correlate of diastolic Ca2+ leakage that is normally analyzed in isolated 
cardiomyocytes. 
 
 
 
4.4 S100A1-mediated gene transfer in normal and failing EHT 
Having established that chronic ET-1 stimulation induced a HF-like phenotype in EHT and that Ca2+ 
and β-AR stimulation induced pro-arrhythmogenic after-contractions, I next aimed to investigate the 
impact of S100A1 overexpression on contractile performance in normal and HF-like EHT and its impact 
of Ca2+ and β-AR triggered after-contractions. 
 
4.4.1 Adenoviral-mediated S100A1 overexpression increases S100A1 protein levels in 
EHT 
For all experiments, an adenovirus with CMV-promoter driving either expression of GFP (AdGFP, 
control virus) or a two-promoter virus co-expressing GFP and S100A1 (AdS100A1, S100A1) was used 
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(see 3.3.1.1.2). GFP expression was monitored directly after viral transduction in living cells to estimate 
transduction efficiency.  
To test in which cell type the adenovirus constructs are preferentially expressed, comparable adenoviral 
transductions were performed in monolayer cell cultures with AdGFP for 24 h. Although CMV promoter 
is supposed to drive general protein expression in all cell types, GFP expression was mainly detectable 
in cardiomyocytes: Applying same multiplicity of infection of (MOI) of 10, pure neonatal rat cardiac 
fibroblasts (NCF) showed only weak and rare GFP expression (Fig. 22), whereas NCM cultures (mixed 
population of cardiomyocytes and fibroblasts) showed a more homogeneous GFP expression and a 
stronger intensity. Thus, cardiomyocytes seem to be the major target of adenoviral expression and it can 
be assumed that similar expression pattern will be seen in EHT cultures, which consist of equal amounts 
of cardiomyocytes and cardiac fibroblasts. 
 
 
Figure 22: AdGFP is predominantly expressed in cardiomyocytes 
Representative fluorescent (upper left) and transmission (lower left) images of NCF (P3, left) and NCM (right) 
24h after adenoviral transduction with AdGFP with MOI 10. Only few NCF showed GFP expression (left, merge), 
whereas NCM showed almost homogeneous GFP expression (right, merge). Scale bar represents 200 µm. 
 
In EHT cultures, higher MOI needed to be applied in order to establish adequate transduction rates. 48 
h after adenoviral transduction with MOI 50, EHT showed a robust and nearly homogeneous GFP 
expression using both vectors (Fig. 23). Although GFP expression was slightly enhanced at the border 
regions and a little weaker at the inner center of the rings, all layers were transduced. Transduction with 
an MOI 50 resulted in an approximately 70-80% transduction efficiency (estimated values from light 
and fluorescent microscopy). 100% transduction efficiency was not achieved, as GFP expression at the 
border regions would increase dramatically and harm cells in the outer layers before homogenously 
transfecting all cells in the inner layer.  
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Figure 23: Adenoviral-mediated gene transfer in EHT 
Representative transmission (left) and epifluorescent images (middle, right) of control (AdGFP) and S100A1 
(AdS100A1) transduced EHT. Images were taken 48 h after adenoviral transduction with a multiplicity of infection 
of 50 (MOI 50) from living cells. Adenoviral transduction with AdGFP (upper panels) and AdS100A1 (lower 
panel) showed homogeneous GFP expression through all cell layers and was comparable between both vectors. 
Scale bar represents 1mm. 
 
In protein lysates, western blotting analysis confirmed an 8-fold increase in S100A1 protein levels in 
AdS100A1 transduced EHT in comparison to AdGFP transduced control EHT. GFP expression was 
similar between both groups. In failing EHT, S100A1 overexpression increased 3-fold compared to 
control (Fig. 24A, B). Again, GFP expression levels did not differ between failing EHT and 
failing/S100A1 overexpressing EHT while still matching control levels. Real-time PCR based analysis 
of human S100A1 mRNA levels, which is only expressed after S100A1 overexpression, confirmed 
equal expression in S100A1 overexpressing and failing/S100A1 overexpressing EHT (Fig. 24C). Thus, 
viral expression seemed to be equal between control and failing EHT. 
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Figure 24: S100A1 overexpression increases S100A1 protein levels in normal and normalizes S100A1 
protein expression in HF-like EHT 
A) Representative immunoblots for S100A1 and GFP expression from control and ET-1 stimulated EHT after 
adenoviral transduction. EHT were stimulated with 4·10-8 M ET-1 for 96 h, transduced for 48 h with an MOI 50 
with either AdGFP or AdS100A1, protein isolated and subjected to western blot analysis for GFP and S100A1. 
Two duplicates for each condition were depicted and densiometric values were normalized to GAPDH. B) 
Statistical analysis from A. S100A1 protein expression increased 8-fold after S100A1 overexpression in normal 
EHT and 3-fold in failing EHT, while GFP expression was matching between all groups. n=10 control, n=5 ET-1, 
from at least 5 isolations; # p<0.05 vs. ET-1, * p<0.05 vs. control; 1-way ANOVA. C) mRNA analysis for human 
S100A1. Human S100A1 expression did not differ between S100A1 and ET-1+S100A1. mRNA expression was 
normalized to 18s. n=4; student’s t-test. 
 
4.4.2 S100A1 overexpression increases isometric force generation in EHT 
As western blot and real-time PCR analysis confirmed increased S100A1 protein and mRNA levels, the 
next step was to analyze the functional outcome of these increased S100A1 levels in normal and failing 
EHT. 
Again, EHT were transduced with a MOI 50 with either AdFGP (control) or AdS100A1 (S100A1). For 
rescue experiments, EHT were stimulated with 4·10-8 M ET-1 for 48 h before adenoviral transduction 
was performed. EHT were cultured for further 48 h with continuing ET-1 treatment before dose-
respond-curves were recorded in the presence of 0.2 mM-1.6 mM Ca2+.  
Maximum contractility was again achieved at 1.6 mM Ca2+. S100A1 overexpression resulted in superior 
contractility at both Ca2+ concentrations, increasing twitch tension from 0.27 mN to 0.48 mN (Fig. 25). 
In the same manner, S100A1 overexpression reduced TTP to 56.6 ms at 0.4 mM Ca2+, however there 
was only a marginal increase to 58.1 ms at 1.6 mM Ca2+. Additionally, S100A1 overexpression slightly 
reduced Tau from 0.025 to 0.021 s. However, the effects of S100A1 overexpression on TTP and Tau 
were only significant at high [Ca2+]. 
Where TT was strongly impaired in failing EHT, S100A1 overexpression normalized it to 0.11 mN at 
0.4 mM Ca2+, which is comparable to the level of control EHT. At 1.6 mM Ca2+, S100A1 overexpression 
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again normalized TT to 0.35 mN (level of control Ca2+ stimulated). Similarly, S100A1 overexpression 
slightly reduced TTP at 0.4 mM Ca2+ to 74 ms and to 78 ms at 1.6 mM Ca2+ in failing EHT, however, 
TTP was still higher than in control EHT. In failing EHT, S100A1 overexpression had no effects on 
Tau. Ca2+ sensitivity, measured as EC50, was slightly increased after S100A1 overexpression (from 0.43 
to 0.38 mM Ca2+). Stronger effects were seen in failing EHT, where S100A1 overexpression almost 
normalized EC50 (0.68 in failing EHT vs. 0.53 mM Ca2+ in S100A1/ failing EHT) (Fig. 25C). 
 
Figure 25: S100A1 overexpression increases isometric force generation in normal and failing EHT 
A) Representative isometric force twitches from control and ET-1 treated EHT (4·10-8 M for 96 h) with S100A1 
overexpression at 0.4 mM Ca2+ and 1.6 mM Ca2+. EHT were stimulated with a pulse of 5 ms length and 110 mA 
at 2 Hz. [Ca2+]extra was stepwise increased after a recording time of 150 sec and contractile parameter analyzed. B) 
Corresponding quantification of TT, TTP and Tau from control and failing EHT and with S100A1 overexpression 
at 0.4 mM Ca2+ and 1.6 mM Ca2+. S100A1 overexpression resulted in superior contractile performance. n=17 
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control, n=13 ET-1 from at least 6 isolations; * p<0.05 vs. 0.4 mM Ca2+, # p<0.05 vs. 1.6 mM Ca2+; 2-way 
ANOVA. C) Corresponding quantification of EC50. n=20 control, n=6 ET-1; * p<0.05 vs. control; 1-way 
ANOVA. 
 
Summarizing, these data provided evidence that S100A1 overexpression increased systolic contractile 
performance in normal EHT, independent of its Ca2+ load. In failing EHT, S100A1 overexpression was 
able to normalize TT to the levels of control EHT. Still, S100A1 overexpression had not such a strong 
impact on other contractile parameters as TTP and Tau.  
As the effects of S100A1 overexpression were independent of the Ca2+-load in EHT, functional 
recordings were repeated with Iso stimulation to test if S100A1’s effect are also independent of β-AR 
activity (Fig. 26). Again, S100A1 overexpression increased TT after Iso stimulation from 0.2 mN to 
0.44 mN (vs. 0.16 mN to 0.31 mN in control). Iso stimulation slightly reduced TTP from 60 ms to 58 
ms, whereas S100A1 overexpression had no further impact. Similarly, Tau was slightly reduced after 
S100A1 overexpression (0.25 s vs. 0.28 s in control), however, Iso stimulation had no impact on Tau.  
Thus, S100A1 effects on contractile performance were also independent of β-AR stimulation.  
 
Figure 26: S100A1 overexpression increases isometric force generation after β-AR stimulation 
Quantification of TT, TTP and Tau from control and S100A1 overexpressing EHT at 0.2 mM Ca2+ and 1 µM 
Iso/0.6 mM Ca2+. S100A1 overexpression resulted in superior contractile performance. n=20, from at least 6 
isolations; * p<0.05 vs. 0.2 mM Ca2+, # p<0.05 vs. 1µM Iso/0.6 mM Ca2+; 2-way ANOVA. 
 
4.4.3 S100A1 overexpression prevents Ca2+-induced after-contractions 
As shown in the previous section, S100A1 overexpression increased contractile force in normal and 
failing EHT. Given that positive inotropic interventions harbor the risk of triggering pro-arrhythmogenic 
events by increasing SR Ca2+ load, the next part focused on the potential arrhythmogenic potential of 
S100A1 in EHT. Previous work could already show that S100A1 overexpression reduces Ca2+ spark 
frequency and amplitude and protects against β-AR-triggered Ca2+ waves in normal and failing isolated 
adult cardiomyocytes (unpublished data). Still, unloaded cardiomyocytes in vitro do not properly 
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recapitulate the complex situation in intact tissue, where cardiomyocyte-cardiomyocyte and 
cardiomyocyte-fibroblast interaction can contribute to arrhythmogenesis. Similarly, Ca2+ waves must 
not necessarily translate into real arrhythmogenic contraction. For these reasons, the EHT model was 
chosen to analyze potential anti-arrhythmic effects in a minimalistic model, where cells are physically 
coupled and isometric force generation is analyzed.  
Normal and failing EHT were transduced with either AdGFP (control) or AdS100A1 (S100A1) and 
exposed to incremental Ca2+ stress (0.2 mM to 4 mM). The occurrence of after-contractions was counted 
manually and the incidence of after-contractions calculated from the number of total stimulated 
contractions.  
In control EHT, incremental increase in Ca2+ resulted in a dose-dependent increase in after-contractions 
(Fig. 27A). At 1.6 mM Ca2+, 50% of all normal contractions were followed by after-contractions and at 
3.2 mM Ca2+, all (100%) contractions were followed by after-contractions (Fig. 27B). In contrast to that, 
S100A1 overexpression desensitized EHT to Ca2+ overload, as only 10% of after-contractions originated 
at 1.6 mM Ca2+. However, this effect was not present at all Ca2+ concentrations, as at 3.2 mM Ca2+, the 
incidence of after-contractions also reached 100%. Hence, S100A1 overexpression shifted EC50 from 
1.6 mM to 2.1 mM Ca2+ and reduced the sensitivity to after-contractions. 
Similar experiments were performed in failing EHT. In general, failing EHT were much less sensitive 
to Ca2+ stress, which might be a consequence of diminished Serca2, PLB and NXC expression. EC50 in 
failing EHT was 1.8 mM Ca2+; however, S100A1 overexpression was still able to rescue the phenotype 
and increased EC50 further to 2.8 mM Ca2+ (Fig. 27B). 
These experiments in normal EHT were repeated with combined β-AR- and Ca2+ stimulation. In general, 
sensitivity to after-contractions was enhanced after Iso stimulation. However, S100A1 overexpression 
was still able to protect EHT against triggered after-contractions and shifted EC50 from 0.68 to 0.82 
mM Ca2+ (Fig. 27C). 
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Figure 27: S100A1 overexpression reduces the incidence of calcium-triggered after-contractions in normal 
and failing EHT 
A) Representative isometric force twitches of control and S100A1 overexpressing normal and failing EHT. EHT 
were stimulated with 4·10-8 M ET-1 for 96 h and transduced with an MOI 50 of AdGFP (control) or AdS100A1 
(S100A1) for 48 h before subjected to functional force recordings. [Ca2+]extra was stepwise increased after a 
recording time of 150 sec and after-contractions counted manually. Lines above indicate stimulation pulses (110 
mA, 5 ms width, 2 Hz), arrows below indicate non-stimulated after-contraction. B) Quantification of the incidence 
of after-contractions. Ca2+extra was plotted against the calculated incidence of after-contractions. Incremental Ca2+ 
stress resulted in a dose-dependent increase in after-contractions that formed a sigmoidal curve and allowed for 
calculation of EC50 in normal and failing EHT. n=17 control, n=9 ET-1; * p<0.05 vs. control; student’s t-test. C) 
Quantification of the incidence of after-contractions after Ca2+/ β-AR stimulation. n=11; * p<0.05 vs. control/ET-
1; student’s t-test. 
 
In summary, S100A1 overexpression protected normal EHT from Ca2+-induced after-contractions, 
inhibiting pro-arrhythmogenic events. Despite overall reduced sensitivity for Ca2+, failing EHT were 
also protected from after-contractions after S100A1 overexpression. β-AR stimulation sensitized normal 
EHT to after-contractions, while S100A1 acted protective.  
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Thus, despite increasing cellular inotropy, S100A overexpression also prevented Ca2+- and β-AR-
triggered after-contractions.  
 
 
4.5 Elucidating S100A1’s molecular effects  
The previous paragraph confirmed that S100A1 is a profound inotropic agent, yet with similar anti-
arrhythmic potency, protecting against Ca2+ and β-AR-stimulated after-contractions. Key mechanisms 
that could explain these effects can originate from changes in protein expression, phosphorylation 
pathways as well as in RyR2 activity. Thus, the next experiments aimed to identify the underlying 
mechanism of this anti-arrhythmic potency. 
 
4.5.1 S100A1 overexpression does not change expression of major Ca
2+
-handling 
proteins 
Changes in contractile performance can originate from different expression levels of major Ca2+ 
handling proteins which are involved in cardiomyocyte EC coupling. 
However, Serca2 and PLB protein levels in normal and failing EHT did not change after S100A1 
overexpression, despite reduced expression after ET-1 stimulation (Fig. 28A). Similarly, mRNA levels 
of RyR2 and NCX also did not differ after S100A1 overexpression (Fig. 28B). Thus, changes in protein 
or mRNA expression are most likely not responsible for increased contractile performance and anti-
arrhythmic potency. This is in line with previous results in isolated adult cardiomyocytes and in vivo 
experiments, which demonstrated that enhanced activity of S100A1’s target proteins most likely to 
account for the enhanced contractile performance.[134, 137] Complementary analyses also confirmed 
unchanged hsTNT and LDH levels as well as TUNEL positive cells after S100A1 overexpression in 
normal and failing EHT (data not shown).  
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Figure 28: S100A1 overexpression does not changes expression of Serca2, PLB, RyR2 and NCX 
A) Representative immunoblots and statistical analysis for Serca2 and PLB protein expression from control and 
S100A1 transduced EHT. After functional recordings, proteins were isolated and subjected to western blot analysis 
for Serca2 and PLB expression, which did not alter between control and S100A1. Two duplicates for each 
condition were depicted and densiometric values were normalized to GAPDH. n=5 from 5 different isolations; 
*p<0.05; 1-way ANOVA. B) mRNA analysis for RyR2 and NCX, which did not differ between control and 
S100A1. mRNA expression was normalized to 18s. n=4 from 4 different isolation; 1-way ANOVA. 
 
4.5.2 S100A1 overexpression might reduce pro-inflammatory activation 
Next, the pro-inflammatory and pro-fibrotic remodeling of normal and failing EHT after S100A1 
overexpression was analyzed (Fig. 29).  
Il-6 mRNA levels were increased 4-fold in failing EHT, while S100A1 overexpression reduced Il-6 
expression after S100A1 overexpression in failing EHT to control levels. Similarly, ICAM-1 expression 
levels were increased 2-fold in failing EHT and S100A1 overexpression normalized ICAM-1 expression 
levels to control levels. However, these effects were not statistically significant. In contrast, S100A1 
overexpression had no effect on ANP, SMA and collagen-1 mRNA expression levels in failing EHT. 
However, due to unstable PCR values, these effects were also not statistically significant. 
Still, S100A1 overexpression seems to have no effect on pro-fibrotic markers but rather reduced the 
increase in pro-inflammatory markers.  
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Figure 29: S100A1 overexpression after ET-1 treatment reduces pro-inflammatory activation 
mRNA analysis for ANP, SMA, collagen-1 and ICAM-1 in control, failing EHT and after S100A1 overexpression. 
While pro-fibrotic markers as collagen-1 and SMA did not change after S100A1 overexpression in normal and 
failing EHT, pro-inflammatory markers IL-6 and ICAM-1 increased in failing EHT, yet were comparable to 
control levels in failing EHT with S100A1 overexpression. However, this effect was not statistical significant. 
mRNA expression was normalized to 18s. n=4; 1-way ANOVA. 
 
4.5.3 S100A1 overexpression does not change Cx43 expression in EHT 
EHT is a 3-dimensional tissue model where CMs interact with neighboring cells, forming complex 
structures and resembling intact heart tissue. Thus, changes in electrical coupling and electrical 
conductance might also be responsible for the anti-arrhythmic effect. 
Among others, Connexin43 (Cx43) is the major gap junction proteins coupling cardiomyocytes and 
changes in its expression, phosphorylation and localization have been linked to arrhythmogenesis. 
Additionally, cardiomyocyte-fibroblast interactions by Cx43 have been reported as well.[170-172] 
Thus, changes in electrical conductance might originate from changed Cx43 expression or 
phosphorylation levels. 
However, S100A1 overexpression had no effect on Cx43 expression and its phosphorylation status (Fig. 
30). Failing EHT showed a slight increase in Cx34 expression and a reduction in Cx43 phosphorylation, 
but this tendency was not significant. Still, there was no effect of S100A1 overexpression in normal and 
failing EHT neither on Cx43 expression nor on its phosphorylation. Hence, changes in Cx43 expression 
or its phosphorylation are probably not accountable for S100A1’s effects. 
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Figure 30: S100A1 overexpression does not change Cx43 expression and phosphorylation 
Representative immunoblots and statistical analysis from control, failing and S100A1 overexpressing EHT. After 
functional recordings, proteins were isolated and subjected to western blot analysis for Cx43 and p-Cx43 
expression. Two duplicates for each condition were depicted and densiometric values were normalized to GAPDH 
or total Cx43. In failing EHT, Cx43 expression was slightly increased and Cx43 phosphorylation was slightly 
reduced; however there were no further change after S100A1 overexpression. n=4 from 4 isolations; 1-way 
ANOVA. 
 
4.5.4 S100A1 overexpression does not change global PKA or CamKII downstream 
signaling 
Increased PKA- and CamKII-activity have been linked to triggered arrhythmias in vitro and in vivo. 
Most important, RyR2 phosphorylation at serine 2808 (Ser-2808, PKA-mediated) and at serine 2814 
(Ser-2814, CamKII-mediated) have been shown to promote cellular arrhythmias.[46, 74, 75, 81] Global 
changes in PKA- and CamKII activity can be analyzed by PLB phosphorylation. PKA phosphorylates 
PLB at serine 16 (Ser-16) and CamKII at threonine 17 (Thr-17); however, local kinase activity at the 
RyR2 is often more important. 
 
First, PLB phosphorylation was analyzed in normal and failing EHT to estimate changes in global PKA 
and CamKII activity. Before and after functional recordings, EHT were subjected to western blot 
analysis for PLB phosphorylation (Fig. 31). 
Ca2+ stimulation (4 mM) resulted in an exclusive increase in PLB Thr-17 phosphorylation. PLB Ser-16 
phosphorylation was not affected by Ca2+ stimulation, indicating that Ca2+-stress activates selectively 
CamKII. After S100A1 overexpression, PLB phosphorylation pattern did not change.  
In failing EHT, basal (0.2 mM Ca2+) PLB Thr-17 phosphorylation levels were comparable to normal 
EHT. Ca2+ stimulation (4 mM) however dramatically increased PLB Thr-17 phosphorylation. Again, 
Ca2+ stimulation had no effect von PLB Ser-16 phosphorylation in failing EHT, but phosphorylation 
levels were slightly enhanced compared to normal EHT. Again, increasing S100A1 protein levels did 
not interfere with PLB phosphorylation pattern.  
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Figure 31: S100A1 overexpression does not change PLB phosphorylation after Ca2+ stimulation 
Representative immunoblots and statistical analysis from control and S100A1 overexpressing normal (A) and 
failing EHT (B) before (0.2 mM Ca2+) and after Ca2+ stimulation (4 mM Ca2+). Before or after functional 
recordings, proteins were isolated and subjected to western blot analysis for PLB, P-PLB serine 16 and P-PLB 
threonine 17 expressions. Densiometric values were normalized to PLB. Ca2+ stimulation increased P-PLB Thr-
17 in normal and failing EHT, however there was no change in phosphorylation pattern after S100A1 
overexpression. control n=5, ET-1 n=4 from 4 isolations; * p<0.05 vs. 0.2mM Ca2+; 1-way ANOVA. 
 
As sole Ca2+ stimulation did not activate PKA, β-AR stimulation dependent PLB phosphorylation was 
also analyzed in normal EHT (Fig. 32). Iso stimulation increased both PLB Ser-16 and Thr-17 
phosphorylation, as increased cAMP levels are known to increase cytosolic Ca2+, activating CamKII 
indirectly.[21] As shown before, S100A1 overexpression did not interfere with PLB phosphorylation 
pattern after β-AR stimulation.  
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Figure 32: S100A1 overexpression does not change PLB phosphorylation after β-AR stimulation 
Representative immunoblots and statistical analysis from control and S100A1 overexpressing EHT after Iso 
stimulation. Iso (1 µM/ 2 mM Ca2+) stimulation increased P-PLB Ser-16 and Thr-17 in normal EHT, however 
there was no change in PLB phosphorylation pattern after S100A1 overexpression. control n=5, from 4 isolations; 
* p<0.05 vs. 0.2 mM Ca2+; 1-way ANOVA. 
 
Thus, S100A1 overexpression did not change PLB phosphorylation in normal and failing EHT, 
indicating that S100A1 does not interfere with global PKA- and CamKII-activity. 
 
4.5.5 S100A1 overexpression does not change RyR2 phosphorylation 
Next, RyR2 immunoprecipitations (IPs) were performed to analyze local PKA- and CamKII-activity at 
the RyR2. Again, RyR2 phosphorylation was analyzed before and after functional recordings. Ca2+ 
stimulation (4 mM) resulted in a profound increase in RyR2 Ser-2814 phosphorylation, but RyR2 Ser-
2808 phosphorylation was also slightly increased, which indicated increased PKA- and CamKII-
mediated RyR2 phosphorylation (Fig. 33). S100A1 overexpression did not change RyR2 
phosphorylation pattern but resulted in an increase in co-precipitating S100A1 protein, which 
demonstrated enhanced binding to the RyR2 after S100A1 overexpression. Similarly, Iso stimulation 
increased RyR Ser-2808 phosphorylation, but Ser-2814 phosphorylation was difficult to analyze due to 
overall low quality of western blot bands.  
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Figure 33: S100A1 overexpression does not change RyR2 phosphorylation 
A) Representative immunoblots and statistical analysis from control and S100A1 overexpressing EHT after Ca2+ 
stimulation. Before (0.2 mM Ca2+) and after (4 mM Ca2+) functional recordings, two EHT were pooled and RyR2 
was immunoprecipitated. Precipitates were subjected to western blot analysis for RyR2, P-RyR2 Ser-2808 and P-
RyR2 Ser-2814 expression. Densiometric values were normalized to total RyR2. Ca2+ stimulation increased P-
RyR Ser-2814 in EHT, but there was no change in phosphorylation pattern after S100A1 overexpression. However, 
S100A1 overexpression increased co-precipitating S100A1. n=5, from 5 isolations; * p<0.05 vs. 0.2mM Ca2+; 1-
way ANOVA. B) Representative immunoblots and statistical analysis from control and S100A1 overexpressing 
EHT after Iso stimulation. Before (0.2 mM Ca2+) and after (1 µM Iso/2 mM Ca2+) functional recordings, two EHT 
were pooled and RyR2 was immunoprecipitated. Precipitates were subjected to western blot analysis for RyR2, P-
RyR2 Ser-2808 and P-RyR2 Ser-2814 expressions. Densiometric values were normalized to total RyR2. Iso 
stimulation increased P-RyR2 Ser-2814 in EHT, but there was no change in phosphorylation pattern after S100A1 
overexpression. n=5, from 5 isolations; * p<0.05 vs. 0.2 mM Ca2+; 1-way ANOVA 
 
These experiments were only performed in normal and not in failing EHT, as it was difficult to generate 
enough material. As PLB phosphorylation pattern did not change after S100A1 overexpression in failing 
EHT, it is reasonable to assume that RyR2 phosphorylation pattern might also not change after S100A1 
overexpression in failing EHT.  
Thus, S100A1 did not change PKA- and CamKII downstream signaling and this mechanism can be 
excluded from possible explanations for S100A1 anti-arrhythmic effects. 
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4.6 Impact of S100A1 on the RyR2 macrocomplex 
The previous paragraph demonstrated that S100A1 overexpression had no effect on PKA- and CamKII-
mediated RyR2 phosphorylation. Next, the impact of S100A1 on the binding of accessory proteins was 
analyzed, as several studies reported that differential binding of CaM, FKBP12.6 or sorcin can change 
systolic and diastolic RyR2 function.  
As these experiment were difficult to perform in EHT, especially with regard to immunohistochemistry, 
isolated adult rat cardiomyocytes (ACM) were used. A most recent study (see introduction) 
demonstrated that S100A1 overexpression increased Ca2+ transient amplitudes and reduced Ca2+ spark 
frequency and waves in normal and failing ACM, which renders these cells suitable to investigate 
S100A1’s positive inotropic and anti-arrhythmic effects. First, biochemical analyses were repeated 
under the same conditions to confirm unchanged PKA- and CamKII activity before investigating RyR2 
complex formation. 
 
4.6.1 S100A1 overexpression increases S100A1 protein levels in ACM 
S100A1 overexpression in ACM was analyzed 24 h after adenoviral transduction. Transduction of ACM 
with MOI 5 of AdGFP (control) or AdS100A1 (S100A1) resulted in a homogeneous GFP expression in 
all cells. Western blot analysis confirmed a 6-fold increase in S100A1 protein levels and comparable 
GFP expression levels in control and S100A1 transduced ACM (Fig. 34).  
 
Figure 34: S100A1 overexpression increases S100A1 protein levels in adult rat cardiomyocytes 
Representative immunoblots and statistical analysis from control and S100A1 overexpressing ACM. 24 h after 
adenoviral transduction, proteins were isolated and subjected to western blot analysis for S100A1 and GFP 
expression. S100A1 overexpression increased 6-fold after adenoviral transduction with AdS100A1. GFP levels 
were matching between both viruses. Two duplicates were depicted and densiometric values were normalized to 
GAPDH. n=4, from 4 isolations; * p<0.05 vs. control; student’s t-test. 
 
4.6.2 S100A1 overexpression does not change PKA or CamKII downstream signaling 
As the analysis in EHT indicated that S100A1 overexpression has no effect on PKA- and CamKII-
mediated PLB and RyR2 phosphorylation, these results first had to be confirmed in ACM to approve 
similar response to external stressors in both models. Here, β-AR stimulation with Iso was chosen, at 
the analysis in EHT indicated that Iso activates both PKA and CamKII. 
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β-AR stimulation with Iso (10-7 M, 10 min) strongly increased PLB Ser-16 phosphorylation (30-fold) 
and slightly increased PLB Thr-17 phosphorylation (2-fold). However, there were no changes in 
phosphorylation pattern after S100A1 overexpression (Fig. 35A).  
Similar results were obtained after RyR2 IP for RyR Ser-2808 and Ser-2814 phosphorylation: Iso 
stimulation increased Ser-2808 phosphorylation 2-fold and Ser-2814 phosphorylation 1.5 fold, but 
S100A1 overexpression did not change phosphorylation levels further (Fig. 35B). As already seen in 
EHT immunoprecipitates, S100A1 overexpression increased co-precipitating S100A1 protein. 
Thus, ACM showed similar effects of PKA and CamKII activation in response to Iso stimulation and 
can be used to further investigate RyR2 complex formation. 
 
 
Figure 35: S100A1 overexpression does not change PLB and RyR2 phosphorylation pattern 
Representative immunoblots and statistical analysis from control and S100A1 overexpressing ACM. 24 h after 
adenoviral transduction, proteins were isolated or RyR2 IPs performed and subjected to western blot analysis for 
PLB, P-PLB Ser-16, P-PLB Thr-17, (A) RyR2, P-RyR Ser-2808 and P-RyR2 Ser-2814 expression (B). Iso 
stimulation increased P-PLB and P-RyR2 by PKA and CamKII but phosphorylation pattern did not change after 
S100A1 overexpression. Densiometric values were normalized to GAPDH. n=4, from 4 isolations; * p<0.05 vs. 
control; 1-way ANOVA. 
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4.6.3 S100A1 overexpression does not change complex formation of RyR2 
Accessory proteins of the RyR2 have been shown to modulate systolic as well as diastolic RyR2 function 
in vivo and in vitro. In general, CaM, FKBP12.6 and sorcin have all been reported to inhibit RyR2 
function.[71]  
Thus, the proximity ligation assay (PLA) was performed to analyze the binding properties of CaM, 
FKBP12.6 and sorcin to RyR2 after S100A1 overexpression. This assay allows in situ analysis of protein 
interactions in the intact cell, when the distance between two proteins/ primary antibodies is less than 
40 nm. This protein interaction can be visualized as immunofluorescent dot in the microscope (Fig. 
36A). As each dot represents one protein/protein interaction, this can be quantified.  
Again, ACM were transduced with either AdGFP or AdS100A1, stimulated with Iso and PLA was 
performed (Fig. 36B). Iso stimulation slightly reduced CaM/RyR2 interaction. Interestingly, S100A1 
overexpression did not change this under basal conditions as well as after Iso stimulation. In contrast, 
Sorcin/RyR2 interaction was increased after Iso stimulation but again S100A1 overexpression had no 
effect on this interaction. Finally, FKBP12.6/RyR2 interaction did not change at all after Iso stimulation. 
However, all changes were not statistically significant, indicating only tendencies towards changed 
interactions after Iso stimulation. 
Thus, S100A1 overexpression had no effect on the binding properties of accessory proteins to the RyR2, 
indicating that S100A1 had no impact on complex assembly of the RyR2. 
 
Figure 36: S100A1 overexpression does not change CaM/RyR2, FKBP12.6/RyR2 and Sorcin/RyR2 
interaction 
A) Representative immunofluorescence image of PLA in ACM. Each red dot represents one protein/protein 
interaction that can be quantified using ImageJ. Scale bar represent 20 µm. B) Statistical analysis from control and 
S100A1 overexpressing ACM and with Iso stimulation. 24 h after adenoviral transduction, cells were stimulated 
with Iso (10-7 M, 10 min) and PLA were performed to analyze CaM/RyR2, FKBP12.6/RyR2 and sorcin/RyR2 
interaction. Iso stimulation reduced CaM/RyR2 interaction, increased sorcin/RyR2 interaction and had no impact 
on FKBP12.6/RyR2 interaction. However, S100A1 overexpression did not change stoichiometry further. n=4, 
from 4 isolations; 1-way ANOVA. 
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4.6.4 S100A1 overexpression enhances S100A1/RyR2 interaction 
Although already shown by Co-IP, PLA was additionally performed to quantify increased S100A1 
binding to the RyR2 and monitor possible changes during β-AR stimulation. Previous studies 
demonstrated that a 3-4 fold S100A1 overexpression increased S100A1/RyR2 ratio 2-fold as analyzed 
by Co-IP (unpublished data).  
PLA confirmed that Iso stimulation had no effect on S100A1/RyR2 interaction but S100A1 
overexpression increased S100A1/RyR2 ratio 2-fold as analyzed by PLA (Fig. 37).  
Thus, direct interaction of S100A1 with RyR2 could be confirmed with the PLA technology and also 
indicated unchanged binding after β-AR stimulation. This might preferentially account for the anti-
arrhythmic effects of S100A1 overexpression on the RyR2, however, if this is due to allosteric regulation 
of the channel or of different origin remains unclear. 
 
Figure 37: S100A1 overexpression enhances S100A1/RyR2 stoichiometry 
Representative immunofluorescence images (left) and statistical analysis (right) from control and S100A1 
overexpressing ACM. 24 h after adenoviral transduction, cells were stimulated with Iso (10-7 M, 10 min) and PLA 
was performed to analyze S100A1/RyR2 interaction. Iso stimulation had no effect on S100A1/RyR2 interaction 
but S100A1 overexpression enhanced S100A1/RyR2 ratio. n=3, from 3 isolations; * p<0.05 vs. control; 1-way 
ANOVA. Scale bar represents 20 µm. 
 
4.6.5 S100A1 overexpression blunts RyR2 s-nitrosylation after β-AR stimulation 
Changes in cellular redox-state and especially changes in RyR S-nitrosylation (SNO) have recently been 
made responsible for short-term regulation of RyR2 function and its open probability (Po).[87, 101, 102, 
108, 109] 
As standard assays for the detection of nitrosylated proteins were difficult to perform (due to low 
abundance of RyR2 in isolated cells), PLA was performed to specifically link s-nitrosylation to 
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RyR2.[173] By combining a general SNO-antibody with a specific RyR2 antibody, RyR2-SNO could 
specifically be detected (Fig. 38).  
Iso stimulated resulted in increased in RyR2-SNO (2-fold). S100A1 overexpression had no effect on 
RyR2-SNO under basal conditions. Interestingly, the increase in RyR2-SNO after Iso stimulation was 
blunted after S100A1 overexpression and even below control levels.  
 
Figure 38: S100A1 overexpression normalized RyR s-nitrosylation 
Representative immunofluorescence images (left) and statistical analysis (right) from control and S100A1 
overexpressing ACM. 24 h after adenoviral transduction, PLA was performed to analyze RyR2-SNO. Iso 
stimulation increased RyR-SNO, whereas S100A1 overexpression blunted the increase after Iso stimulation. 
n=3, from 3 isolations; * p<0.05 vs. control, # p<0.05 vs. Iso; 1-way ANOVA. Scale bar represent 20 µm.  
 
For the first time, altered RyR2-SNO after S100A1 overexpression might explain S100A1’s differential 
effects on RyR2 function. However, if different redox-modifications (oxidation, glutathionylation) are 
also changed after S100A1 overexpression and if these changes in the redox-status have a functional 
implication need to be investigated in greater detail.  
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5 Discussion 
 
The small Ca2+ binding protein S100A1 controls major Ca2+ driven networks within the CM. The 
positive inotropic actions of S100A1 are mainly dependent on enhanced Ca2+ transients and are 
preserved under β-adrenergic receptor (β-AR) stimulation without affecting cAMP-dependent kinase 
activities.[133-135, 137, 138, 141, 145, 146, 174] In contrast to the current understanding of the action 
of positive inotropes, S100A1 overexpression is in accordance with a reduced diastolic Ca2+ leak in 
isolated cells in vitro (unpublished data). However, until now it remained unclear if the inhibition of the 
diastolic Ca2+ leak also impedes mature arrhythmogenic contractions. 
Within this work, I analyzed the impact of S100A1 on diastolic contraction abnormalities in a 
multicellular tissue model under isometric conditions and unveiled some important mechanistic 
properties.  
 
5.1 Pharmacological stimulation of EHT with ET-1 – an in vitro model of 
failing cardiac tissue 
5.1.1 Classification of EHT into current models for cardiac hypertrophy or heart failure  
Understanding the basic mechanisms of diseases requires experimental in vitro and in vivo models, 
which allow to reconstruct the disease state.  
Rodent models are widely appreciated to understand the etiology of various cardiovascular diseases and 
to study the effects of therapeutic interventions in vivo.[175-177] Still, it is difficult to discriminate 
between direct alterations from systemic and humoral effects seen in these in vivo models. For this 
reason, in vitro models of neonatal and adult rat and mice cardiomyocytes have been utilized to 
circumvent this limitation. For example neonatal and adult rat cardiomyocytes have been stimulated 
with α-AR agonists, endothelin-1, or cultured on silicon membranes and subjected to phasic stretch to 
induce hypertrophy.[154, 178-180] Still, they do not adequately recapitulate changes occurring in vivo 
and have major limitations: First, cardiomyocytes (CMs) in cell culture are distributed diffusely. This 
may limit their informative values as CMs in the heart tissue are highly organized in a 3-dimensional 
network. Second, standard 2-dimensional monolayer cell cultures do not allow measurement of 
contractile function, an important parameter to distinguish hypertrophied from failing CMs. Third and 
even more important, neonatal CMs do not exhibit the same characteristic and mechanistic features as 
adult myocardium as they are not completely differentiated and have an immature phenotype.[181] This 
might bias outcomes of certain studies and lead to false assumptions of regulatory mechanisms in the 
intact heart.[182] Culturing adult CMs can only be performed in good quality for a maximum of 48 h, 
which renders the time period for pharmacological and therapeutic interventions extremely short (own 
observations).[154] 
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To overcome some of these limitations, the model of Engineered Heart Tissue (EHT) was developed. 
Despite build of neonatal rat cells, CMs develop an adult-like phenotype over the culture period (12 
days), which also allows enough time for pharmacological manipulations.[151, 152] Although initially 
developed as tissue repair model to support failing myocardium, current research focuses on the 
utilization of EHT as model system for cardiac hypertrophy, ischemic damage and therapeutic 
testing.[163, 182-188]  
In this work, according to the state-of-the art methods in neonatal cultures, EHT were stimulated with 
low-dose of ET-1 (4·10-8 M for 96 h) to induce heart failure (HF)-like remodeling.[189] This resulted in 
a strong impairment of systolic contractility, as measured by reduced twitch tension (TT). The duration 
of the contraction, measured as time to peak (TTP), was longer in failing EHT at high [Ca2+], which 
indicates stronger effects at higher Ca2+ levels. However, diastolic function, measured by tau, was not 
affected, which points towards an exclusive impairment of systolic function. Furthermore, Ca2+ 
sensitivity was reduced in failing EHT, where similar effects have been shown in isolated muscle fibers 
of failing heart.[190] 
Functional impairment was accompanied by a complex cellular remodeling: In line with the current 
concepts of heart failure, PLB, Serca2 and RyR2 expression were all downregulated and ANP 
expression was upregulated. In contrast, NCX expression was also downregulated in this model, where 
increased expression levels had been reported in failing hearts.[47, 52, 164] Still, it has to be considered 
that this model system might regulate not all proteins in the same way than in the intact heart.  
S100A1 expression has been reported to be reduced in failing hearts, whereas compensated hypertrophy 
showed no reduction is S100A1 levels in vivo.[191] Similarly, stimulation of neonatal rat 
cardiomyocytes with hypertrophic factors resulted in a time and concentration dependent reduction in 
S100A1 expression levels, which might be part of the fetal gene program.[138] Here, S100A1 
expression was also strongly diminished, which underlines a HF-like remodeling.[192]  
Increased fibroblast activation in HF has been attributed to increased smooth muscle actin (SMA), 
collagen-1 and connective tissue growth factor (CTGF) expression.[165, 193] Despite an increase in 
SMA and CTGF levels, there was no change in collagen-1 expression in failing EHT, which might 
originate from the vast amount of collagen in the matrix. Inflammatory markers as interleukin 6 (IL-6) 
and intercellular adhesion molecule 1 (ICAM-1) were also increased, which indicates inflammatory 
remodeling.[194] Thus, failing EHT express markers for pathological cardiomyocyte dysfunction and 
fibroblast activation.  
Furthermore, cell death analysis pointed towards increased necrosis in failing EHT, but no increase of 
apoptotic cell death. Most recently, necrosis has been appreciated to occur in failing hearts in vivo, 
whereas apoptosis occurred only at lower levels in the chronic state.[195, 196] Hence, cell death analysis 
in EHT emphasize on similar effects than the in vivo situation.  
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In contrast to this, nuclei numbers in failing EHT were slightly increased, which suggests no substantial 
increase in cell death. However, in early stages of necrosis, DNA is still intact, thus cell numbers might 
not decrease despite ongoing necrosis.[196] Increased nuclei number might also originate from 
polynucleation of cardiomyocytes or proliferation of fibroblast, which both have been reported to occur 
in failing hearts.[168] Similarly, polynucleation of cardiomyocytes in EHT has been reported after ET-
1 stimulation.[152]  
Altogether, failing EHT showed most features of failing hearts in vitro. Still, heart failure is a clinical 
syndrome and not easily transferable to the culture dish. Although, in vivo experiments will remain the 
gold standard for analysis of functional recovery following myocardial injury and pharmacological 
interventions, EHT might be an attractive model to replace the adult heart to study the effects of different 
stressors and treatments on contractile performance and molecular expression changes. 
 
5.1.2 After-contractions – a model for Ca2+-triggered arrhythmias  
Triggered ventricular arrhythmias are characterized by an abnormal heartbeat, which can become life-
threatening when the heart is unable to fill or empty completely and support the body with oxygenated 
blood. Mechanisms for the origin of ventricular arrhythmias are multifaceted as well as the models 
which have been utilized for their analysis in vivo.[170] 
Investigating this effect in vitro exposed Ca2+ mishandling as major cause of arrhythmias in ventricular 
CMs: Ca2+ overload results in diastolic Ca2+ leakage, which in turn can induce delayed after-
depolarizations (DADs) that lead to mature action potentials and extra contractions.[9, 48-50] State-of-
the-art techniques for the analysis of abnormal diastolic Ca2+ handling include confocal Ca2+ imaging of 
Ca2+ sparks and Ca2+ waves and action potential recordings to monitor DADs.[197] However, these 
effects are mainly explored in isolated ACMs, which are not cultivated under loaded conditions. 
Additionally, cell-cell interactions, which might contribute to arrhythmogenesis, are not 
considered.[171, 172] Thus, EHT may represent a more refined model to analyze arrhythmogenesis as 
cells are cultivated under loaded conditions and contraction abnormalities can be recorded under 
isometric conditions.  
Although described before, optical imaging techniques as FURA-2-based Ca2+ imaging and di-4-
ANEPPS-based electrical recording remained difficult in EHT, as penetration of the dye into the EHT 
matrix was incomplete and a special setup for the optical recording additionally to the force recordings 
would have been needed.[185] Moreover, the conduction of electric currents during force recordings 
was unmanageable, as artefacts from the stimulation electrodes were too strong to detect electrical 
currents. Thus, it was not possible to resolve Ca2+ cycling or electrical currents in combination with 
functional recordings. 
On a cellular level, Ca2+ overload is known to induce store-overload-induced Ca2+-release (SOICR) in 
single cells, which can manifest itself in extra contractions.[50, 57] Thus, this mechanisms might also 
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take place in EHT. Indeed, increasing [Ca2+] in the tyrode solution (above physiological levels) did not 
only increase contractile force of EHT, but after accomplishment of max. TT, Ca2+ overload induced 
concentration-dependent contraction abnormalities, referred to as after-contractions. Thus, it is quite 
plausible that cellular Ca2+ overload also occurs in EHT and triggers diastolic Ca2+ leakage, resulting in 
mature contractions. Additionally, these after-contractions were profoundly inhibited by ryanodine and 
known anti-arrhythmic drugs as Flecainide without loss of overall TT, supporting that known cellular 
mechanisms are the origin of after-contractions.  
Similarly, Schaaf et al. reported the nascent of contraction abnormalities in respond to pro-
arrhythmogenic drugs in a similar model of reconstituted heart tissue from human embryonic stem 
cells.[187] Automatically detection of irregular beating pattern was used to describe the arrhythmogenic 
potential, which is similar to the manual tracking of after-contractions applied for this study. 
Here, the contraction abnormalities, or after-contractions, were counted manually over a wide range of 
[Ca2+] (0.2 mM-4 mM Ca2+). First, after-contractions originated sporadically with no loss of overall TT. 
During this phase, the SR might still be able to compensate diastolic Ca2+ loss and maintain SR Ca2+ 
load. With increasing [Ca2+], after-contractions were more pronounced, which was accompanied by a 
strong decrease in TT. This might originate from improper diastolic SR filling due to massive diastolic 
Ca2+ loss.[47] Unfortunately, standard methods for the estimation of SR Ca2+ load (e.g. by the rapid 
application of high doses caffeine or rapid cooling to 4°C) were unsuccessful, as the diffusion into the 
tissue might take to long for homogeneous effects. Additionally, β-AR stimulation with isoproterenol 
(Iso) sensitized EHT to much lower Ca2+ concentrations (EC50Ca=1.8 mM Ca2+, EC50Iso=0.7 mM Ca2+). 
β-AR stimulation is known to further increase SR Ca2+ load, promoting SOICR and supporting the 
diastolic Ca2+ leak.[86] Knowing this underlying mechanism in single cells and the combined treatment 
with anti-arrhythmic drugs argue for SOICR as basis for the origin of after-contractions. 
All in all, this model showed a simple and robust induction of after-contractions that will be useful in 
evaluating potential therapeutic anti-arrhythmic approaches. 
 
 
 
5.2 Validation of S100A1’s therapeutic potential in normal and failing EHT 
Therapeutic effects of S100A1 have been demonstrated in different studies in vivo and in vitro.[133-
135, 137-139, 141, 145, 146] So why use another model to investigate S100A1 effects if different in 
vivo and in vitro models are available and therapeutic effects have already been shown? Animal models 
are great to demonstrate efficacy of therapeutic interventions and to investigate if side effect or 
compensatory mechanisms take place. Yet, when it comes down to the identification of the underlying 
mechanism, the whole body might be too complex to elucidate key mechanisms. Just the other way 
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around, in vitro models are great to investigate cellular effects and decipher the exact mechanism, 
however if these mechanisms also take place in intact heart tissue remains elusive. 
Thus, EHT represents an intermediate model, where the effects of S100A1 can be analyzed in a 
minimalistic system. Here, cells are cultivated under cyclic stretch and functional recordings are 
performed under isometric conditions. This allows analysis of functional effects as well as the 
breakdown of key mechanisms. Furthermore, novel therapeutic actions might be unveiled that cannot 
be seen in isolated cells and have not been uncovered in vivo yet. 
   
5.2.1 S100A1 acts positive inotropic and anti-arrhythmic in EHT 
Positive inotropic effects of S100A1 have been shown in various experimental HF models in vivo and 
in vitro.[133-135, 137-139, 141, 145, 146] Therefore, positive inotropic effects of S100A1 in EHT were 
first validated to show efficacy of adenoviral-mediated S100A1 gene transfer in this model.  
As expected, S100A1 overexpression in normal EHT showed superior systolic contractility, which was 
preserved under Ca2+ and β-AR stimulation. Improved contraction duration (TTP) and relaxation (tau) 
were only seen at high [Ca2+]. This might indicate that S100A1’s effects are even more pronounced at 
high [Ca2+]. S100A1 overexpression in failing EHT demonstrated normalized systolic contractility 
comparable to control EHT. Here, not effects on other contractility parameters were seen, but S100A1 
normalized Ca2+ sensitivity of failing EHT.  
Summarizing, S100A1 inotropy could be confirmed in this model, which demonstrates feasibility and 
efficacy of S100A1 gene transfer in EHT. Applying different inotropic stimulation (Ca2+ alone or 
combined β-AR/ Ca2+ stimulation) revealed that S100A1 acts on top of Ca2+/ cAMP-dependent 
pathways.  
The potential anti-arrhythmic effect of S100A1 has only been shown in isolated adult CMs so far. A 
most recent study by Völkers et al. (unpublished data) demonstrated that adenoviral-mediated 
overexpression of S100A1 in normal and failing adult rat CMs was able to inhibit SOICR. This reduced 
the diastolic Ca2+ leak, which manifested in a diminished frequency of triggered Ca2+ sparks and Ca2+ 
waves.  
Thus, the inhibition of after-contractions by S100A1 in normal and failing EHT was able to confirm and 
even extend these data: Manual counting of after-contractions after Ca2+ and β-AR stimulation was used 
to quantify susceptibly to triggered arrhythmias and subsequent calculation of EC50 allowed estimation 
of the therapeutic potential. Thus, S100A1 overexpression increased EC50 both after Ca2+ as well as 
after β-AR stimulation, suggesting enhanced resistance against Ca2+ triggered after-contractions.  
Although failing EHT were much less sensitive to Ca2+, S100A1 overexpression also prevented Ca2+ 
triggered after-contractions in these EHT. The reduced sensitivity of failing EHT to Ca2+ could originate 
from the great reduced contractile performance and the reduced expression of Ca2+ handling proteins. 
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This would lead to general reduced cytosolic Ca2+ uptake, reduced SR Ca2+ load and subsequently 
reduced [Ca2+]i, that would be too little to trigger after-contractions.  
Previous experiments in isolated CM only used β-AR stimulation a stressor, focusing on the impact of 
S100A1 on diastolic Ca2+ handling after β-AR stimulation. In this study, experiments were conducted 
with exclusive Ca2+ stimulation as well as combined β-AR stimulation. This indicates that S100A1 does 
not rely on cAMP-dependent signal pathways but directly targets the Ca2+ mishandling.   
For therapeutic purpose, it would be interesting to perform further pharmacological studies and test 
current anti-arrhythmic drugs that target different steps in the development of Ca2+ triggered arrhythmias 
against S100A1 and see if S100A1’s effects are on top of other anti-arrhythmic drugs. However, these 
experiments were beyond the scope of this study.  
 
5.2.2 S100A1 effects are independent of changes in contractile protein expression pattern 
In previous studies, expression analyses yielded that S100A1-mediated effects on Ca2+ cycling and 
contractile performance did not result from an altered abundance of SR proteins, but changes in 
S100A1’s target protein activity might account for these effects.[134, 137] Here, S100A1 
overexpression also had no effect on the expression on major Ca2+ handling proteins in normal and 
failing EHT. More precisely, despite persistent changes in protein and mRNA expression pattern, 
S100A1 acted positive inotropic and anti-arrhythmic. 
Anti-hypertrophic and anti-fibrotic effects of S100A1 have only been demonstrated in vivo so far and 
analysis in isolated cells could not confirm any anti-hypertrophic or -fibrotic effects of S100A1.[135, 
138, 141] Therefore it can be assumed that feedback mechanisms, potentially by normalized 
catecholamine levels, most probably account for these effects in vivo which do not take place in isolated 
cells. In this study, S100A1 overexpression also had no effect on hypertrophic or fibrotic remodeling in 
EHT, as neurohumoral regulation does not take place in this model.  
Although negligible in isolated cells, electrical coupling in intact tissue can have a major impact on 
electrical coupling, action potential propagation and the development of arrhythmias.[170] As depicted 
before, the recording of the electrical current was impossible in the organ bath setup and analysis with 
fluorescent dyes also failed. Thus, a more easy readout to measure electrical conductance in EHT was 
chosen: Cardiomyocytes are electrically coupled via gap junctions, which consist of Connexin43 
(Cx43), Connexin40 and 50. Cx43 is the most abundant gap junction protein and altered expression, 
phosphorylation and localization have been linked to arrhythmogenesis.[170-172] Thus, analysis of 
Cx43 expression and phosphorylation pattern might shed light on the conduction properties in EHT. 
However, there were no changes neither in expression nor on the phosphorylation of Cx43 between 
normal and failing EHT and after S100A1 overexpression. Thus, changes in electrical coupling do 
mostly likely not account for the anti-arrhythmic effects of S100A1 in EHT.  
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5.3 Challenging current concepts for the development of Ca2+ triggered 
arrhythmias 
5.3.1 S100A1 acts independent of PKA/CamKII signaling 
Changes in local PKA- and CamKII signaling at the RyR2 have been made responsible for the 
development of cellular arrhythmias.[39, 74, 75, 198] Current research focusses on RyR2 
phosphorylation by PKA (Ser-2808) and CamKII (Ser-2814) as important regulators of RyR2 function. 
In heart failure, hyperphosphorylation by both kinases is supposed to mediate the diastolic Ca2+ leak. 
However, not all groups have been able to reproduce these results and there is an ongoing debate which 
kinase is more important.[74, 75, 198, 199] Still, most researchers agree on the fact that RyR2 
phosphorylation is important for its function. 
Illuminating the impact of S100A1 on RyR2 phosphorylation showed no changes is phosphorylation 
patterns: In EHT, Ca2+ stimulation activated exclusively CamKII as analyzed by phosphorylation of 
PLB Thr-17 and RyR2 Ser-2814 in normal EHT. Failing EHT showed not increase in PLB Thr-17 under 
basal conditions, however PLB Thr-17 phosphorylation was exaggerated after Ca2+ stimulation, 
indicating enhanced CamKII activity in failing EHT. Still, S100A overexpression had no effect on PLB 
phosphorylation pattern. As analysis of RyR2 phosphorylation in failing EHT was difficult to perform 
due to low abundance of the RyR2, the PLB phospho-signature was extrapolated and it is assumed that 
S100A1 also has no effect on RyR2 phosphorylation in failing EHT. To test the effects of S100A1 
overexpression on combined β-AR/Ca2+ stimulation, analysis in normal EHT were repeated with both 
stimulations. Again, there were no changes in RyR2 and PLB phosphorylation pattern after S100A1 
overexpression, so these experiments were not repeated in failing EHT. In ACM, similar effects were 
seen with β-AR stimulation. According to this, S100A1 does not change PKA- and CamKII-mediated 
phosphorylation pattern in isolated cells. 
In this study, the expression of phosphatases (eg. PP1 and PP2a) and their activity was not analyzed. So 
it remains unclear if S100A1 has a direct impact on their activity. However, as S100A1 overexpression 
did not change phosphorylation patterns of their targets it can be assumed that their activity did not 
change. In a very unlikely situation, phosphatase and kinase activity could both be regulated by S100A1; 
however net effects (phosphorylation pattern) would not change and therefore this more theoretical 
concept can be neglected. 
Summarizing, these experiments indicate that S100A1’s inotropic and anti-arrhythmic effects do not 
rely on PKA/CamKII signaling but that S100A1 acts independent on phospho-dependent changes. This 
challenges current anti-arrhythmic concepts, which assume normalized RyR2 phosphorylation as 
prerequisite for proper RyR2 function and anti-arrhythmic effects.  
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5.3.2 Regulating the RyR2 macrocomplex - S100A1/RyR2 interaction as key for anti-
arrhythmic effects 
As described before, the RyR2 is one of the largest ion channels that is tightly regulated not only by 
phosphorylation but also by the binding of accessory proteins. These are supposed to mediate channel 
opening and further regulate short- and long-term channel activity.[71, 200] 
Currents concepts argue for a major role of FKBP12.6 in the development of Ca2+ triggered arrhythmias. 
In combination with RyR2 Ser-2808 hyperphosphorylation, FKBP12.6 dissociation is supposed to 
increase the diastolic Ca2+ leak.[74, 75, 81, 83, 198, 201]  
Supporting this notion, Vinet et al. demonstrated that transgenic overexpression of FKB12.6 protected 
against triggered ventricular tachycardia in vivo.[202] However, latest research by Galfré et al. (2012) 
and Zissimopoulos et al. provided evidence that not only FKBP12.6, but also its isoform FKBP regulates 
RyR2 channel opening and that their stoichiometry might be species dependent.[203, 204] This fact 
would also explain the differential outcome of in vivo and in vitro studies, using mice and isolated rat, 
sheep or pig sarcoplasmic reticulum vesicles respectively. In rat CMs, FKBP12.6 is supposed to be the 
predominant isoform.[204] 
In this study, FKBP12.6 binding properties were analyzed in intact isolated rat ACM with the proximity 
ligation assay (PLA) technology, which has been demonstrated to be a reliable method to detect protein-
protein interaction. Iso stimulation, which was shown to increases RyR Ser-2808 and Ser-2814 
phosphorylation, was applied. Interestingly, FKBP12.6 binding did not change under β-AR stimulation 
nor after S100A1 overexpression. Thus, S100A1 overexpression has no effect on FKBP12.6 binding. 
So far, this study also does not support the hypothesis that RyR2 Ser-2808 phosphorylation is the major 
trigger for FKBP12.6 dissociation but that other factors might mediate this effect. It could also be that 
FKBP12.6/RyR2 interaction is not dynamic and that dissociation only occurs with chronic or long-term 
stimulation.  
Sorcin is a general inhibitor of the RyR2, reducing Ca2+ transients and decreasing Ca2+ spark 
frequency.[97-99] Interestingly, this study revealed that sorcin binding to the RyR2 was slightly 
increased after β-AR stimulation; however, S100A1 overexpression had no impact on sorcin binding. 
Interestingly, Anthony et al. and Lokuta et al. provided evidence that sorcin can be phoyphorylated by 
both CamKII and PKA, thereby losing its inhibitory effect on the RyR2 despite persistent binding.[96, 
205] Thus, it is rather speculating that activated CamKII and PKA (which has been demonstrated in this 
study by increased RyR Ser-2814 and Ser-2808 phosphorylation) phosphorylated sorcin. However, this 
does not explain the increased sorcin/RyR2 interaction after β-AR stimulation. As sorcin was reported 
to translocate quickly upon increasing [Ca2+]i, from the cytosol to the membrane, it might also be 
possible that increasing [Ca2+] rather increases sorcin binding to the RyR2, coordinating EC 
coupling.[97]  
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CaM binding to the RyR2 is supposed to occur rather static although CaM affinity is supposed to decline 
with decreasing [Ca2+].[71, 92, 93] The binding site of CaM to cardiac as well as skeletal RyR is well 
defined, however shows distinct discrepancies: In skeletal muscle, CaM binding to RyR1 is Ca2+ 
dependent and apoCaM (Ca2+-free CaM) and CaM show different affinities for the RyR1.[71, 206, 207] 
Additionally, structural studies suggest that S100A1 competes for the same binding site as CaM.[208] 
In cardiac muscle, CaM decreases RyR2 opening at all [Ca2+].[71, 91, 92] Previous reports suggested 
that S100A1 binds to the same binding domain as CaM, however fluorescence resonance energy transfer 
(FRET) studies point towards differential binding sites of S100A1 and CaM (unpublished data).[209]  
This study indicates that S100A1 has no impact on CaM binding to the RyR2 neither under basal 
condition nor after β-AR stimulation. However, this must not necessarily mean that S100A1 and CaM 
have distinct binding sites but can have other reasons: 1) Comprehensive data suggests that CaM 
interacts with the RyR2 in 1:1 ratio, thus every RyR2 tetramer is loaded with 4 molecules CaM, although 
only 1 CaM/RyR2 is necessary for proper channel inhibition.[92] The ratio of S100A1:RyR2 remains 
elusive. However, these studies could overestimate the CaM/RyR2 ratio and it might be possible that 
only a subset of RyR2 is loaded with CaM. Assumed that only 20% of RyR2 are loaded with S100A1 
and a 5-fold overexpression doubles S100A1/RyR2 interaction (40%), 60% of RyR2 might be loaded 
with CaM under physiological conditions. However, if the majority (50% or more) of RyR2 is loaded 
with S100A1, doubling this interactions would leave no space for CaM/RyR2 interaction. Thus, 
CaM/RyR2 needs to be lower than estimated if S100A1 competes for the same binding site or 
S100A1/RyR2 interaction needs to be extremely low. 2) S100A1 has a distinct binding site that is 
allosterically regulated by CaM. In this scenario, CaM and S100A1 binding would be dependent on each 
other but binding ratio would not interfere directly. However, a current work demonstrated that mutating 
one amino acid (aa) in the CaM binding site on the RyR2 distracts S100A1 effects on RyR2 Po.[209] 
Still, there is no evidence about how this mutation affects channel structure and this might disturb 
S100A1/RyR2 interaction due to structural changes. Therefore, it will become quite interesting to 
identify the exact binding site of S100A1 on the RyR2 and to determine the exact binding stoichiometry.  
In summary, S100A1 overexpression had no impact on the binding of accessory proteins to the RyR2 
and thus changes in their binding properties do most likely not account for S100A1’s effect. In line with 
this conclusion, a most recent study demonstrated that recombinant S100A1 reduced RyR Po in lipid 
bilayers.[209] Thus, increased S100A1/RyR2 interaction might indeed reduce the diastolic Ca2+ leak 
and prevent Ca2+ triggered arrhythmias.  
Expanding current theories for the regulation of RyR2, redox-modifications have come to fore as novel 
mediator of RyR2 activity.[87, 101, 102, 108, 109] However, analyzing their effects is not easy and it 
is important not only to consider one redox-modifications, but the whole spectrum as they are highly 
interactive and mostly dependent on each other.[210] In this study, quiescent cardiomyocytes were used 
and physiological amounts of Iso used for a short-term stimulation. This is not supposed to have 
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oxidative effects but rather increase cell activity in a physiological manner.[104] In failing CMs, the 
situation becomes more complex, as oxidation already takes place under basal conditions.[108] Still, 
S100A1 positive effects have also been seen in quiescent cells with physiological β-AR stimulation. 
Thus, effects seen in this state might also hold true in failing cells. 
In this study, RyR2 s-nitrosylation (SNO) was analyzed with the PLA technology, which allows to 
specifically detect nitrosylated RyR2, as an unspecific nitro-antibody is linked to the RyR2-antibody. 
RyR2-SNO has been reported to increase RyR2 channel PO in lipid bilayer recordings.[101, 107] In 
contrast, NOS1 knock-out mice demonstrated reduced RyR2-SNO and an increased diastolic Ca2+ 
leak.[102] However, oxidation of RyR2 was also increased in this study, which underlines the 
interaction of different redox-modifications. In failing hearts, reduced RyR2-SNO is also a results of 
increased oxidation, contributing to the diastolic Ca2+ leak.[103, 105, 108]  
Here, β-AR increased RyR-SNO. As oxidation is supposed to reduce RyR2-SNO, Iso stimulation might 
not be oxidative in this setting.[104] Interestingly, S100A1 overexpression had no impact on RyR2-
SNO under basal conditions, however, it blunted the increase in RyR2-SNO after Iso stimulation.  
For the first time, this study demonstrates that S100A1 has an impact of protein modifications as RyR2-
SNO. However, the reason for this effects might be pleiotropic and are beyond of the scope of this work.  
 
 
 
5.4 Conclusion and Outlook 
While the results presented in this work are far from providing a complete understanding of the 
mechanistic properties of S100A1’s action in CM, they substantially extend our knowledge about 
S100A1’s actions: 
S100A1 anti-arrhythmic properties could be confirmed in a 3-dimensional tissue culture model and will 
most probably also account for anti-arrhythmic effects in vivo.  
With regard to its mechanism, this study clearly demonstrated that S100A1 does not rely on phospho-
dependent changes at the RyR2 nor on the differential binding of accessory proteins but that enhanced 
binding of S100A1 to the RyR2 will most probably account for its effects. This is contrary to the current 
understanding of the mechanism of anti-arrhythmic therapies, which assume normalization of 
phosphorylation-dependent changes at the RyR2 and restoration of complex formation with accessory 
proteins as prerequisite for anti-arrhythmic effects. However, this study also indicated that enhanced 
S100A1/RyR2 stoichiometry might furthermore be responsible for redox-dependent modifications of 
the RyR2. 
 
Still, some questions from this study remain unanswered: 
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- Where is the binding site for S100A1 on the RyR2 and what is the binding ratio of 
S100A1:RyR2? 
- How does S100A1 change RyR2 nitrosylation? Is this a direct effect and due to changes in 
redox-enzymes or is this due to general improved redox-balance in the cell? 
- Are S100A1’s effects dependent on its own redox-changes (e.g. changes in nitrosylation)? 
 
Answering these questions will help us to even better understand S100A1’s effect in cardiomyocytes, 
however they will be the goal of future studies. 
 
  
 
References 
83 
 
6 References 
 
1. (AHA), A.H.A., Cardiovascular Disease Statistics. 2010. 
2. (WHO), W.H.O., Fact Sheet No 317. 2009. 
3. Hunt, S.A., et al., ACC/AHA guidelines for the evaluation and management of chronic heart 
failure in the adult: executive summary. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to 
revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll 
Cardiol, 2001. 38(7): p. 2101-13. 
4. Ho, K.K., et al., The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol, 
1993. 22(4 Suppl A): p. 6A-13A. 
5. Berridge, M.J., M.D. Bootman, and P. Lipp, Calcium--a life and death signal. Nature, 1998. 
395(6703): p. 645-8. 
6. Berridge, M.J., P. Lipp, and M.D. Bootman, The versatility and universality of calcium 
signalling. Nat Rev Mol Cell Biol, 2000. 1(1): p. 11-21. 
7. Kretsinger, R.H., Calcium-binding proteins. Annu Rev Biochem, 1976. 45: p. 239-66. 
8. Berridge, M., P. Lipp, and M. Bootman, Calcium signalling. Curr Biol, 1999. 9(5): p. R157-9. 
9. Berridge, M.J., Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem Soc 
Trans, 2006. 34(Pt 2): p. 228-31. 
10. Bootman, M.D., et al., Calcium signalling--an overview. Semin Cell Dev Biol, 2001. 12(1): p. 
3-10. 
11. Berridge, M.J., Calcium microdomains: organization and function. Cell Calcium, 2006. 40(5-
6): p. 405-12. 
12. Berridge, M.J., M.D. Bootman, and H.L. Roderick, Calcium signalling: dynamics, homeostasis 
and remodelling. Nat Rev Mol Cell Biol, 2003. 4(7): p. 517-29. 
13. Kretsinger, R.H., Structure and evolution of calcium-modulated proteins. CRC Crit Rev 
Biochem, 1980. 8(2): p. 119-74. 
14. Kretsinger, R.H., Evolution and function of calcium-binding proteins. Int Rev Cytol, 1976. 46: 
p. 323-93. 
15. Kretsinger, R.H., The informational role of calcium in the cytosol. Adv Cyclic Nucleotide Res, 
1979. 11: p. 1-26. 
16. Kretsinger, R.H. and N.D. Moncrief, Evolution of calcium modulated proteins. Va Explor, 1989. 
5(5): p. 7-9. 
17. Bers, D.M., Excitation-Contraction Coupling  and Cardiac Contractile Force. Kluwer 
Academic Publishers, 2001. Second Edition: p. Chapter 1 Ultrastructure   
18. Bers, D.M., Cardiac excitation-contraction coupling. Nature, 2002. 415(6868): p. 198-205. 
References 
84 
 
19. Lehnart, S.E., et al., Stabilization of cardiac ryanodine receptor prevents intracellular calcium 
leak and arrhythmias. Proc Natl Acad Sci U S A, 2006. 103(20): p. 7906-10. 
20. Lompre, A.M., M. Anger, and D. Levitsky, Sarco(endo)plasmic reticulum calcium pumps in 
the cardiovascular system: function and gene expression. J Mol Cell Cardiol, 1994. 26(9): p. 
1109-21. 
21. Robertson, S.P., et al., The effect of troponin I phosphorylation on the Ca2+-binding properties 
of the Ca2+-regulatory site of bovine cardiac troponin. J Biol Chem, 1982. 257(1): p. 260-3. 
22. Wehrens, X.H., et al., FKBP12.6 deficiency and defective calcium release channel (ryanodine 
receptor) function linked to exercise-induced sudden cardiac death. Cell, 2003. 113(7): p. 829-
40. 
23. Wehrens, X.H. and A.R. Marks, Altered function and regulation of cardiac ryanodine receptors 
in cardiac disease. Trends Biochem Sci, 2003. 28(12): p. 671-8. 
24. Fabiato, A. and F. Fabiato, Contractions induced by a calcium-triggered release of calcium 
from the sarcoplasmic reticulum of single skinned cardiac cells. J Physiol, 1975. 249(3): p. 469-
95. 
25. Bers, D.M. and V.M. Stiffel, Ratio of ryanodine to dihydropyridine receptors in cardiac and 
skeletal muscle and implications for E-C coupling. Am J Physiol, 1993. 264(6 Pt 1): p. C1587-
93. 
26. Cheng, H. and W.J. Lederer, Calcium sparks. Physiol Rev, 2008. 88(4): p. 1491-545. 
27. Marx, S.O., et al., Coupled gating between cardiac calcium release channels (ryanodine 
receptors). Circ Res, 2001. 88(11): p. 1151-8. 
28. Huxley, H.E., Sliding filaments and molecular motile systems. J Biol Chem, 1990. 265(15): p. 
8347-50. 
29. Laver, D.R., et al., Termination of calcium-induced calcium release by induction decay: an 
emergent property of stochastic channel gating and molecular scale architecture. J Mol Cell 
Cardiol, 2013. 54: p. 98-100. 
30. Ruegg, J.C., Towards a molecular understanding of contractility. Cardioscience, 1990. 1(3): p. 
163-8. 
31. Tada, M., et al., Calcium transport by cardiac sarcoplasmic reticulum and phosphorylation of 
phospholamban. Mol Cell Biochem, 1982. 46(2): p. 73-95. 
32. Delbridge, L.M., J.W. Bassani, and D.M. Bers, Steady-state twitch Ca2+ fluxes and cytosolic 
Ca2+ buffering in rabbit ventricular myocytes. Am J Physiol, 1996. 270(1 Pt 1): p. C192-9. 
33. Dibb, K.M., D.A. Eisner, and A.W. Trafford, Regulation of systolic [Ca2+]i and cellular Ca2+ 
flux balance in rat ventricular myocytes by SR Ca2+, L-type Ca2+ current and diastolic 
[Ca2+]i. J Physiol, 2007. 585(Pt 2): p. 579-92. 
34. Tada, M. and T. Toyofuku, SR Ca(2+)-ATPase/phospholamban in cardiomyocyte function. J 
Card Fail, 1996. 2(4 Suppl): p. S77-85. 
References 
85 
 
35. Sato, D. and D.M. Bers, How does stochastic ryanodine receptor-mediated Ca leak fail to 
initiate a Ca spark? Biophys J, 2011. 101(10): p. 2370-9. 
36. Ly, H., et al., Gene therapy in the treatment of heart failure. Physiology (Bethesda), 2007. 22: 
p. 81-96. 
37. Pogwizd, S.M., et al., Arrhythmogenesis and contractile dysfunction in heart failure: Roles of 
sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic 
responsiveness. Circ Res, 2001. 88(11): p. 1159-67. 
38. Knollmann, B.C. and D.M. Roden, A genetic framework for improving arrhythmia therapy. 
Nature, 2008. 451(7181): p. 929-36. 
39. Lehnart, S.E., et al., Cardiac ryanodine receptor function and regulation in heart disease. Ann 
N Y Acad Sci, 2004. 1015: p. 144-59. 
40. Dixit, S.S., et al., Effects of CaMKII-mediated phosphorylation of ryanodine receptor type 2 on 
islet calcium handling, insulin secretion, and glucose tolerance. PLoS One, 2013. 8(3): p. 
e58655. 
41. Mazzini, G.S., et al., The ischemic rat heart releases S100B. Life Sci, 2005. 77(8): p. 882-9. 
42. Kranias, E.G. and R.J. Solaro, Phosphorylation of troponin I and phospholamban during 
catecholamine stimulation of rabbit heart. Nature, 1982. 298(5870): p. 182-4. 
43. Witcher, D.R., et al., Unique phosphorylation site on the cardiac ryanodine receptor regulates 
calcium channel activity. J Biol Chem, 1991. 266(17): p. 11144-52. 
44. Marx, S.O., et al., PKA phosphorylation dissociates FKBP12.6 from the calcium release 
channel (ryanodine receptor): defective regulation in failing hearts. Cell, 2000. 101(4): p. 365-
76. 
45. Bers, D.M. and E. Grandi, Calcium/calmodulin-dependent kinase II regulation of cardiac ion 
channels. J Cardiovasc Pharmacol, 2009. 54(3): p. 180-7. 
46. Wehrens, X.H., et al., Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates 
the cardiac ryanodine receptor. Circ Res, 2004. 94(6): p. e61-70. 
47. Houser, S.R., V. Piacentino, 3rd, and J. Weisser, Abnormalities of calcium cycling in the 
hypertrophied and failing heart. J Mol Cell Cardiol, 2000. 32(9): p. 1595-607. 
48. Hobai, I.A. and B. O'Rourke, Decreased sarcoplasmic reticulum calcium content is responsible 
for defective excitation-contraction coupling in canine heart failure. Circulation, 2001. 103(11): 
p. 1577-84. 
49. Wasserstrom, J.A., et al., Multiple defects in intracellular calcium cycling in whole failing rat 
heart. Circ Heart Fail, 2009. 2(3): p. 223-32. 
50. Belevych, A., et al., Enhanced ryanodine receptor-mediated calcium leak determines reduced 
sarcoplasmic reticulum calcium content in chronic canine heart failure. Biophys J, 2007. 
93(11): p. 4083-92. 
References 
86 
 
51. Piacentino, V., 3rd, et al., Modulation of contractility in failing human myocytes by reverse-
mode Na/Ca exchange. Ann N Y Acad Sci, 2002. 976: p. 466-71. 
52. Hasenfuss, G. and B. Pieske, Calcium cycling in congestive heart failure. J Mol Cell Cardiol, 
2002. 34(8): p. 951-69. 
53. Schwinger, R.H., et al., Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium 
due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol, 1999. 31(3): p. 
479-91. 
54. Hobai, I.A. and B. O'Rourke, Enhanced Ca(2+)-activated Na(+)-Ca(2+) exchange activity in 
canine pacing-induced heart failure. Circ Res, 2000. 87(8): p. 690-8. 
55. Marks, A.R., Cardiac intracellular calcium release channels: role in heart failure. Circ Res, 
2000. 87(1): p. 8-11. 
56. Kilter, H. and M. Bohm, [From hypertension to heart failure-a pathophysiological continuum]. 
Herz, 2004. 29(3): p. 239-47. 
57. Shannon, T.R., S.M. Pogwizd, and D.M. Bers, Elevated sarcoplasmic reticulum Ca2+ leak in 
intact ventricular myocytes from rabbits in heart failure. Circ Res, 2003. 93(7): p. 592-4. 
58. Venetucci, L.A., et al., Reducing ryanodine receptor open probability as a means to abolish 
spontaneous Ca2+ release and increase Ca2+ transient amplitude in adult ventricular 
myocytes. Circ Res, 2006. 98(10): p. 1299-305. 
59. Venetucci, L.A., A.W. Trafford, and D.A. Eisner, Increasing ryanodine receptor open 
probability alone does not produce arrhythmogenic calcium waves: threshold sarcoplasmic 
reticulum calcium content is required. Circ Res, 2007. 100(1): p. 105-11. 
60. Aistrup, G.L., et al., Pacing-induced heterogeneities in intracellular Ca2+ signaling, cardiac 
alternans, and ventricular arrhythmias in intact rat heart. Circ Res, 2006. 99(7): p. e65-73. 
61. Wasserstrom, J.A., et al., Variability in timing of spontaneous calcium release in the intact rat 
heart is determined by the time course of sarcoplasmic reticulum calcium load. Circ Res. 
107(9): p. 1117-26. 
62. Brunello, L., et al., Decreased RyR2 refractoriness determines myocardial synchronization of 
aberrant Ca2+ release in a genetic model of arrhythmia. Proc Natl Acad Sci U S A, 2013. 
110(25): p. 10312-7. 
63. Nattel, S., et al., Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial 
infarction, and atrial fibrillation. Physiol Rev, 2007. 87(2): p. 425-56. 
64. Venetucci, L.A., et al., Na/Ca exchange: regulator of intracellular calcium and source of 
arrhythmias in the heart. Ann N Y Acad Sci, 2007. 1099: p. 315-25. 
65. Fujiwara, K., et al., Burst emergence of intracellular Ca2+ waves evokes arrhythmogenic 
oscillatory depolarization via the Na+-Ca2+ exchanger: simultaneous confocal recording of 
membrane potential and intracellular Ca2+ in the heart. Circ Res, 2008. 103(5): p. 509-18. 
References 
87 
 
66. Wang, Y. and J.A. Hill, Electrophysiological remodeling in heart failure. J Mol Cell Cardiol, 
2010. 48(4): p. 619-32. 
67. Beuckelmann, D.J., M. Nabauer, and E. Erdmann, Intracellular calcium handling in isolated 
ventricular myocytes from patients with terminal heart failure. Circulation, 1992. 85(3): p. 
1046-55. 
68. Houser, S.R., Can novel therapies for arrhythmias caused by spontaneous sarcoplasmic 
reticulum Ca2+ release be developed using mouse models? Circ Res, 2005. 96(10): p. 1031-2. 
69. Pogwizd, S.M., J.P. McKenzie, and M.E. Cain, Mechanisms underlying spontaneous and 
induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. 
Circulation, 1998. 98(22): p. 2404-14. 
70. Lanner, J.T., et al., Ryanodine receptors: structure, expression, molecular details, and function 
in calcium release. Cold Spring Harb Perspect Biol, 2010. 2(11): p. a003996. 
71. Bers, D.M., Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol 
Cell Cardiol, 2004. 37(2): p. 417-29. 
72. Hohenegger, M. and J. Suko, Phosphorylation of the purified cardiac ryanodine receptor by 
exogenous and endogenous protein kinases. Biochem J, 1993. 296 ( Pt 2): p. 303-8. 
73. Yoshida, A., et al., Phosphorylation of ryanodine receptors in rat myocytes during beta-
adrenergic stimulation. J Biochem, 1992. 111(2): p. 186-90. 
74. Shan, J., et al., Role of chronic ryanodine receptor phosphorylation in heart failure and beta-
adrenergic receptor blockade in mice. J Clin Invest, 2010. 120(12): p. 4375-87. 
75. Shan, J., et al., Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight 
response in mice. J Clin Invest, 2010. 120(12): p. 4388-98. 
76. Xiao, B., et al., Characterization of a novel PKA phosphorylation site, serine-2030, reveals no 
PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circ Res, 
2005. 96(8): p. 847-55. 
77. Huke, S. and D.M. Bers, Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 
in rat cardiomyocytes. Biochem Biophys Res Commun, 2008. 376(1): p. 80-5. 
78. Anderson, M.E., Multiple downstream proarrhythmic targets for calmodulin kinase II: moving 
beyond an ion channel-centric focus. Cardiovasc Res, 2007. 73(4): p. 657-66. 
79. Kohlhaas, M., et al., Increased sarcoplasmic reticulum calcium leak but unaltered contractility 
by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res, 2006. 98(2): p. 
235-44. 
80. Wehrens, X.H., et al., Ryanodine receptor/calcium release channel PKA phosphorylation: a 
critical mediator of heart failure progression. Proc Natl Acad Sci U S A, 2006. 103(3): p. 511-
8. 
81. Wehrens, X.H., et al., Protection from cardiac arrhythmia through ryanodine receptor-
stabilizing protein calstabin2. Science, 2004. 304(5668): p. 292-6. 
References 
88 
 
82. Lehnart, S.E., et al., Sudden death in familial polymorphic ventricular tachycardia associated 
with calcium release channel (ryanodine receptor) leak. Circulation, 2004. 109(25): p. 3208-
14. 
83. Bers, D.M., Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red 
herring. Circ Res, 2012. 110(6): p. 796-9. 
84. Belevych, A.E., et al., Shortened Ca2+ signaling refractoriness underlies cellular 
arrhythmogenesis in a postinfarction model of sudden cardiac death. Circ Res, 2012. 110(4): p. 
569-77. 
85. Belevych, A.E., et al., The relationship between arrhythmogenesis and impaired contractility 
in heart failure: role of altered ryanodine receptor function. Cardiovasc Res, 2011. 90(3): p. 
493-502. 
86. Curran, J., et al., Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in 
cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res, 2007. 
100(3): p. 391-8. 
87. Gonano, L.A., et al., Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias. Circ 
Arrhythm Electrophysiol, 2011. 4(6): p. 947-57. 
88. Zhang, H., et al., Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not 
involved in cardiac dysfunction after myocardial infarction. Circ Res, 2012. 110(6): p. 831-40. 
89. Franzini-Armstrong, C., L.J. Kenney, and E. Varriano-Marston, The structure of calsequestrin 
in triads of vertebrate skeletal muscle: a deep-etch study. J Cell Biol, 1987. 105(1): p. 49-56. 
90. Zhang, L., et al., Complex formation between junctin, triadin, calsequestrin, and the ryanodine 
receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem, 
1997. 272(37): p. 23389-97. 
91. Yamaguchi, N., et al., Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release 
channel (ryanodine receptor). J Biol Chem, 2003. 278(26): p. 23480-6. 
92. Balshaw, D.M., et al., Calmodulin binding and inhibition of cardiac muscle calcium release 
channel (ryanodine receptor). J Biol Chem, 2001. 276(23): p. 20144-53. 
93. Yamaguchi, N., et al., Early cardiac hypertrophy in mice with impaired calmodulin regulation 
of cardiac muscle Ca release channel. J Clin Invest, 2007. 117(5): p. 1344-53. 
94. Guo, T., et al., Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac 
myocytes and effects on Ca sparks. Circ Res, 2010. 106(11): p. 1743-52. 
95. Huang, F., et al., Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of 
heart failure by calstabin2 in mice. Proc Natl Acad Sci U S A, 2006. 103(9): p. 3456-61. 
96. Lokuta, A.J., et al., Modulation of cardiac ryanodine receptors by sorcin. J Biol Chem, 1997. 
272(40): p. 25333-8. 
97. Farrell, E.F., et al., Sorcin inhibits calcium release and modulates excitation-contraction 
coupling in the heart. J Biol Chem, 2003. 278(36): p. 34660-6. 
References 
89 
 
98. Farrell, E.F., et al., Regulation of cardiac excitation-contraction coupling by sorcin, a novel 
modulator of ryanodine receptors. Biol Res, 2004. 37(4): p. 609-12. 
99. Seidler, T., et al., Effects of adenovirus-mediated sorcin overexpression on excitation-
contraction coupling in isolated rabbit cardiomyocytes. Circ Res, 2003. 93(2): p. 132-9. 
100. Eager, K.R. and A.F. Dulhunty, Cardiac ryanodine receptor activity is altered by oxidizing 
reagents in either the luminal or cytoplasmic solution. J Membr Biol, 1999. 167(3): p. 205-14. 
101. Xu, L., et al., Activation of the cardiac calcium release channel (ryanodine receptor) by poly-
S-nitrosylation. Science, 1998. 279(5348): p. 234-7. 
102. Gonzalez, D.R., et al., Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic 
reticulum calcium leak and arrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci U S A, 
2007. 104(51): p. 20612-7. 
103. Gonzalez, D.R., et al., Impaired S-nitrosylation of the ryanodine receptor caused by xanthine 
oxidase activity contributes to calcium leak in heart failure. J Biol Chem, 2010. 285(37): p. 
28938-45. 
104. Bovo, E., S.L. Lipsius, and A.V. Zima, Reactive oxygen species contribute to the development 
of arrhythmogenic Ca(2)(+) waves during beta-adrenergic receptor stimulation in rabbit 
cardiomyocytes. J Physiol, 2012. 590(Pt 14): p. 3291-304. 
105. Cutler, M.J., et al., Aberrant S-nitrosylation mediates calcium-triggered ventricular arrhythmia 
in the intact heart. Proc Natl Acad Sci U S A, 2012. 109(44): p. 18186-91. 
106. Donoso, P., et al., Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front 
Biosci, 2011. 16: p. 553-67. 
107. Lim, G., et al., Does nitric oxide modulate cardiac ryanodine receptor function? Implications 
for excitation-contraction coupling. Cardiovasc Res, 2008. 77(2): p. 256-64. 
108. Terentyev, D., et al., Redox modification of ryanodine receptors contributes to sarcoplasmic 
reticulum Ca2+ leak in chronic heart failure. Circ Res, 2008. 103(12): p. 1466-72. 
109. Xie, H. and P.H. Zhu, Biphasic modulation of ryanodine receptors by sulfhydryl oxidation in 
rat ventricular myocytes. Biophys J, 2006. 91(8): p. 2882-91. 
110. Yano, M., Ryanodine receptor as a new therapeutic target of heart failure and lethal 
arrhythmia. Circ J, 2008. 72(4): p. 509-14. 
111. Mohler, P.J. and X.H. Wehrens, Mechanisms of human arrhythmia syndromes: abnormal 
cardiac macromolecular interactions. Physiology (Bethesda), 2007. 22: p. 342-50. 
112. Donato, R., Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. 
Biochim Biophys Acta, 1999. 1450(3): p. 191-231. 
113. Donato, R., Intracellular and extracellular roles of S100 proteins. Microsc Res Tech, 2003. 
60(6): p. 540-51. 
References 
90 
 
114. Osterloh, D., V.V. Ivanenkov, and V. Gerke, Hydrophobic residues in the C-terminal region of 
S100A1 are essential for target protein binding but not for dimerization. Cell Calcium, 1998. 
24(2): p. 137-51. 
115. Wright, N.T., et al., S100A1: Structure, Function, and Therapeutic Potential. Curr Chem Biol, 
2009. 3(2): p. 138-145. 
116. Goch, G., et al., Affinity of S100A1 protein for calcium increases dramatically upon 
glutathionylation. FEBS J, 2005. 272(10): p. 2557-65. 
117. Zhukov, I., A. Ejchart, and A. Bierzynski, Structural and motional changes induced in apo-
S100A1 protein by the disulfide formation between its Cys 85 residue and beta-
mercaptoethanol. Biochemistry, 2008. 47(2): p. 640-50. 
118. Zhukova, L., et al., Redox modifications of the C-terminal cysteine residue cause structural 
changes in S100A1 and S100B proteins. Biochim Biophys Acta, 2004. 1742(1-3): p. 191-201. 
119. Lenarcic Zivkovic, M., et al., Post-translational S-nitrosylation is an endogenous factor fine 
tuning the properties of human S100A1 protein. J Biol Chem, 2012. 287(48): p. 40457-70. 
120. Haimoto, H. and K. Kato, S100a0 (alpha alpha) protein in cardiac muscle. Isolation from 
human cardiac muscle and ultrastructural localization. Eur J Biochem, 1988. 171(1-2): p. 409-
15. 
121. Maco, B., et al., Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human 
heart. Physiol Res, 2001. 50(6): p. 567-74. 
122. Kato, K. and S. Kimura, S100ao (alpha alpha) protein is mainly located in the heart and striated 
muscles. Biochim Biophys Acta, 1985. 842(2-3): p. 146-50. 
123. Kato, K., et al., S100a0 (alpha alpha) protein: distribution in muscle tissues of various animals 
and purification from human pectoral muscle. J Neurochem, 1986. 46(5): p. 1555-60. 
124. Pleger, S.T., et al., Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res, 
2008. 102(7): p. 786-94. 
125. Ritterhoff, J. and P. Most, Targeting S100A1 in heart failure. Gene Ther, 2012. 
126. Boerries, M., et al., Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an 
increased ATP content in cardiomyocytes. Mol Cell Biol, 2007. 27(12): p. 4365-73. 
127. Brezova, A., C.W. Heizmann, and B. Uhrik, Immunocytochemical localization of S100A1 in 
mitochondria on cryosections of the rat heart. Gen Physiol Biophys, 2007. 26(2): p. 143-9. 
128. Heierhorst, J., et al., Ca2+/S100 regulation of giant protein kinases. Nature, 1996. 380(6575): 
p. 636-9. 
129. Heierhorst, J., R.J. Mann, and B.E. Kemp, Interaction of the recombinant S100A1 protein with 
twitchin kinase, and comparison with other Ca2+-binding proteins. Eur J Biochem, 1997. 
249(1): p. 127-33. 
130. Hanson, J. and H.E. Huxley, Structural basis of the cross-striations in muscle. Nature, 1953. 
172(4377): p. 530-2. 
References 
91 
 
131. Fukushima, H., C.S. Chung, and H. Granzier, Titin-isoform dependence of titin-actin interaction 
and its regulation by S100A1/Ca2+ in skinned myocardium. J Biomed Biotechnol. 2010: p. 
727239. 
132. Gutierrez-Cruz, G., A.H. Van Heerden, and K. Wang, Modular motif, structural folds and 
affinity profiles of the PEVK segment of human fetal skeletal muscle titin. J Biol Chem, 2001. 
276(10): p. 7442-9. 
133. Most, P., et al., S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A, 
2001. 98(24): p. 13889-94. 
134. Most, P., et al., Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin 
Invest, 2004. 114(11): p. 1550-63. 
135. Pleger, S.T., et al., S100A1 gene therapy preserves in vivo cardiac function after myocardial 
infarction. Molecular Therapy, 2005. 12: p. 1120-1129. 
136. Kettlewell, S., et al., S100A1 increases the gain of excitation-contraction coupling in isolated 
rabbit ventricular cardiomyocytes. J Mol Cell Cardiol, 2005. 39: p. 900-910. 
137. Remppis, A., et al., The small EF-hand Ca2+ binding protein S100A1 increases contractility 
and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol, 2002. 97 Suppl 1: p. I56-62. 
138. Most, P., et al., Cardiac S100A1 protein levels determine contractile performance and 
propensity toward heart failure after myocardial infarction. Circulation, 2006. 114(12): p. 
1258-68. 
139. Pleger, S.T., et al., Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic 
functional heart failure rescue. Circulation, 2007. 115(19): p. 2506-15. 
140. Remppis, A., et al., Altered expression of the Ca(2+)-binding protein S100A1 in human 
cardiomyopathy. Biochim Biophys Acta, 1996. 1313(3): p. 253-7. 
141. Most, P., et al., Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart 
leads to increased in vivo myocardial contractile performance. J Biol Chem., 2003. 278(5): p. 
33809-33817. 
142. Desjardins, J.F., et al., Lack of S100A1 in mice confers a gender-dependent hypertensive 
phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ 
Physiol, 2009. 296(5): p. H1457-65. 
143. Brinks, H., et al., S100A1 genetically targeted therapy reverses dysfunction of human failing 
cardiomyocytes. J Am Coll Cardiol, 2011. 58(9): p. 966-73. 
144. Most, P., et al., Distinct subcellular location of the Ca2+-binding protein S100A1 differentially 
modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci, 2005. 118(Pt 2): p. 421-
31. 
145. Remppis, A., et al., S100A1 gene transfer : A strategy to strenghten engineered cardiac grafts. 
J Gene Medicine, 2004. 6: p. 387-394. 
References 
92 
 
146. Pleger ST, S.C., Kziencek J, Mueller O, Bekeredjian R, Remppis A et al. , Retroinfusion-
facilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically 
relevant pig heart failure model Circulation, 2008. 118: p. S_792. 
147. Voekers M, W.C., Herzog N, Friedrich O, Fink RHA, Koch WJ et al. , S100A1 prevents 
arrhythmogenic diastolic sarcoplasmic reticulum Calcium leak in ventricular cardiomyocytes. 
Circulation, 2008. 118: p. S_527. 
148. Volkers, M., et al., S100A1 decreases calcium spark frequency and alters their spatial 
characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium, 2007. 41(2): 
p. 135-43. 
149. Eisner, D.A., et al., From the ryanodine receptor to cardiac arrhythmias. Circ J, 2009. 73(9): 
p. 1561-7. 
150. Gyorke, S. and C. Carnes, Dysregulated sarcoplasmic reticulum calcium release: potential 
pharmacological target in cardiac disease. Pharmacol Ther, 2008. 119(3): p. 340-54. 
151. Zimmermann, W.H., et al., Tissue engineering of a differentiated cardiac muscle construct. Circ 
Res, 2002. 90(2): p. 223-30. 
152. Tiburcy, M., et al., Terminal differentiation, advanced organotypic maturation, and modeling 
of hypertrophic growth in engineered heart tissue. Circ Res. 109(10): p. 1105-14. 
153. Graham, F.L., et al., Characteristics of a human cell line transformed by DNA from human 
adenovirus type 5. J Gen Virol, 1977. 36(1): p. 59-74. 
154. Louch, W.E., K.A. Sheehan, and B.M. Wolska, Methods in cardiomyocyte isolation, culture, 
and gene transfer. J Mol Cell Cardiol, 2011. 51(3): p. 288-98. 
155. He, T.C., et al., A simplified system for generating recombinant adenoviruses. Proc Natl Acad 
Sci U S A, 1998. 95(5): p. 2509-14. 
156. Akhter, S.A., et al., Restoration of beta-adrenergic signaling in failing cardiac ventricular 
myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A, 1997. 94(22): p. 
12100-5. 
157. Tollefson, A.E., et al., Preparation and titration of CsCl-banded adenovirus stocks. Methods 
Mol Med, 2007. 130: p. 223-35. 
158. Piper, H.M.V., A. ; Schwartz, P., Adult Rat Heart Cells:  Cell Culture 
Techniques in Heart and Vessel Research. Springer, 1990: p. S. 36-60. 
159. Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 1970. 227(5259): p. 680-5. 
160. Kyhse-Andersen, J., Electroblotting of multiple gels: a simple apparatus without buffer tank for 
rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods, 
1984. 10(3-4): p. 203-9. 
161. Bioscience, O., http://www.olink.com, 2013. 
References 
93 
 
162. Walker, J.S., X. Li, and P.M. Buttrick, Analysing force-pCa curves. J Muscle Res Cell Motil, 
2010. 31(1): p. 59-69. 
163. Hirt, M.N., et al., Increased afterload induces pathological cardiac hypertrophy: a new in vitro 
model. Basic Res Cardiol, 2012. 107(6): p. 307. 
164. Hoshijima, M. and K.R. Chien, Mixed signals in heart failure: cancer rules. J Clin Invest, 2002. 
109(7): p. 849-55. 
165. Gupta, V. and K.J. Grande-Allen, Effects of static and cyclic loading in regulating extracellular 
matrix synthesis by cardiovascular cells. Cardiovasc Res, 2006. 72(3): p. 375-83. 
166. Celik, S., et al., Cardiac troponin T concentrations above the 99th percentile value as measured 
by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary 
syndromes undergoing routine early invasive strategy. Clin Res Cardiol, 2011. 100(12): p. 
1077-85. 
167. Hessel, M.H., et al., Release of cardiac troponin I from viable cardiomyocytes is mediated by 
integrin stimulation. Pflugers Arch, 2008. 455(6): p. 979-86. 
168. Olivetti, G., et al., Myocyte nuclear and possible cellular hyperplasia contribute to ventricular 
remodeling in the hypertrophic senescent heart in humans. J Am Coll Cardiol, 1994. 24(1): p. 
140-9. 
169. Zucchi, R. and S. Ronca-Testoni, The sarcoplasmic reticulum Ca2+ channel/ryanodine 
receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev, 1997. 
49(1): p. 1-51. 
170. Jin, H., A.R. Lyon, and F.G. Akar, Arrhythmia mechanisms in the failing heart. Pacing Clin 
Electrophysiol, 2008. 31(8): p. 1048-56. 
171. Lampe, P.D. and A.F. Lau, Regulation of gap junctions by phosphorylation of connexins. Arch 
Biochem Biophys, 2000. 384(2): p. 205-15. 
172. Lampe, P.D. and A.F. Lau, The effects of connexin phosphorylation on gap junctional 
communication. Int J Biochem Cell Biol, 2004. 36(7): p. 1171-86. 
173. Charles, R., T. Jayawardhana, and P. Eaton, Gel-based methods in redox proteomics. Biochim 
Biophys Acta, 2013. 
174. Rohde, D., et al., S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical 
trials. J Mol Cell Cardiol, 2010. 50(5): p. 777-84. 
175. Pfeffer, M.A., et al., Myocardial infarct size and ventricular function in rats. Circ Res, 1979. 
44(4): p. 503-12. 
176. Hasenfuss, G., Animal models of human cardiovascular disease, heart failure and hypertrophy. 
Cardiovasc Res, 1998. 39(1): p. 60-76. 
177. Klocke, R., et al., Surgical animal models of heart failure related to coronary heart disease. 
Cardiovasc Res, 2007. 74(1): p. 29-38. 
References 
94 
 
178. Simpson, P., Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an 
alpha 1 adrenergic response. J Clin Invest, 1983. 72(2): p. 732-8. 
179. Yamazaki, T., et al., Stretching the evidence in the case of cardiac growth. Cardiovasc Res, 
1996. 31(4): p. 493-8. 
180. Tung, L. and J. Cysyk, Imaging fibrillation/defibrillation in a dish. J Electrocardiol, 2007. 40(6 
Suppl): p. S62-5. 
181. Chiesi, M., A. Wrzosek, and S. Grueninger, The role of the sarcoplasmic reticulum in various 
types of cardiomyocytes. Mol Cell Biochem, 1994. 130(2): p. 159-71. 
182. Naito, H., et al., Optimizing engineered heart tissue for therapeutic applications as surrogate 
heart muscle. Circulation, 2006. 114(1 Suppl): p. I72-8. 
183. Zimmermann, W.H., I. Melnychenko, and T. Eschenhagen, Engineered heart tissue for 
regeneration of diseased hearts. Biomaterials, 2004. 25(9): p. 1639-47. 
184. Zimmermann, W.H., et al., Engineered heart tissue grafts improve systolic and diastolic 
function in infarcted rat hearts. Nat Med, 2006. 12(4): p. 452-8. 
185. Katare, R.G., et al., Engineered heart tissue: a novel tool to study the ischemic changes of the 
heart in vitro. PLoS One, 2010. 5(2): p. e9275. 
186. Hansen, A., et al., Development of a drug screening platform based on engineered heart tissue. 
Circ Res, 2010. 107(1): p. 35-44. 
187. Schaaf, S., et al., Human engineered heart tissue as a versatile tool in basic research and 
preclinical toxicology. PLoS One, 2011. 6(10): p. e26397. 
188. Yildirim, Y., et al., Development of a biological ventricular assist device: preliminary data from 
a small animal model. Circulation, 2007. 116(11 Suppl): p. I16-23. 
189. Ito, H., et al., Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific 
genes in cultured neonatal rat cardiomyocytes. Circ Res, 1991. 69(1): p. 209-15. 
190. van Hees, H.W., et al., Levosimendan improves calcium sensitivity of diaphragm muscle fibres 
from a rat model of heart failure. Br J Pharmacol, 2011. 162(3): p. 566-73. 
191. Du, X.J., et al., Impaired cardiac contractility response to hemodynamic stress in S100A1-
deficient mice. Mol Cell Biol, 2002. 22(8): p. 2821-9. 
192. Tsoporis, J.N., et al., The myocardial protein S100A1 plays a role in the maintenance of normal 
gene expression in the adult heart. Mol Cell Biochem, 2003. 242(1-2): p. 27-33. 
193. Santiago, J.J., et al., Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: 
expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. 
Dev Dyn, 2010. 239(6): p. 1573-84. 
194. Gullestad, L., et al., Inflammatory cytokines in heart failure: mediators and markers. 
Cardiology, 2012. 122(1): p. 23-35. 
195. Whelan, R.S., V. Kaplinskiy, and R.N. Kitsis, Cell death in the pathogenesis of heart disease: 
mechanisms and significance. Annu Rev Physiol, 2010. 72: p. 19-44. 
References 
95 
 
196. Chiong, M., et al., Cardiomyocyte death: mechanisms and translational implications. Cell 
Death Dis, 2011. 2: p. e244. 
197. Wang, S.Q., et al., Imaging microdomain Ca2+ in muscle cells. Circ Res, 2004. 94(8): p. 1011-
22. 
198. Wehrens, X.H. and A.R. Marks, Sudden unexplained death caused by cardiac ryanodine 
receptor (RyR2) mutations. Mayo Clin Proc, 2004. 79(11): p. 1367-71. 
199. Bers, D.M., Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red 
herring. Circ Res. 110(6): p. 796-9. 
200. Meissner, G., Ryanodine receptor/Ca2+ release channels and their regulation by endogenous 
effectors. Annu Rev Physiol, 1994. 56: p. 485-508. 
201. Lehnart, S.E., X.H. Wehrens, and A.R. Marks, Calstabin deficiency, ryanodine receptors, and 
sudden cardiac death. Biochem Biophys Res Commun, 2004. 322(4): p. 1267-79. 
202. Vinet, L., et al., Cardiac FKBP12.6 overexpression protects against triggered ventricular 
tachycardia in pressure overloaded mouse hearts. Basic Res Cardiol, 2012. 107(2): p. 246. 
203. Galfre, E., et al., FKBP12 activates the cardiac ryanodine receptor Ca2+-release channel and 
is antagonised by FKBP12.6. PLoS One, 2012. 7(2): p. e31956. 
204. Zissimopoulos, S., et al., Disparities in the association of the ryanodine receptor and the 
FK506-binding proteins in mammalian heart. J Cell Sci, 2012. 125(Pt 7): p. 1759-69. 
205. Anthony, D.F., et al., Interaction of calcium/calmodulin-dependent protein kinase IIdeltaC with 
sorcin indirectly modulates ryanodine receptor function in cardiac myocytes. J Mol Cell 
Cardiol, 2007. 43(4): p. 492-503. 
206. Boschek, C.B., et al., Loss of the calmodulin-dependent inhibition of the RyR1 calcium release 
channel upon oxidation of methionines in calmodulin. Biochemistry, 2008. 47(1): p. 131-42. 
207. Boschek, C.B., et al., Calcium occupancy of N-terminal sites within calmodulin induces 
inhibition of the ryanodine receptor calcium release channel. Biochemistry, 2007. 46(37): p. 
10621-8. 
208. Wright, N.T., et al., S100A1 and calmodulin compete for the same binding site on ryanodine 
receptor. J Biol Chem, 2008. 283(39): p. 26676-83. 
209. Yamaguchi, N., et al., Cardiac hypertrophy associated with impaired regulation of cardiac 
ryanodine receptor by calmodulin and S100A1. Am J Physiol Heart Circ Physiol, 2013. 
210. Fauconnier, J., et al., Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular 
dystrophy. Proc Natl Acad Sci U S A, 2010. 107(4): p. 1559-64. 
List of publications 
96 
 
V. List of publications 
 
2012 Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, Rohde D, Goodman 
C, Busch CJ, Laube F, Heissenberg J, Pleger ST, Weiss N, Katus HA, Koch WJ, Peppel 
K. 
S100A1 Deficiency Impairs Post-Ischemic Angiogenesis via Compromised 
Proangiogenic Endothelial Cell Function and Nitric Oxide Synthase Regulation.  
Circ Res. 2012 Oct 9. 
 Ritterhoff J, Most P.  
 Targeting S100A1 in heart failure. 
 Gene Ther. 2012 Jun;19(6):613-21. 
2011 Raake PW, Tscheschner H, Reinkober J, Ritterhoff J, Katus HA, Koch WJ, Most P.  
 Gene therapy targets in heart failure: the path to translation. 
 ClinPharmacolTher. 2011 Oct;90(4):542-53. 
 Rohde D, Brinks H, Ritterhoff J, Qui G, Ren S, Most P.  
 S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials.  
 Mol Cell Cardiol. 2011 May;50(5):777-84. 
2010 Rohde D, Ritterhoff J, Voelkers M, Katus HA, Parker TG, Most P.  
 S100A1: a multifaceted therapeutic target in cardiovascular disease.  
 J CardiovascTransl Res. 2010 Oct;3(5):525-37. 
 
 
V.I Poster presentation and talks 
 
04/2013 79. Jahrestagung der Deutschen Gesellschaft für Kardiologie, Mannheim, Germany, 
oral presentation: 
The positive inotropic S100A1 prevents arrhythmogenic sarcoplasmic reticulum Ca2+ 
leak and ventricular arrhythmias by modulating defective RyR2 function 
11/2012 Scientific Sessions American Heart Association 2012, Los Angeles, USA, poster 
presentation: 
S100A1 prevents SR Ca2+ leak and protects against arrhythmias in ventricular 
cardiomyocytes 
06/2012 Gordon Research conference on Cardiac regulatory mechanisms, New London, USA; 
poster presentation:   
List of publications 
97 
 
S100A1 protects cardiomyocytes against pro-arrhythmogenic Ca2+ waves and after-
contractions 
04/2012 Frontiers in Cardiovascular Biology European Society of Cardiology, London, Great 
Britain; poster presentation:  
S100A1 gene therapy protects cardiomyocytes against pro-arrhythmogenic Ca2+ waves 
and after-contractions 
  
Acknowledgments 
98 
 
Acknowledgments 
 
At this point, I would like to express my gratitude to all those, who contributed to the success of this 
work. 
First of all, I am very grateful for the support of Prof. Dr. med. Patrick Most and for the opportunity to 
work in his group, for the trust he placed in me, the inspiring discussions, the great freedom that he has 
given me in carrying out this work and for his guidance, support and encouragement during my PhD. 
I also want to thank the members of my thesis committee PD Dr. Martin Müller and PD Dr. Johannes 
Backs for their valuable advice on my project as well as Prof. Dr. Thomas Wieland and Prof. Dr. Hilmar 
Bading for agreeing to participate in the examination. 
Further thanks go to Nicole and Jasmin for excellent technical support and to Tamara for exceptional 
help with any organizational issues.  
I would also like to thank all my colleagues for the good working atmosphere, for the great time and 
their helpfulness. During this time I could not only learn a lot, I could also win great friends. Special 
thanks go to Sabine, Julia, Henni, Susi and Suzan.  
Finally, I owe a very special thanks to Tobi. For his continuous support, his unfailing trust in me and 
my work and his tireless cheerfulness every morning.   
 
 
 
